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Summary 
Background: Preventive chemotherapy is a strategy of delivering anthelmintic drugs to 
people at-risk of schistosomiasis without prior diagnosis. Currently, World Health 
Organization (WHO) recommends this strategy for morbidity control targeting six major 
helminthiases among the 17 neglected tropical diseases (NTDs) which pose a considerable 
public health problem and impair the economic development of tropic and sub-tropical 
countries. Among these helminthiases, schistosomiasis affects more than 250 million people, 
mainly in sub-Sahara Africa. Since the mid-1980s, preventive chemotherapy with 
praziquantel has been advocated by WHO for schistosomiasis control. It is believed that high-
coverage of preventive chemotherapy in endemic settings not only prevents morbidity and 
long-term sequelae of schistosomiasis, but might also interrupt the transmission of the 
disease. The present WHO goal for schistosomiasis morbidity control is to regularly reach at 
least 75% and up to 100% of school-aged children in endemic areas. This ambitious target 
was supported by international donors and pharmaceutical companies who decided to offer 
praziquantel tablets free of charge to endemic countries. While, preventive chemotherapy with 
praziquantel is being scaled up there are several concerns, such as treatment failure to clear 
infection, development and spread of drug resistance, low drug coverage particularly after 
several years of administration, lack of baseline data for better assessment of the treatment 
impact and sustainability of this strategy. 
Goal and specific objectives: The overarching goal of this Ph.D. thesis was to deepen our 
understanding of the epidemiology and spatial distribution of schistosomiasis mansoni in four 
regions of western Côte d’Ivoire, and to assess the impact of preventive chemotherapy with 
praziquantel on schistosomiasis one-year post-treatment. The study was readily integrated 
into a multi-country investigation financed by the Schistosomiasis Consortium for 
Operational Research and Evaluation (SCORE). This thesis pursued four specific objectives. 
First, to contribute to the design of a study protocol with the aim to sustain the control of 
Schistosoma mansoni in moderate endemicity areas (prevalence of infection of baseline: 10-
24%). Second, to map and predict the spatial distribution of S. mansoni in the western part of 
Côte d’Ivoire. Third, to determine the baseline parasitological and social-ecological situation 
of local communities before the implementation of a randomised controlled trial to sustain 
schistosomiasis mansoni control. Fourth, to assess the impact of preventive chemotherapy 
with praziquantel on the prevalence and intensity of S. mansoni and to determine the 
dynamics of infection one year after the treatment intervention. 
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Methods: The field work for this Ph.D. was split into three parts: eligibility, baseline and 
one-year post-treatment surveys. The eligibility survey took place from June to August 2011 
and in December 2011. School-based cross-sectional parasitological surveys were conducted 
in Cavally, Guemon, Tonkpi, and Haut-Sassandra, regions of western Côte d’Ivoire. Around 
50 children aged 13-14 years per school were screened for S. mansoni infection using 
duplicate Kato-Katz thick smears. 75 schools with S. mansoni prevalence ranging between 
10% and 24% were selected for a more detailed baseline survey and randomised to one of 
three treatment arms (A, B and C). Baseline surveys were carried out from December 2011 to 
February 2012. Approximately 100 children aged 9-12 years per school provided three stool 
samples on three consecutive days, while a single stool sample was collected from 100 first 
graders. The stool samples were subjected to the Kato-Katz method (duplicate Kato-Katz 
thick smears per stool sample) for identification and enumeration of S. mansoni eggs. In 
addition, a questionnaire on socio-demographic and ecological factors that might influence 
S. mansoni transmission was delivered to school directors and village leaders. In June 2012, a 
combined school- and community-based mass drug administration with praziquantel (single 
dose of 40 mg/kg) was conducted, targeting school-aged children living in the school 
catchment areas. Praziquantel treatment was delivered to children by trained school teachers. 
In May 2013, One-year post-treatment, a survey was conducted in the 50 schools of treatment 
arms A and B. Approximately, 100 children aged 9- 12 years per school were screened on 
three consecutive days for S. mansoni infection using the Kato-Katz method. The prevalence 
and intensity of S. mansoni infection were compared between the baseline and the one-year 
follow-up surveys at the respective schools.  
Results: At the eligibility survey, 264 schools were screened. The overall prevalence of S. 
mansoni was 39.9%, ranging from 0% to 100% at the unit of the school. High S. mansoni 
prevalence rates were mostly observed in Tonkpi region. Overall, 157 (59.5%) schools had 
prevalence of S. mansoni above 24%, 78 (29.5%) schools had a prevalence ranging between 
10% and 24%, while the remaining 29 schools (11.0%) showed prevalences below 10%. 
Bayesian geostatistical analysis showed that age, sex, altitude and difference between land 
surface temperature at day and night were significantly correlated with S. mansoni infection. 
Rice cultivation, open defecation, use of traditional pit latrine, use of natural open freshwater 
bodies for washing and bathing were potential risk factors associated with S. mansoni in local 
communities. At the baseline survey, after considering at least quadruplicate Kato-Katz thick  
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smears per child, among the 75 schools where the prevalence of S. mansoni was moderate in 
the eligibility survey (10-24%) we found that the prevalence of infection was higher than 24% 
in 28 schools (37.3%), while it was below 10% in 7 schools (9.3%). At treatment arm level, 
we found that the S. mansoni prevalence of treatment arm C was slightly higher compared to 
arms A and B. Our data showed that the directly observed treatment coverage was 84.2%. At 
the unit of the school, we found that coverage of ≥75% was achieved in 57 schools (76.0%). 
One year post-treatment, the overall prevalence of S. mansoni in the 50 schools of treatment 
arms A and B decreased from 19.7% to 12.8%, while the intensity of the infection slightly 
increased from 94.9 eggs per gram of stool among infected children to 109.3 eggs per gram of 
stool. The dynamics of prevalence and intensity of S. mansoni were heterogeneous. 
Conclusion: The understanding of the spatial distribution of schistosomiasis can help 
decision-makers for better planning disease control. In the frame of this Ph.D., a spatial 
explicit risk map of S. mansoni was generated for the western part of Côte d’Ivoire that was 
already been used by the national control programme for spatial targeting of control 
interventions. In addition, the study showed that the classification of communities according 
to WHO guideline is fragile which calls for a more accurate tool of categorisation of 
communities based on the schistosomiasis endemicity. The baseline parasitological and 
social-ecological situation in the villages provided important information for the 4-year 
cluster-randomised intervention trial founded by SCORE, which will help to determine the 
best strategies to sustainably control schistosomiasis mansoni. Our results demonstrated that 
the dynamics of schistosomiasis in the study areas one-year post-treatment was 
heterogeneous. Thus, on one hand, there is a need to regularly assess the dynamics of 
schistosomiasis during this SCORE study to deepen our understanding of the dynamics of 
schistosomiasis transmission, while on the other hand it might be necessary to implement 
more integrated control interventions to sustain gains made by preventive chemotherapy and 
more from morbidity control to elimination. 
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Zusammenfassung 
Hintergrund: Die präventive Massenbehandlung von Menschen mit Anthelminthika ohne 
vorausgehende Diagnose in Gebieten mit hohem Infektionsrisiko für die Bilharziose ist eine 
vorsorgende Maßnahme. Zurzeit empfiehlt die Weltgesundheitsorganisation (WHO) diese 
Strategie zur Kontrolle der sechs Hauptwurmerkrankungen unter den 17 sogenannten 
vernachlässigten Tropenkrankheiten („Neglected tropical diseases“, NTDs), die ein 
beachtliches Problem der öffentlichen Gesundheit darstellen und die ökonomische 
Entwicklung in tropischen und sub-tropischen Ländern hemmen. 
Innerhalb dieser Wurmerkrankungen betrifft die Bilharziose mehr als 250 Millionen 
Menschen, vor allem in Afrika südlich der Sahara. Seit Mitte der 80er Jahre empfiehlt die 
WHO zur Kontrolle der Bilharziose die präventive Massenbehandlung von Risikogruppen mit 
Praziquantel. Man nimmt an, dass durch eine ausreichende flächendeckende Behandlung in 
endemischen Gebieten nicht nur die Morbidität und Spätschäden vermindert werden, sondern 
auch eine Unterbrechung der Übertragung der Krankheit stattfinden kann. Das Ziel der WHO 
zur Kontrolle der Bilharziose ist im Moment, regelmäßig mindestens 75% bis 100% aller 
Kinder im Schulalter, die in endemischen Gebieten leben, zu behandeln. Dieses ehrgeizige 
Ziel wird von internationalen Spendern und Pharmaunternehmen unterstützt, die entschieden 
haben endemischen Ländern Praziquantel umsonst zur Verfügung zu stellen. Währendem die 
präventive Massenbehandlung mit Praziquantel ausgeweitet wird, gibt es einige Vorbehalte, 
wie zum Beispiel das Versagen des Medikaments zur vollständigen Heilung der Infektion, die 
Entwicklung und Ausbreitung von Resistenzen gegen das Medikament, die geringe 
Akzeptanz und Flächendeckung bei der Massenbehandlung, speziell nach ein paar Jahren 
regelmäßiger Entwurmungen, und der Mangel an ursprünglichen Daten, die helfen würden, 
die Auswirkungen der Behandlungen und die Nachhaltigkeit dieser Strategie abzuschätzen. 
Allumfassende und spezifische Ziele: Das allumfassende Ziel dieser Doktorarbeit war unser 
Verständnis der Epidemiologie und der räumlichen Verteilung der Darm-Bilharziose in vier 
westlichen Regionen der Elfenbeinküste zu erweitern und zu erfassen, welche Auswirkung 
die Massenbehandlung mit Praziquantel ein Jahr nach der ersten Behandlung auf das 
Vorkommen der Bilharziose in Schulkindern hat. Die Studie war Teil einer Untersuchung, die 
in mehreren Ländern stattfand und von dem Schistosomiasis Consortium for Operational 
Research and Evaluation (SCORE) finanziert wurde. 
Diese Doktorarbeit hatte vier spezifische Ziele. Erstens sollte sie bei dem Entwurf eine 
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s Studienprotokolls helfen, das zum Ziel hat die Kontrolle der Bilharziose in moderaten 
Endemiegebieten von Schistosoma mansoni (Prävalenzrate der Infektion: 10-24%) nachhaltig 
zu gestalten. Zweitens sollte sie bei der Erhebung der Ausgangsdaten helfen und die 
geographische Verteilung von S. mansoni Infektionen in der westlichen Elfenbeinküste mit 
statistischen Modellen vorhersagen und graphisch anhand von Karten darstellen. Drittens 
sollten der parasitologische Infektionsstatus und der sozioökologische Kontext der lokalen 
Gemeinschaften erfasst werden, bevor die randomisiert kontrollierte Studie zur Nachhaltigkeit 
der Kontrolle von S. mansoni Infektionen begann. Viertens sollte die Auswirkung einer 
Massenbehandlung mit Praziquantel auf die Prävalenz und Intensität von S. mansoni 
Infektionen festgestellt werden und die Dynamik der Infektion ein Jahr nach der Behandlung 
abgeschätzt werden. 
Methoden: Die Feldarbeit für diese Doktorarbeit wurde in drei Abschnitte aufgeteilt: die 
Datenaufnahme zur Abschätzung der Eignung der Studiengebiete, die Erhebung der 
Ausgangsdaten für die eigentliche Studie, und die Datenaufnahme ein Jahr nach der 
Behandlung. Die Eignungsstudie fand von Juni bis August 2011 und von Dezember 2011 bis 
Januar 2012 statt. Parasitologische Querschnittstudien wurden in den Schulen der Regionen 
Cavally, Guemon, Tonkpi und Haut-Sassandra, in der westlichen Elfenbeinküste 
durchgeführt. Pro Schule wurden jeweils um die 50 Kinder im Alter von 13-14 Jahren mittels 
mikroskopischem Befunds von zwei Kato-Katz Ausstrichen auf S. mansoni Infektionen 
untersucht. Im Ganzen wurden 75 Schulen mit einer S. mansoni Prävalenz zwischen 10% und 
24% für die detailliertere Erhebung der Ausgangsdaten ausgewählt und in einen der drei 
Behandlungsarme (A, B und C) randomisiert. Die Erhebung der Ausgangsdaten fand von 
Dezember 2011 bis Februar 2012 statt. In jeder Schule gaben ungefähr 100 Kinder im Alter 
von 9-12 Jahren an drei Tagen in Folge ihre Stuhlprobe ab, wohingegen von Erstklässlern 
eine einzelne Stuhlprobe eingesammelt wurde. Die Stuhlproben wurden mit der Kato-Katz 
Methode untersucht (zwei Ausstriche pro Stuhlprobe), um Eier von S. mansoni zu 
identifizieren und zu zählen. Zusätzlich wurden Schuldirektoren und Dorfoberhäupter mit 
einem Fragebogen über sozio-ökonomische und ökologische Faktoren interviewt, die die 
Übertragung von S. mansoni beeinflussen könnten. Im Juni 2012 wurde eine 
Massenbehandlung mit Praziquantel (einmalige Dosis von 40 mg/kg) in Schulen und 
Gemeinschaften durchgeführt, um Kinder im Schulalter zu erreichen, die in den jeweiligen 
Schuleinzugsgebieten lebten. Die Praziquantel behandlung wurde von geschulten Lehrern an 
die Kinder verabreicht. Im Mai 2013, ein Jahr nach der Behandlung, wurde eine  
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Evaluierungsstudie in den Schulen der Studienarme A und B durchgeführt. Hierbei wurden 
pro Schule ungefähr 100 Kinder im Alter von 9-12 Jahren an drei aufeinanderfolgenden 
Tagen mit der Kato-Katz Methode auf eine S. mansoni Infektion untersucht. Für jede Schule 
wurde die Prävalenz und Intensität der S. mansoni Infektion zwischen der ursprünglichen 
Studie und der Studie, die ein Jahr nach der Behandlung durchgeführt wurde, verglichen. 
Ergebnisse: Im Rahmen der Eignungsstudie wurden 264 Schulen untersucht. Die generelle 
S. mansoni Prävalenz war 39.9%, bewegte sich aber je nach Schule zwischen 0% und100%. 
Hohe Prävalenzraten wurden vor allem in der Tonkpi Region beobachtet. 
Zusammengenommen hatten 157 (59.5%) Schulen eine Prävalenz von mehr als 24%, 78 
(29.5%) Schulen hatten eine Prävalenz zwischen 10% und 24%, und die verbleibenden 29 
Schulen (11.0%) hatten eine Prävalenz unter 10%. 
Mit Hilfe von Bayesischer Geostatistischer Analyse konnte gezeigt werden, dass Alter, 
Geschlecht, Höhe und unterschiedliche Landoberflächentemperaturen zu Tag und Nachtzeiten 
signifikant mit S. mansoni Infektionen korrelierten. Potentielle Risikofaktoren, die mit einer 
S. mansoni Infektion in den lokalen Gemeinschaften assoziiert waren, waren Reisanbau, 
offene Defäkation, die Benutzung von traditionellen Plumpsklos und die Nutzung von 
natürlichen offenen Süssgewässern zum Waschen und Baden. 
Bei der Erhebung der Ausgangsdaten fanden wir in 28 (37.3%) von den 75 Schulen, deren 
S. mansoni Prävalenz bei der Eignungsstudie als moderat eingeschätzt worden war (10-24%), 
eine Prävalenz von mehr als 24%, wenn mindestens vier Kato-Katz Ausstriche pro Kind in 
Betracht gezogen wurden. In 7 Schulen (9.3%) war die Prävalenz unter 10%. 
In Bezug auf die Behandlungsarme fanden wir, dass die S. mansoni Prävalenz in Arm C 
geringfügig höher als in Arm A oder B war. Unsere Daten zeigten, dass die Behandlung, die 
direkt beobachtet wurde, 84.2% der Kinder erreichte. Auf Schulebene wurde in 57 Schulen 
(76.0%) eine Behandlungsrate von mehr als 75% erreicht. Ein Jahr nach der Behandlung hatte 
sich die S. mansoni Prävalenz in den Behandlungsarmen A und B von 19.7% auf 12.8% 
verringert. Die Intensität der Infektion hatte sich hingegen leicht von 94.9 Eiern pro Gramm 
Stuhl auf 109.3 Eier pro Gramm Stuhl erhöht. Die Dynamik der S. mansoni Prävalenz und 
Intensität war heterogen.  
 
Schlussfolgerung: Genauere Informationen über die räumliche Verteilung der Bilharziose 
können Entscheidungsträgern dabei helfen Interventionen zur Kontrolle der Erkrankung  
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besser zu planen. Im Rahmen dieser Doktorarbeit wurde eine räumlich explizite Risikokarte 
für S. mansoni im westlichen Teil der Elfenbeinküste erstellt, die bereits von dem Nationalen 
Kontrollprogramm benutzt wurde, um die Kontrollinterventionen gebietsweise zu planen. 
Zusätzlich zeigte die Studie, dass die Einordnung von Gemeinschaften basierend auf den 
Bilharziose Endemizitätskategorien gemäß der WHO Leitlinien anfällig ist und dass ein 
genaueres Mittel für die Einordnung von Gemeinschaften nötig ist. Die Erfassung der 
Ausgangsdaten der parasitologischen und sozioökonomischen Lage in den Dörfern lieferte 
wichtige Informationen für die vierjährige cluster-randomisierte Interventionsstudie die von 
SCORE finanziert wird, und welche dazu beitragen wird die besten Strategien zur 
nachhaltigen Kontrolle der intestinalen Bilharziose zu entwickeln. 
Unsere Ergebnisse zeigten, dass die Dynamik der Bilharziose in den Studiengebieten ein Jahr 
nach der Behandlung heterogen war. Demzufolge besteht einerseits eine Notwendigkeit einer 
regelmäßigen Erfassung der Dynamik der Bilharziose während dieser SCORE Studie um 
unser Verständnis der Übertragungsdynamik zu vertiefen, andererseits könnte es sein, dass 
zusätzliche ganzheitlichere Kontrollinterventionen nötig sind, um die Erfolge der präventiven 
Massenbehandlung nachhaltig zu machen und um von der Morbiditätsreduzierung zur 
Elimination voranzuschreiten. 
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Résumé 
Introduction: La chimiothérapie préventive est une stratégie de délivrance de médicaments 
antihelminthiques aux populations à risque de schistosomiase sans diagnostic préalable. 
Actuellement, l’Organisation Mondiale de la Santé (OMS) recommande cette stratégie de 
lutte contre la morbidité en ciblant six helminthiases majeures parmi les 17 maladies 
tropicales négligées (MTN) qui posent un considérable problème de santé publique and 
freinent le développement économique des pays tropicaux et subtropicaux. Parmi ces 
helminthiases, la schistosomiase affecte plus de 250 millions de personnes, principalement en 
Afrique sub-saharienne. Depuis le milieu des années 1980, la chimiothérapie préventive au 
praziquantel a été préconisée par l'OMS pour la lutte contre la schistosomiase. Un taux de 
couverture élevé de la chimiothérapie préventive dans les zones d'endémie prévient non 
seulement la morbidité et les séquelles à long terme de la schistosomiase, mais pourrait 
également interrompre la transmission de la maladie. L'objectif actuel de l'OMS pour le 
contrôle de la morbidité due à la schistosomiase  est d'atteindre régulièrement au moins 75% 
et jusqu'à 100% des enfants d'âge scolaire dans les zones endémiques. Cet objectif ambitieux 
était soutenu par les donateurs internationaux et les compagnies pharmaceutiques qui ont 
décidé d'offrir gratuitement des comprimés de praziquantel aux pays endémiques. Pendant 
que la chimiothérapie préventive au praziquantel est employé à grande échelle, il y a plusieurs 
préoccupations, tels que l'échec du traitement à éliminer l'infection, le développement et la 
propagation de la résistance au médicament, le faible taux de couverture du médicament 
notamment après plusieurs années de traitement de masse, le manque de données de base pour 
une meilleure évaluation de l’impact du traitement et la durabilité de cette stratégie.  
Objectifs: L'objectif général de cette thèse de doctorat Ph.D. était d’approfondir notre 
compréhension de l'épidémiologie et de la distribution spatiale de la schistosomiase mansoni 
dans quatre régions de l'ouest de la Côte d'Ivoire, et d'évaluer l'impact de la chimiothérapie 
préventive au praziquantel sur la schistosomiase un an après le traitement. L'étude a été 
réalisée dans le cadre d’une enquête multi-pays financée par le Consortium schistosomiase de 
recherche opérationnelle et d'évaluation (SCORE). Cette thèse avait quatre objectifs 
spécifiques. Tout d'abord, de contribuer à la conception d'un protocole d'étude dans le but de 
maintenir le contrôle de S. mansoni dans les zones d'endémicité modérée (prévalence de 
l'infection de référence: 10-24%). Deuxièmement, pour cartographier et prévoir la répartition 
spatiale de S. mansoni dans la partie ouest de la Côte d'Ivoire. Troisièmement, de déterminer  
la situation parasitologique et socio-écologique de base des communautés locales avant la 
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mise en œuvre d'un essai contrôlé randomisé pour le contrôle durable de la schistosomiase 
mansoni. Quatrièmement, pour évaluer l'impact de la chimiothérapie préventive au 
praziquantel sur la prévalence et l'intensité de S. mansoni et à déterminer la dynamique de 
l'infection, un an après le traitement. 
Méthodes: Le travail sur le terrain pour ce Ph.D. a été subdivisé en trois parties: les enquêtes 
d'éligibilité, de base et de suivi un an post-traitement. L'enquête d'éligibilité a eu lieu de Juin à 
Août 2011 et en Décembre 2011. Des enquêtes parasitologiques transversales en milieu 
scolaire ont été menées dans les régions de Cavally, Guemon, Tonkpi, et Haut-Sassandra à 
l'ouest de la Côte d'Ivoire. Environ 50 enfants âgés de 13-14 ans par école ont été examinés 
pour la présence de l'infection à S. mansoni en utilisant la méthode Kato-Katz. Deux lames de 
Kato-Katz ont été preparées par échantillon de selles. 75 écoles avec prévalence de S. 
mansoni comprise entre 10% et 24% ont été sélectionnées pour une enquête de base plus 
détaillée et randomisées dans l'un des trois bras de traitement (A, B et C). Les enquêtes de 
base ont été réalisées entre Décembre 2011 et Février 2012. Environ 100 enfants âgés de 9-12 
ans par école ont fourni trois échantillons de selles sur trois jours consécutifs, alors qu'un seul 
échantillon de selles a été collecté chez 100 élèves de première année. Les échantillons de 
selles ont été soumis à la méthode de Kato-Katz (double lames de Kato-Katz par échantillon 
de selles) pour l'identification et le dénombrement des œufs de S. mansoni. En outre, un 
questionnaire sur les facteurs socio-démographiques et écologiques susceptibles d'influencer 
la transmission de S. mansoni a été livré aux directeurs d'école et les chefs de village. En Juin 
2012, un traitement de masse à base scolaire et communautaire au praziquantel (dose unique 
de 40 mg / kg) a été mené, ciblant les enfants d'âge scolaire vivant dans les zones avoisinantes 
des écoles. Le traitement au praziquantel a été administré aux enfants par des enseignants 
formés. En Mai 2013, un an post-traitement, une enquête a été menée dans les 50 écoles du 
bras de traitement A et B. Environ 100 enfants âgés de 9- 12 ans par école ont été examinés 
sur trois jours consécutifs pour la présence de l'infection à S. mansoni en utilisant la méthode 
de Kato-Katz. La prévalence et l'intensité de l'infection à S. mansoni ont été comparées entre 
les enquêtes de base et de suivi un an post-traitement dans les écoles respectives. 
Résultats: A l'enquête d'éligibilité, 264 écoles ont été sélectionnées. La prévalence globale de 
S. mansoni était de 39,9%, variant de 0% à 100% à l'échelle des écoles. Les taux élevés de 
prévalence de S. mansoni ont surtout été observées dans la région de Tonkpi. Dans  
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l'ensemble, 157 (59,5%) écoles avaient une prévalence de S. mansoni au-dessus de 24%, 78 
(29,5%) écoles avaient une prévalence comprise entre 10% et 24%, tandis que les 29 écoles 
restantes (11,0%) avaient des prévalences en dessous de 10%. L’analyse géostatistique 
Bayésienne a montré que l'âge, le sexe, l’altitude et la différence entre la température de 
surface la journée et la nuit étaient significativement corrélées avec l'infection à S. mansoni. 
La culture du riz, défécation en plein air, l'utilisation des latrines traditionnelles, l'utilisation 
des eaux douces naturelles ouvertes pour le lavage et le bain ont été des facteurs de risque 
potentiels associés à S. mansoni dans les communautés locales. A l'enquête de base, après 
avoir examiné au moins quadruple lames de Kato-Katz par enfant, parmi les 75 écoles où la 
prévalence de S. mansoni était modérée pendant l'enquête d'éligibilité (10-24%), nous avons 
trouvé que la prévalence de l'infection était plus de 24% dans 28 écoles (37,3%), alors qu’elle 
était en dessous de 10% dans 7 écoles (9,3%). Au niveau des bras de traitement, nous avons 
trouvé que la prévalence de S. mansoni du bras de traitement C était légèrement supérieure 
par rapport aux armes A et B. Nos données ont montré que le taux de couverture du traitement 
directement observé était de 84,2%. A l'échelle des écoles, nous avons trouvé que le taux de 
couverture ≥75% était atteint dans 57 écoles (76,0%). Un an après traitement, la prévalence 
globale de S. mansoni dans les 50 écoles de bras de traitement A et B a diminué de 19,7% à 
12,8%, tandis que l'intensité de l'infection a légèrement augmenté de 94,9 œufs par gramme 
de selles chez les enfants infectés à 109,3 œufs par gramme de selles. La dynamique de la 
prévalence et l'intensité de S. mansoni étaient hétérogènes.  
Conclusion: La compréhension de la répartition spatiale de la schistosomiase peut aider les 
décideurs à une meilleure planification de la lutte contre la maladie. Dans le cadre de cette 
thèse, une cartographie spatiale explicite des risques de S. mansoni a été générée pour la partie 
ouest de la Côte d'Ivoire et a déjà été utilisée par le programme national de lutte pour le 
ciblage spatial des interventions de lutte. En outre, l'étude a montré que la classification des 
communautés selon les critères de l'OMS est fragile ce qui appelle à un outil plus précis de 
catégorisation des communautés sur la base de l'endémicité de la schistosomiase. La situation 
parasitologique et socio-écologique de base dans les villages ont fourni des informations 
importantes pour l'essai d'intervention randomisé en grappes de 4 ans financé par SCORE, 
pourra aider à déterminer les meilleures stratégies pour contrôler durablement la 
schistosomiase mansoni. 
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1. Introduction 
 
1.1. Schistosomiasis 
 
1.1.1. Biology and life cycle 
Schistosomiasis is a water-associated parasitic disease, caused by blood flukes of the genus 
Schistosoma. Six out of the 19 species of schistosomes infecting mammals are recognised 
pathogenic for humans: Schistosoma guineensis, S. haematobium, S. intercalatum, S. 
japonicum, S. mansoni and S. mekongi (WHO, 1993; WHO, 2013a; WHO, 2015). S. 
haematobium provokes urogenital schistosomiasis, while the other schistosome species cause 
intestinal schistosomiasis (Chen and Mott, 1989; Ross et al., 2002; Gryseels et al., 2006; 
WHO, 2013a; Colley et al., 2014).  
The life cycle of Schistosoma spp is complex comprising five different morphologic 
forms: eggs, miracidia, sporocysts, cercariae and adult worms (Figure 1.1). Adult 
schistosomes are small haematophagous worms with a length ranging from 7 mm to 28 mm 
and a width from 0.3 mm to 0.6 mm, depending on species and sex (Krauss et al., 2003). 
Sexual dimorphism in schistosomes is marked: the male is larger than the female (average 
length: 12 mm, average width: 1.0 mm versus length: 16 mm, width: 0.5 mm). The body of 
the male worm is folded upon its ventral side forming a groove called the gynaecophoric 
canal where the slender female develop and maintain its reproductive activity.  
Worm couples of the species S. mansoni live within the mesenteric veins and S. haematobium 
worm pairs inhabit the terminal venules in the wall of the bladder, the genitourinary system 
and the pelvic plexus within the distribution of the inferior vena cava of the definitive human 
host (Davis, 1996). The average life span of S. mansoni ranges between 3 and 10 years, but 
can be as long as 40 years (Warren et al., 1974; Chabasse et al., 1985). S. haematobium can 
live up to 3.4 years (Wilkins et al., 1984). 
Adulte female S. mansoni worms lay around 200-300 eggs per day, while S. 
haematobium and S. japonicum can produce up to 300 and 3,000 eggs per day, respectively 
(Grevelding, 2004; Larry et al., 2005). Approximately, half of the eggs are trapped in the 
tissues and cause the inflammations that give rise to morbidity. The remaining eggs are shed 
into the environment through urine (S. haematobium) or faeces (other species) and can stay 
viable at least 7 days (Gryseels et al., 2006). 
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Figure 1.1: Life cycle of Schistosoma spp. (Gray et al., 2011) 
 
In a suitable freshwater bodies, the egg releases ciliated miracidia with 150 µm length 
which can penetrate into specific intermediate host snails (Beltran et al., 2008). S. mansoni 
penetrates into the aquatic snails of genus Biomphalaria; S. haematobium, S. intercalatum and 
S. guineensis infect snails of the genus Bulinus; S. mekongi is transmitted by Neotricula 
aperta and S. japonicum infects amphibious snails of the genus Oncomelania (Gryseels et al., 
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2006; Attwood and Upatham, 2013; Rollinson et al., 2013). An egg produces approximately 
250 to 600 miracidia (S. mansoni) and slightly (200) in case of S. haematobium (Ayad, 1974). 
Once a miracidium has penetrated into the snail, it multiplies asexually into sporocysts and 
then into cercariae. Cercariae measure about 450 µm in length (Beltran et al., 2008). After 4-6 
weeks the snail infection, cercariae are released into the freshwater (Gryseels et al., 2006). If 
cercariae penetrate actively into the skin of humans (the definitive host) they migrate 
successively to the lungs and the liver, and transform into schistosomulae. In the portal vein, 
the schistosomulae mature into adult worms, which migrate to the vesical plexus (S. 
haematobium) or mesenteric venule (other species) mate, produce eggs and the life cycle 
continues. 
 
1.1.2. Global burden of human schistosomiasis 
Schistosomiasis is a complex of acute, but mainly chronic disease (Davis, 1996). 
Schistosomiasis negatively impacts the social and economic development of endemic 
countries. It has been estimated that approximately 800 million people in the world are at risk 
of schistosomiasis and more than 250 million people are infected (Steinmann et al., 2006; 
Colley et al., 2014; Hotez et al., 2014). The burden of schistosomiasis is essentially 
concentrated in Africa; indeed, 90% of the infections and 85% of the people at risk live in 
Africa (Xue et al., 2011; WHO, 2013b). In sub-Saharan Africa, the burden of schistosomiasis 
is estimated at 2.79 million disability-adjusted life years (DALYs) (IHME, 2013). 
In 2010, it was estimated that the burden of schistosomiasis in Côte d’Ivoire was 69,700 
DALYs (IHME, 2013). The estimated prevalence of Schistosoma spp infection among 
school-aged children in Côte d’Ivoire was 17.4% (Lai et al., 2015). 
 
1.1.3. Epidemiology 
Figure 1.2 displays the distribution of schistosomiasis worldwide (Gryseels et al., 2006). S. 
japonicum is endemic in the people’s Republic of China, the Philippines and Indonesia; S. 
mansoni is found in Africa, the Arabian Peninsula and South America; S. haematobium 
occurs in Africa and the Arabian Peninsula. S. intercalatum is endemic in Central and 
Western Africa, while S. guineensis shows a more restricted geographical distribution and 
occurs in Cameroon, Gabon, Equatorial Guinea, Nigeria and São Tomé and Principe. S. 
mekongi is found only on Khong Island in Lao People’s Democratic Republic and in 
Cambodia (Utzinger and Keiser, 2004; Muth et al., 2010; Rollinson et al., 2013). Recent 
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investigations showed that S. haematobium is endemic in Europe, particularly in 
Mediterranean areas (de Laval et al., 2014; Holtfreter et al., 2014; Boissier et al., 2015). 
With regard to schistosomiasis in Côte d’Ivoire, the two species S. mansoni and S. 
haematobium overlap in the central and southern parts of the country (N’Guessan et al., 2007; 
Chammartin et al., 2013). S. mansoni is predominantly found in western Côte d’Ivoire while 
S. haematobium is mostly reported in the central part of the Côte d’Ivoire (N’Goran et al., 
1998; Utzinger et al., 2000; Raso et al., 2005; N’Guessan et al., 2007; Coulibaly et al., 2012).  
An important feature of schistosomiasis is its focal distribution, which is the result of a 
combination of several factors: lack of access to sanitation and clean water, occurrence of 
suitable freshwater habitats for the intermediate host snails and human water contact activities 
(Lengeler et al., 2002; Beck-Worner et al., 2007; Krauth et al., 2015). Spatial heterogeneity of 
schistosome infections has been observed at district, country and regional levels (Raso et al., 
2005; Schur et al., 2011; Chammartin et al., 2013). As it has been observed for other 
helminths of humans, aggregated distributions of the infection intensities have also been 
reported for schistosomiasis (Anderson and May, 1991). 
 
 
Figure 1.2: Global distribution of schistosomiasis (Ferrari and Moreira, 2011) 
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1.1.4. Pathology 
Schistosome morbidity is largely due to the eggs retained in the tissues during the perivesical 
or peri-intestinal migration or after embolisation in the liver, spleen, lungs or cerebrospinal 
system. Those eggs secrete a proteolytic enzyme that lead to the infected immune responses 
and then the disease manifestations. In sub-Saharan Africa, it was estimated that more than 
half of the estimated 180 million schistosome-infected individuals suffer considerable 
associated morbidity, 18 million have bladder wall pathology, 10 million have hydronephrosis 
and 8.5 million have hepatomegaly (van der Werf et al., 2003). 
Urogenital schistosomiasis due to S. haematobium can affect the urinary tract, 
resulting in haematuria, strictures, obstruction, super-infection and, ultimately, cancer (Salem 
et al., 2011). Intestinal schistosomiasis due to S. mansoni can cause several symptoms, 
including blood in the stool, abdominal pain, bloody diarrhoea, hepatomegaly, splenomegaly 
and marked eosinophilia (Lambertucci et al., 2000). Systemic effects such as anaemia, 
malnutrition, stunted growth and impaired cognition can be profound in children with heavy 
schistosome infections (Salem et al., 2011). Pulmonary schistosomiasis due to eggs of S. 
haematobium and S. mansoni can lead to glomerulonephritis (Schwartz et al., 2000; Barsoum, 
2004). Genital schistosomiasis is due to eggs of S. haematobium and S. mansoni in the 
reproductive organs. In females, the symptoms include hypertrophic and ulcerative lesions of 
the vulva, vagina and cervix, which might facilitate sexual transmission of infections. The 
disease can lead to infertility. In men, the epididymis, testicles, spermatic chord and prostate 
can be affected; haemospermia is a common symptom (Gryseels et al., 2006). 
Neuroschistosomiasis is defined as the symptomatic or asymptomatic involvements of the 
central nervous system (CNS) by schistosomes. Infection of the spinal venous is due to eggs 
of S. mansoni and S. haematobium, while cerebral disease is associated with eggs of S. 
japonicum (Ferrari, 2004). The association of intestinal schistosomiasis and typhoid fever, 
hepatitis, pancreatitis, milliary tuberculosis, myelitis and appendicitis have also been reported 
(Neves et al., 1993; Knopp et al., 2013).  
 
1.1.5. Diagnosis and treatment 
Direct detection of schistosome eggs in the urine (i.e. S. haematobium) and stool samples all 
other schistosome species under a microscope is the most widely used diagnostic approach in 
epidemiological surveys. A commonly employed direct method for the diagnosis of urogenital 
schistosomiasis is the standard urine filtration method that involves the detection and 
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quantification of S. haematobium eggs in a 10 ml filtrate of a urine specimen that should be 
collected between 10:00 and 14:00 hours corresponding to the diurnal peak egg output 
(Plouvier et al., 1975; Mott et al., 1982). This method has high specificity and sensitivity 
(Plouvier et al., 1975). Quantification of faecal egg counts with the Kato-Katz method is the 
most widely used technique in epidemiological surveys pertaining to intestinal 
schistosomiasis and also other helminth infections (Katz et al., 1972; Booth et al., 2003). This 
technique is relatively simple and requires minimal equipment, but laboratory technicians 
have to be well-trained. Kato-Katz thick smears are usually prepared using 41.7 mg plastic 
templates (Speich et al., 2010; Yap et al., 2012). However, in area where infection intensities 
are low, this method presents some limitations as limited stool sampling may miss light 
infections due to poor sensitivity and day-to-day fluctuation in egg excretion (Barreto et al., 
1990; Engels et al., 1996). Multiple stool sampling, with at least duplicate Kato-Katz thick 
smears per sample, is warranted to achieve a reasonable sensitivity (Utzinger et al., 2011; 
Utzinger et al., 2015). 
Other parasitological, immunological, molecular and metabolic methods, such as Mini-
FLOTAC, point-of-care circulating cathodic antigen (POC-CCA) urine assay, polymerase 
chain reaction (PCR) are specific and more sensitive (Utzinger et al., 2011; Weerakoon et al., 
2015). However, these methods require expensive laboratory infrastructure and highly 
accurate handling of samples, kits and equipment. Hence, such methods are often out of reach 
in resource-constrained settings. 
 
1.2. Spatial distribution 
 
1.2.1. Mapping tools: geographical information systems and remote sensing 
A key epidemiological feature of schistosomiasis is its focal distribution resulting from many 
transmission factors. The common factors influencing schistosomiasis distribution are 
climate, vegetation and geographical location. Human exposure to contaminated water is 
influenced by the lack of sanitation, proper hygiene behaviours, irrigation and health system-
related factors. Environmental transformations such as dam constructions and water 
management activities have been shown to play an important role in transmission (Steinmann 
et al., 2006). Therefore, development of models for predicting the spatial distribution of 
Chapter 1 – Introduction 
 
7 
 
schistosomiasis, taking into account the wealth of risk factors, is crucial for efficient control 
of the disease.  
Remote sensing, in the broadest sense, refers to the acquisition of information of an 
object or phenomenon, employing a sensing device that is not in physical or intimate contact 
with the object itself. Remote sensing consists of the use of imaging sensor technologies 
aboard satellites primarily for the acquisition of environmental data. In 1984, remote sensing 
applications have been employed for the first time to predict the occurrence of human 
schistosomiasis in the Caribbean and the Philippines (Cross et al., 1984; Cross and Bailey, 
1984). Geographical information systems (GIS) has been defined as ‘‘an organized collection 
of computer hardware, software, geographical data, and personnel designed to efficiently 
capture, store, update, manipulate, analyse, and display all forms of geographically referenced 
information’’(ESRI, 1990). For disease epidemiology at an exploratory level, GIS is well 
suited for the study of associations between location, disease, vector/intermediate host and 
environment, due to its display capabilities. In 1994, remote sensing data coupled with a GIS 
were used to predict human schistosomiasis in the Nile delta area (Malone et al., 1994). 
Subsequently, numerous schistosomiasis studies combining remote sensing and GIS with 
spatial statistics have shown the importance of these tools in schistosomiasis control (Malone, 
2005; Yang et al., 2005; Brooker, 2007). In western Côte d’Ivoire, a study has identified risk 
factors explaining the geographical distribution of S. mansoni infections in 57 randomly 
selected villages in the Man region and made predictions at non-sampled locations, using an 
integrated risk profiling approach consisting of remote sensing, GIS and Bayesian models 
(Raso et al., 2005). However, since the distribution of S. mansoni is focal, it is still necessary 
to extend such a study to the entire western part of Côte d’Ivoire in order to implement an 
effective control programme. 
 
1.2.2. Risk factors 
 
Anthropogenic factors 
Human intrinsic factors such as genetics and immunity play a key role in the distribution of 
schistosomiasis. Several epidemiological observations suggest that the intensities of S. 
mansoni infection depend on host genetic factors, which could lead to susceptibility or 
resistance to infection (Katz et al., 1978; Butterworth et al., 1985; Dessein et al., 1988). It has 
been noted that immunity to S. mansoni develops progressively during childhood, peaking 
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around the age of puberty (Abel et al., 1991). Demographic features, including sex, ethnicity 
and socio-economic status, also showed a strong influence on the geographical variation of S. 
mansoni (Raso et al., 2005; Pinot de Moira et al., 2010). Tourism, irrigated agriculture and 
dam construction further contribute to the dissemination of S. mansoni because these 
activities create favourable conditions for the intermediate host snails and facilitate the 
introduction of the schistosome to new areas (Poda et al., 2004; Steinmann et al., 2006; Enk 
et al., 2010). It was estimated that 106 million people at risk of schistosomiasis lived in 
irrigation schemes or in close proximity to large dam reservoirs (Steinmann et al., 2006). 
 
Climatic factors 
Rainfall is a key climatic factor that governs favourable conditions in numerous breeding sites 
for the intermediate host snails, and hence rainfall patterns, snail population density and 
schistosome transmission are associated (Xue et al., 2011). Intermediate host snails for human 
schistosomes are unable to tolerate water flows of approximately 0.3 m/s, and above, and 
hence, intense rainfall and flooding reduce the number of snails found at potential 
transmission sites (Woolhouse and Chandiwana, 1990). On the other hand, intense rainfall 
and flooding could also be responsible for the re-introduction of snails and schistosomes to 
areas from which they had previously been eliminated and facilitate the spread of infected 
snails to areas that are newly suitable for snail populations and/or schistosome development 
(Walz et al., 2015; McCrees hand Booth, 2013). Therefore, rainfall accounts for a substantial 
part of the geographical variation in the prevalence of S. mansoni infection (Raso et al., 
2005). 
The influence of temperature of water bodies on the development rate of the parasites 
within snails, the infectivity of cercariae and snail distribution is well known. The temperature 
is an important determinant of the limits of snail distribution and population size because egg 
production, hatching, juvenile maturation and death rates, and adult death rates are all affected 
by temperature (El-Hassan, 1974; Walz et al., 2015). The rate of cercarial maturation inside 
infected snails increases as temperature increases (Foster, 1964). It is estimated that the 
optimum temperature for the development of S. mansoni is 20-27°C (Malone, 2005). 
 
Environmental factors 
Numerous studies on environmental features such as altitude, vegetation and distance from 
freshwater bodies have been used for mapping and prediction of schistosomiasis distribution. 
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Altitude is usually negatively correlated with the prevalence of schistosome infection. A 
previous study reported that children living in western Côte d’Ivoire at locations below 400 m 
were at a 5-fold higher risk of a S. mansoni infection when compared to those living at 
altitudes above this threshold (Raso et al., 2005). The altitudinal threshold limit for S. 
mansoni transmission varies according to study area. It is less than 1,600 m in western 
Uganda, while an annual incidence of 0.20 infections per person at risk has been found at 
altitudes of 1,800-2,200 m in northern Ethiopia (Ghebreyesus et al., 2002; Rubaihayo et al., 
2008). Water plants provide snails with shelter from the sun, egg-laying sites and a source of 
food. Thus, aquatic vegetation influences the distribution of snails across the globe (Brown, 
1994; Pointier et al., 2005). Several studies supported the use of vegetation for assessment of 
the distribution of schistosomiasis (Bavia et al., 2001; Kristensen et al., 2001). Distance from 
water body is usually negatively associated with S. mansoni prevalence (Handzel et al., 2003; 
Odiere et al., 2012). However, it was reported that there was no significant association 
between distance to permanent water bodies and S. mansoni infections in western Côte 
d’Ivoire (Raso et al., 2005). 
 
1.3. Prevention and control 
 
1.3.1. Water, sanitation and hygiene (WASH) 
In many part of the world, people do not have access to clean water, adequate sanitation 
facilities and good hygiene. In 2015, an estimated 663 million people still used unprotected 
wells, springs and surface water, half of them live in sub-Saharan Africa (UNICEF and WHO, 
2015). Around 2.4 billion people worldwide still use inappropriate sanitation structures and 
more than 690 million of them living in sub-Saharan Africa (UNICEF and WHO, 2015). 
Recent observations revealed that inadequate WASH are common in large part of low- and 
middle-income countries and overlapped with schistosomiasis distribution (Campbell et al., 
2014). Numerous epidemiological studies demonstrated that the implementation of adequate 
WASH could reduce the prevalence and intensity of schistosome infections and other 
intestinal helminthic infections (Jordan et al., 1978; Esrey et al., 1991; Wang et al., 2009; 
Grimes et al., 2014). Therefore, in mid- 2012 the World Health Assembly (WHA) 
recommended on integrated control strategy that emphasis WASH alongside preventive 
chemotherapy. In schistosomiasis control, the role of safe water supply, adequate sanitation 
and good hygiene are to reduce water contact, prevent the contamination of freshwater with 
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excreta, to reduce the infectivity of cercariae and miracidia (Grimes et al., 2015). However, 
the success of the WASH interventions is associated to the setting characteristics such as the 
environmental factors such as the location of freshwater bodies and the presence of 
intermediate host snails, social and cultural factors that influence water-contact patterns and 
contamination behaviour (Grimes et al., 2015). Failure of these interventions to reduce 
schistosomiasis to low endemicity settings has been reported (Freeman et al., 2013; Knopp et 
al., 2013). In addition, the implementation of WASH is expensive and there are several 
challenges such as lack of health professional involvement, lack of local government 
involvement and local public-private partnerships for sanitation facilities construction, 
insufficient financial investment from governments and international foundations (OECD, 
2000; Cairncross, 2003; Bartram and Cairncross, 2010). 
 
1.3.2. Information, education and communication (IEC) 
According to WHO, health education is an aspect of health care directed towards promoting 
and reinforcing healthy behaviour through full participation of the individuals and 
communities concerned (WHO, 1990). Since the 1930s, health education has been an integral 
part of schistosomiasis control program (Warren and Newill, 1967). The main purpose of IEC 
is to change the population behaviour in order to limit water contact, thus to reduce the risk of 
schistosomiasis transmission (Stothard et al., 2006; Stothard et al., 2009; Knopp et al., 2012). 
The intervention requires the involvement of people at all the levels of the community. 
Therefore, during the implementation of IEC, in addition to the education system, various 
communication tools must be considered, such as television and radio spots (mass media), 
road shows, public criers, leaflets, posters, comic strips, among others (Gabrielli et al., 2006; 
Garba et al., 2006; Omedo et al., 2014). The key messages about the transmission of 
schistosomiasis and how the disease can be prevented have to be tailored to specific settings 
and translated and communicated in different languages. This strategy leads to widen the 
knowledge of the population about the transmission of schistosomiasis and how the disease 
can be prevent and controlled. 
Several epidemiological research studies and national schistosomiasis control 
programme demonstrated that IEC could be used to lower the prevalence and intensity of 
Schistosoma infection (Santana et al., 1997; Chen et al., 2009). The important strength of the 
IEC is the ability to prevent the schistosomiasis but also to increase compliance with regard to 
other control tools (Utzinger et al., 2005). Previous studies underscored the relevance of 
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community participation in schistosomiasis control (Tanner et al., 1986; Guo et al., 2005). 
Recent studies revealed that IEC increased the awareness and compliance of other 
schistosomiasis control interventions (Zhou et al., 2013; Omedo et al., 2014). Therefore, IEC 
is a useful tool, which can be readily integrated with other control strategies, such as the 
preventive chemotherapy to control and ultimately eliminate schistosomiasis. Although IEC is 
a relevant aspect of schistosomiasis control; it has a limited impact on schistosomiasis in short 
term (Schall, 1995; Stothard et al., 2006; Rollinson et al., 2013). Therefore behaviour change 
by IEC requires long-term commitment (Stothard et al., 2006; Kojima et al., 2007). 
 
1.3.3. Snail control 
Reducing the intermediate host snail population by applying molluscicide, competitor snails, 
predator fish, prawns and environmental management is an important component of 
schistosomiasis control programmes. Niclosamide is the only chemical molluscicide 
recommended by WHO as it has high efficacy, low toxicity and causes comparatively little 
environmental contamination. During the 1950s and 1960s, large-scale schistosomiasis 
control programmes have been implemented in Sudan and Egypt with the use of 
molluscicides (Sharaf and Nagar, 1955; Chu, 1976). Despite its track record to have a 
significant impact on the transmission dynamics of schistosomiasis by killing snails, 
molluscicides are rarely used in contemporary schistosomiasis control programmes because 
such a control strategy remains expensive and unsustainable (Fenwick and Savioli, 2011; 
Knopp et al., 2012). 
 
1.3.4. Chemotherapy 
 
Drugs 
Chemotherapy for human schistosomiasis consists of antischistosomal drugs for prevention of 
morbidity in high-risk populations and treatment of patients by eliminating adult worms, 
whose eggs, when deposited in human tissue, cause pathogenesis (Liu et al., 2011). At 
present, chemotherapy is the main measure employed for the control of schistosomiasis in 
endemic countries (WHO, 2002; WHO., 2012). Praziquantel remains the only drug currently 
recommended by WHO for individual treatment and community-based morbidity control for 
all types of schistosomiasis (WHO, 2013b). At the individual patient level, praziquantel is 
usually administered at a single oral dose of 40 mg/kg of body weight (WHO, 1995). For 
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preventive chemotherapy, praziquantel is often administered based on a dose pole, which 
allows drug administration based on people’s height rather their weight (Montresor et al., 
2002). Praziquantel is efficacious against adult schistosome species that infect humans (Liu et 
al., 2011). This drug is safe and often provided for free of charge to national control 
programmes. The main limitation of praziquantel is the lack of therapeutic efficacy against 
young developing schistosomes, which might explain local treatment failure in highly 
endemic areas and observed high rates of re-infection post-treatment (Del Villar et al., 2012). 
Moreover, praziquantel remains the only drug recommended by the WHO for the treatment of 
all forms of schistosomiasis, and hence, it has become the drug of choice in both clinical 
practice and public health interventions (WHO, 2013b).  
Oxamniquine, a drug that exhibits activity against S. mansoni is more effective against 
male parasites (Ferrari et al., 2003). Its immediate toxicity is low and presents weak side 
effects. Many studies have reported the failures of oxamniquine treatment that could explain 
the decline of its use (Conceicão et al., 2000; Clarke et al., 1976).  
Metrifonate (10 mg/kg) administered three times with four months intervals showed 
similar benefit compared to one dose of praziquantel (40 mg/kg) in reducing prevalence and 
intensity of S. haematobium and associated morbidity (King et al., 1990). Despite, the 
efficacy of metrifonate against S. haematobium, this drug has recently been withdrawn from 
the market because of medical, operational and economic drug criteria (Cioli, 2000).  
Artemether and artesunate and other artemisinin derivatives with anti-schistosomal 
potential are active against S. japonicum, S. mansoni and S. haematobium, mainly targeting 
the immature, stage (Xiao and Catto, 1989). Although a series of randomised controlled trials 
have shown potential of the artemisinis to fight schistosomiasis (Utzinger and Keiser, 2004), 
they are not being recommended against schistosomiasis, perhaps because of the fear of 
malaria resistance development.  
 
Preventive chemotherapy 
Since the mid-1980s, WHO emphasises morbidity control using praziquantel as the main 
pillar of the global strategy to control schistosomiasis (WHO., 1985). The cornerstone of this 
recommendation is the repeated large-scale administration of anthelminthic drugs to at-risk 
populations (WHO., 2006). The population at risk is usually categorised according to school-
aged children (5-14 years of age) and adults (≥15 years) in the general population. The 
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frequency of preventive chemotherapy depends on the population risk category (Table 1) 
(WHO, 2002).  
According to data published by WHO, more than 39 million Africans were treated for 
schistosomiasis in 2013 (WHO, 2015). However, this represents only 12.7% of the 
individuals requiring preventive chemotherapy. Therefore, much effort is still needed in order 
to achieve recommended coverage levels of at least 75 % among school-aged children (WHO, 
2002; WHO, 2006). 
 
1.4. Identified research needs 
The upscale of schistosomiasis control in the next years will not only need highly dedicated 
development partners, governments, health workers, drug distributors and local communities, 
but will also involve major costs. To assess which strategy for mass drug administration 
(MDA) of praziquantel provides the best balance in terms of cost and reductions in prevalence 
and intensity of S. mansoni and/or S. haematobium in school-aged children, the 
Schistosomiasis Consortium for Operational Research and Evaluation (SCORE), in 
collaboration with African, American and European partners, designed a series of multi-year 
cluster-randomised trials that are being implemented since 2010 in Côte d’Ivoire, Kenya, 
Mozambique, Niger and the United Republic of Tanzania (Figure 1.3). 
Two of the studies are evaluating alternative approaches to MDA in communities with 
high prevalence rates (>25% in school-aged children) of either S. mansoni or S. haematobium 
and are termed “Gaining control of schistosomiasis” studies. These studies are conducted in 
Kenya, Mozambique, Niger and the United Republic of Tanzania. The remaining two studies 
are evaluating alternative approaches to MDA in areas of moderate prevalence (10-24% in 
school-aged children) of either S. mansoni or S. haematobium and are entitled “Sustaining 
control of schistosomiasis” studies. The latter studies are conducted in Côte d’Ivoire and 
Kenya. 
The current Ph.D. thesis is embedded in the SCORE project which is taking place in 
western Côte d’Ivoire. This work consists of a rigorous evaluation of alternative strategies of 
MDA with praziquantel in areas where the prevalence of S. mansoni is moderate. 
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Table 1.1: Recommended treatment strategies against schistosomiasis, as recommended by WHO. 
 
Community 
category 
Prevalence in school survey Intervention in schools enrolled 
and non-enrolled children 
Health services and community-based 
intervention 
I 
High prevalence 
≥30% visible haematuria 
(S. haematobium, by questionnaire) 
or ≥50% infected (S. mansoni, by 
parasitological method) 
Targeted treatment of school-aged 
children, 
once a year 
 
Access to praziquantel for passive case 
treatment; community-directed treatment 
for high-risk groups recommended 
II  
Moderate 
prevalence 
<30% (S. haematobium by 
questionnaire) 
or ≥10% but <50% infected 
(S. mansoni and S. haematobium, 
by parasitological methods) 
Targeted treatment of school-aged 
children, once every 2 years 
 
 
Access to praziquantel for passive case 
treatment 
III 
Low prevalence 
 
<10% infected (S. mansoni and 
S. haematobium, by parasitological 
methods) 
Targeted treatment of school-aged 
children twice during primary 
schooling (once on entry, again on 
leaving) 
Access to praziquantel for passive case 
treatment 
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Figure 1.3: African countries where “Gaining and sustaining schistosomiasis control” 
studies are currently being implemented. 
*After 2 years, Niger has been subjected to another control programme. 
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1.5. Goal and specific objectives 
 
1.5.1. Goal 
The overarching goal of this Ph.D. project is to implement and adhere to a SCORE study 
protocol for sustaining the control of schistosomiasis mansoni in the western part of Côte 
d’Ivoire. 
 
1.5.2. Specific objectives 
 To contribute to the development and implementation of a study protocol that will be 
implemented to control S. mansoni in an area with moderate endemicity. 
 To map and predict the spatial distribution of S. mansoni in the western part of Côte 
d’Ivoire.  
 To determine the baseline characteristic of local communities before the 
implementation of a cluster-randomised controlled trial to sustain schistosomiasis 
mansoni control. 
 To assess the impact of preventive chemotherapy with praziquantel on the prevalence 
and intensity of S. mansoni and the dynamic of the infection one year after the 
intervention. 
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2.1. Abstract 
Background: Schistosomiasis is a parasitic disease that occurs in the tropics and subtropics. 
The mainstay of control is preventive chemotherapy with praziquantel. In Africa, an estimated 
230 million people require preventive chemotherapy. In western Côte d’Ivoire, infections 
with Schistosoma mansoni are widespread. To provide an evidence-base for programme 
decisions about preventive chemotherapy to sustain control of schistosomiasis, a 5-year multi-
country study with different treatment arms has been designed by the Schistosomiasis 
Consortium for Operational Research and Evaluation (SCORE) and is currently being 
implemented in various African settings, including Côte d’Ivoire. 
Methods/Design: We report the study protocol, including ethics statement and insight from a 
large-scale eligibility survey carried out in four provinces in western Côte d’Ivoire. The study 
protocol has been approved by the ethics committees of Basel and Côte d’Ivoire. A total of 
12,110 children, aged 13–14 years, from 264 villages were screened for S. mansoni using 
duplicate Kato-Katz thick smears from single stool samples. Among the schools with a S. 
mansoni prevalence of 10-24%, 75 schools were selected and randomly assigned to one of 
three treatment arms. In each school, three stool samples are being collected from 100 
children aged 9–12 years annually and one stool sample from 100 first-year students at 
baseline and in the final year and subjected to duplicate Kato-Katz thick smears. Cost and 
coverage data for the different intervention arms, along with environmental, political and 
other characteristics that might impact on the infection prevalence and intensity will be 
recorded in each study year, using a pretested village inventory form. 
Discussion: The study will document changes in S. mansoni infection prevalence and 
intensity according to different treatment schemes. Moreover, factors that determine the 
effectiveness of preventive chemotherapy will be identified. These factors will help to 
develop reasonable measures of force of transmission that can be used to make decisions 
about the most cost-effective means of lowering prevalence, intensity and transmission in a 
given setting. The gathered information and results will inform how to effectively sustain 
control of schistosomiasis at a low level in different social-ecological contexts. 
 Trial registration: ISRCTN99401114 (date assigned: 12 November 2014). 
 
Keywords: Schistosomiasis, Schistosoma mansoni, Control, Morbidity control, Preventive 
chemotherapy, Praziquantel, Prevalence, Intensity of infection, Côte d’Ivoire, SCORE 
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2.2. Background 
 
2.2.1. Burden and transmission of schistosomiasis, with an emphasis on Schistosoma 
mansoni in Africa 
Human schistosomiasis, a disease caused by chronic infection with parasitic trematodes of the 
genus Schistosoma, is endemic in 78 tropical and subtropical countries, 42 of which are 
located in Africa (WHO, 2014). An estimated 779 million people are at risk of 
schistosomiasis, more than 230 million are infected, 120 million are symptomatic and 20 
million suffer from severe and debilitating forms of schistosomiasis (Chitsulo et al., 2000; 
Steinmann et al., 2006; Vos et al., 2012; Colley et al., 2014). The burden of the disease is 
essentially concentrated in Africa, where more than 90% of the infections worldwide occur 
(Utzinger et al., 2009; WHO, 2013; Colley et al., 2014). Schistosomiasis is intimately 
connected with poverty, and hence, the disease delays the social and economic development 
in endemic countries (Gryseels et al., 2006; King, 2010; Utzinger et al., 2011; Colley et al., 
2014). 
The life cycle of schistosomiasis involves a phase of sexual reproduction by adult 
schistosome worms in the definitive human host, and an asexual phase in the intermediate 
host, a specific freshwater snail. In Côte d’Ivoire, for example, Biomphalaria pfeifferi is the 
only intermediate host snail for Schistosoma mansoni (N’Goran et al., 1989). From the snail, 
cercariae are released into the surrounding water and can invade humans through the skin. 
Infection with S. mansoni causes intestinal schistosomiasis. Typical symptoms include blood 
in the stool, (bloody) diarrhoea, chronic or intermittent abdominal pain, anaemia, general 
fatigue, weight loss, hepatomegaly, splenomegaly and marked eosinophilia (Lambertucci et 
al., 2000; Gryseels et al., 2006). Moreover, chronic infection can impair children’s physical 
and cognitive development and nutritional status (King et al., 2005). Associations of intestinal 
schistosomiasis with hepatitis, acquired immunodeficiency syndrome (AIDS) and malaria 
hypertension have been reported (Al-Shamiri et al., 2011; Mazigo et al., 2013; Kinung'hi et 
al., 2014). 
Several factors contribute to the spread of schistosomiasis. Demographic features, 
including age, gender, ethnicity and socioeconomic status have a strong influence on the 
spatial distribution of schistosomiasis, particularly S. mansoni (Raso et al., 2005; Pinot de 
Moira et al., 2010). Tourism, construction and operation of water resource developments (i.e. 
irrigation schemes and dams) are associated with higher risks of S. mansoni, explained by the 
creation of favorable conditions for intermediate host snails and higher frequencies of human 
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water contacts (Poda et al., 2004; Enk et al., 2010; Colley et al., 2014). It is estimated that 
more than 100 million people at risk of schistosomiasis live in irrigation schemes or in close 
proximity to reservoirs of large dams (Colley et al., 2014). Intense rainfall and flooding might 
be responsible for the reintroduction of intermediate host snails to areas from which 
schistosomiasis had previously been eliminated (McCreesh and Booth, 2013). 
 
2.2.2. Schistosomiasis control in Africa 
According to the World Health Organization (WHO), comprehensive schistosomiasis control 
programmes should include treatment of at-risk groups, provision of clean water, adequate 
sanitation, hygiene education and snail control (WHO, 2002). The current mainstay of control 
is preventive chemotherapy – that is the periodic administration of the antischistosomal drug 
praziquantel to entire at risk populations without prior diagnosis. The goal is to cover at least 
75% of those at risk of schistosomiasis by preventive chemotherapy in 2020 (WHO, 2013). 
The frequency of preventive chemotherapy is guided by infection prevalence in specific age 
groups. In areas where the prevalence of Schistosoma infection in school-aged children (5–14 
years) is 50% or higher, entire communities should be treated once every year; if the 
prevalence is between 10% and 50%, treatment is focussed on school-aged children with a 
frequency once every two years; if the prevalence is below 10%, school-aged children should 
be treated twice, at school entry and again before they finish schooling (WHO, 2002; WHO., 
2012b). In Africa, approximately 35.5 million people were treated with praziquantel in 2012 
(WHO, 2014). This estimate accounts for a coverage of only 13.6% of schoolaged children. 
Hence, concerted efforts are needed to massively scale-up preventive chemotherapy to reach 
the 75% coverage goal by the year 2020. In Côte d’Ivoire, where both S. mansoni and S. 
haematobium are endemic and many people suffer from intestinal or urogenital 
schistosomiasis (Doumenge et al., 1987; N’Goran et al., 1998; Utzinger et al., 2000c; Raso et 
al., 2005; N’Guessan et al., 2007; Tchuem Tchuenté and N’Goran, 2009; Chammartin et al., 
2013), no large-scale preventive chemotherapy programme was in place prior to the onset of 
this study in 2011 (Utzinger et al., 2000a; Raso et al., 2004; Tchuem Tchuenté and N’Goran, 
2009). 
 
2.2.3. Operational research for schistosomiasis control 
Further up-scaling of schistosomiasis control in the years to come will not only need political 
commitment, national strategic plans, dedicated development partners, functioning health 
systems and community volunteers, but will also involve major costs. To assess which 
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strategy of preventive chemotherapy will provide the best balance in terms of reduction in 
prevalence and intensity of schistosome infection in school-aged children on one hand, and 
costs on the other hand, the Schistosomiasis Consortium for Operational Research and 
Evaluation (SCORE; http://score.uga.edu/) designed a series of largescale, multi-country 
intervention studies. In response to a request for proposals to gain and sustain control of 
schistosomiasis in Africa, several investigators from Africa, in partnership with colleagues 
from Europe and the United States of America, put forward their ideas. The proposals were 
evaluated by a panel of experts against predefined criteria. Initially, three projects were 
selected under the heading “Sustaining control of schistosomiasis”, focusing either on S. 
mansoni (two projects; Côte d’Ivoire and Kenya) or S. haematobium (one project; Niger). The 
overarching goal is to evaluate alternative approaches to preventive chemotherapy in areas 
with moderate prevalence of infection at baseline (10-24% in school-aged children). Of note, 
the sustaining schistosomiasis haematobium project in Niger has been terminated after two 
years due to an issue with the randomisation of study villages. 
Here, we summarise the relevant part of a harmonized study protocol that is being 
followed by partners conducting the sustaining control of schistosomiasis mansoni studies in 
Côte d’Ivoire and Kenya. The field and laboratory procedures for the sustaining S. mansoni 
control project in moderate endemicity areas of Côte d’Ivoire will be presented in greater 
detail, including results of the initial eligibility survey, which guided the selection of 75 
communities or villages for subsequent treatment interventions. 
 
2.2.4. Goal, aims and objectives 
The goal of the SCORE projects aiming at sustaining control of schistosomiasis at a low level 
is to generate an evidence-base for programme decisions about preventive chemotherapy-
based approaches to sustain the control of S. mansoni infections. The studies will determine 
which strategy for preventive chemotherapy provides the best balance in terms of cost and the 
reduction in prevalence and intensity of infection in school-aged children after four years of 
intervention. The studies are designed to answer the following question: How can we sustain 
control of S. mansoni in communities/villages with a moderate endemicity level (prevalence 
of 10-24%, as assessed by a single stool examination with duplicate Kato-Katz thick smears)? 
Specifically, we are addressing the following research questions: 
• What combination of annual school-based treatment (SBT) and “drug holidays” yields 
the best outcomes for the lowest cost? 
• What are the factors that determine the effectiveness of preventive chemotherapy? 
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• Can reasonable measures of force of transmission be developed that can be utilised to 
make decisions about the most cost-effective means of lowering prevalence, intensity and 
transmission in a given setting? 
 
2.3. Methods/Design 
 
2.3.1. Study design 
The SCORE sustaining schistosomiasis control studies are designed as randomised 
intervention trials with three study arms. Each arm comprises 25 communities or villages. 
Hence, the studies will include 75 communities per country. Communities will be provided 
with various combinations of SBT and “drug holidays” over a 4-year period, followed by 
final data collection, analysis and dissemination of results in the fifth year. The intervention 
arms in the sustaining schistosomiasis control studies are designed as shown in Figure 2.1. In 
brief: 
• schools of arm A will receive annual SBT for four years; 
• schools of arm B will receive SBT in the first two years, followed by “drug holidays”; 
and 
• schools of arm C will receive SBT in years 1 and 3, alternated by “drug holidays” in 
years 2 and 4. 
Preventive chemotherapy with praziquantel is being provided as single oral dose of 40 
mg/kg, using a dose pole. Standard praziquantel treatment exclusion criteria apply (WHO, 
2002). No treatment will be provided during “drug holidays” and no parasitological data are 
collected in those years. During SBT, praziquantel will be administered by trained teachers to 
all school-going children. Children in all schools in the community will be treated, and hence, 
children attending schools not otherwise involved in the study will also receive treatment. 
Any time SBT will take place, additional efforts will be made to enhance treatment coverage, 
such as community sensitization and mobilization efforts, radio announcements, and other 
means of information, education and communication (IEC) strategies. Non-school attendees 
who span the same age range as school-going children will also be invited for treatment. No 
other major treatment strategies outside the education sector venue will be implemented. The 
school attendance rates and treatment coverage will be documented throughout the study. 
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Figure 2.1: Study arms for the sustaining control of Schistosoma mansoni studies in 
moderate endemicity areas (prevalence: 10-24%). 
SBT, school-based treatment; Holiday, no drug delivery. 
 
2.3.2. Justification of the number of intervention arms and participants 
The protocol for the sustaining schistosomiasis control studies was developed through a series 
of expert consultations, facilitated by the SCORE secretariat and its scientific advisory board. 
The decision to choose three intervention arms for the current studies took into consideration 
formal sample size calculation and operational feasibility. For sample size calculation, it was 
assumed that the treatment interventions will reduce Schistosoma prevalence in moderate 
endemicity areas from 25% to 10%. Analyses determined the minimum effect size that may 
be detected with 90% power for a 2-sided α = 0.05 level test as a function of the number of 
children m tested per village, the number n of villages sampled per treatment, the 
overdispersion parameter φ, and the correlation ρ between observations in year 1 at baseline 
and in year 4 at the end of the study. The calculations revealed that studying 20 communities 
or schools per arm and evaluating 100 individuals per school would result in minimum effect 
sizes of 5-12% with or without overdispersion. This minimum effect size was deemed 
reasonable. To further increase the chance of detecting differences between the interventions 
arms, the number of the units of interventions, and hence, the number of schools, was 
increased to 25 per arm. Taken together, the trial protocol asked to examine 100 children aged 
9–12 years every year whenever drug intervention will be implemented as primary outcome. 
Additionally, 100 first-year students will be examined in years 1 and 5. 
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2.3.3. Eligibility of study communities 
Sustaining schistosomiasis control studies will include 75 communities with an initial S. 
mansoni prevalence of 10-24%. Selection of these large numbers of communities has been 
determined through a rapid appraisal eligibility survey. A single stool sample from each of 50 
children aged 13–14 years has been subjected to duplicate Kato-Katz thick smears (Katz et 
al., 1972; Knopp et al., 2013). Additional criteria applied for eligibility determination are as 
follows. First, a study community must have a primary school, because the arms of the study 
are school-based and every participating community must be eligible to be randomised to any 
of the study arms. However, it is permitted that a study community may have more than one 
school. If two nearby communities have schools with less than 100 children per school but 
they are similar in terms of ecology and socioeconomic status, they can be combined for 
purposes of this study and be considered as a single study community. Second, two nearby 
communities that share water sources and/or whose schools have overlapping catchment areas 
will not be considered separate villages for the purposes of this study; one of the two schools 
will be chosen. Third, there is no pre-set population requirement for the size of a community, 
as long as it includes at least 100 children aged 9-12 years who attend school. Fourth, 
preference is for settings that have not recently been subjected to preventive chemotherapy 
targeting schistosomiasis. If communities have been previously treated, historic treatment data 
should be included where available. Fifth and finally, to the extent possible, study 
communities should be as similar as possible in characteristics that could affect transmission 
dynamics, including, for example, a history of past treatment and the availability of water 
sources. 
 
2.3.4. Eligilbility of study participants 
For the eligibility study to rapidly identify the 75 communities with a baseline prevalence of 
10-24%, children were eligible to participate if they were 13 or 14 years old and provided an 
informed consent sheet signed by their parents. In the baseline and the yearly follow-up 
surveys conducted to assess the change in prevalence and intensity of Schistosoma infection 
in each intervention arm, children aged 9–12 years who provide a written informed consent 
from their parents will be included. Additionally, in years 1 and 5, first-year students will 
provide written informed consent from their parents and will participate in the study. 
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2.3.5. Details of the S. mansoni control study in western Côte d’Ivoire 
 
Study area and population 
The sustaining S. mansoni control study in Côte d’Ivoire is being conducted by a team of 
researchers from the Université Félix Houphouët-Boigny, who work in close collaboration 
with the Programme National de Lutte contre la Schistosomiase, les Géohelminthiases et la 
Filariose Lymphatique (PNL-SGF) at the Ministry of Health and Public Hygiene, the ‘Centre 
Suisse de Recherches Scientifiques en Côte d’Ivoire (CSRS), all based in Abidjan, and the 
Swiss Tropical and Public Health Institute (Swiss TPH) in Basel, Switzerland. 
The study area is located in western Côte d’Ivoire in the four regions Cavaly, Guemon, Haut-
Sassandra and Tonkpi (Figure 2.2). The area was chosen because it is a well known S. 
mansoni focus (N'Goran et al., 1998) and our teams conducted schistosomiasis research there 
since the mid- 1990s, including treatment of individuals found positive upon Kato-Katz 
examination (Doumenge et al., 1987; Utzinger et al., 1998; Keiser et al., 2002; Raso et al., 
2005; Beck-Worner et al., 2007; Matthys et al., 2007; Tchuem Tchuenté & N’Goran, 2009; 
Chammartin et al., 2013). Cavaly, Guemon and Tonkpi regions are located west of the 
Sassandra River and belong to the district des Montagnes. Ten departments of this district are 
included in our study: Bangolo, Biankouma, Danané, Douékoué, Facobly, Guiglo, Kouibly, 
Man, Sipilou and Zoukougbeu. The district des Montagnes is a mountainous area with an 
average altitude ranging between 300 m and slightly above 1,000 m. The climate is humid 
tropical with two seasons. The rainy season usually lasts from March to October. The Haut-
Sassandra region is located East of the Sassandra River. Zoukougbeu is the only department 
of that region which is included in our study. Here, the average altitude ranges between 200 m 
and 300 m. The climate is sub-equatorial, characterised by two rainy seasons. The long rainy 
season occurs from March to July and the short rainy season from September to October. 
According to the national population census carried out in 1998 (the most recent census at the 
time of writing the current piece), the total population in the study area is 1.5 million people 
(unpublished data; Institut National de la Statistique en Côte d’Ivoire). Most people belong to 
one among the four ethnic groups: Bété, Guéré, Wobé and Yacouba. People are mainly 
engaged in subsidence farming (cassava, maize, plantain and rice). There is also production of 
cash crops (coffee and cocoa) and a small forestry industry in the town of Man (Utzinger et 
al., 2000b). The annual rainfall in the study area varies between 1,100 and 2,000 mm. The 
vegetation is composed of two types of forests (semi-deciduous and evergreen mountain 
forest). The average annual temperature is around 26°C. 
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Figure 2.2: Map of Côte d’Ivoire with the four study regions in the western part where 
the SCORE sustaining S. mansoni control project is being implemented. 
 
Selection and randomisation of study villages 
The 75 villages with a S. mansoni prevalence of 10-24% in western Côte d’Ivoire were 
identified as follows. First, our team organised a series of meetings with health and education 
authorities in the four study regions. The purpose and procedures of the study were explained 
and a total of 264 communities fulfilling the following criteria were identified: (i) village has 
a school attended by at least 100 children aged 9–12 years in grades 2–5 and 50 children aged 
at least 13 years in grades 4–6; (ii) village and school had no recent history of preventive 
chemotherapy using praziquantel against schistosomiasis (within the past 12 months); (iii) 
village is accessible also in the rainy season; and (iv) it is safe for our teams to work in the 
village. The latter issue was a real concern, as Côte d’Ivoire suffered from a decade-long 
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political unrest that culminated in armed conflict and war in late 2010/early 2011 (Bonfoh et 
al., 2011). Before the onset of the surveys in each school, we conducted a brief interview with 
the school teachers to assess the selectability of the villages, according to the aforementioned 
criteria. Then, schoolchildren in grades 1–6 were informed about the mode of transmission of 
S. mansoni, its health impact and the importance of the current project. Children aged 13 or 
14 years were randomly selected from grades 4–5 until the number of children reached 50. In 
settings where less than 50 children aged 13–14 years were present, the sample was 
completed with 12-year-old children, but these children will not be enrolled in the subsequent 
randomised controlled trial. 
 Children were asked to provide a written informed consent from their parents or legal 
guardians. Children with written informed consent were supplied with plastic containers to 
collect a small amount of their own early morning stool specimen. Collection containers were 
labelled with unique identification numbers. The name, sex, age and school grade of each 
child were recorded. Stool samples were transferred to the Centre Hospitalier Regional de 
Man for parasitological examination. From each stool sample, duplicate Kato-Katz thick 
smears were prepared on microscope slides using 41.7 mg templates (Katz et al., 1972; 
Knopp et al., 2013). After allowing the slides to clear for at least 60 min, they were examined 
under a microscope by experienced laboratory technicians for the presence of S. mansoni and 
soil-transmitted helminths (i.e. Ascaris lumbricoides, hookworm and Trichuris trichiura). 
The prevalence of S. mansoni was calculated for each school. A total of 12,110 
children submitted a stool sample that was subjected to duplicate Kato-Katz thick smears. The 
prevalence at the unit of the school in the eligibility survey ranged from 0% to 100% (Figure 
2.3). In brief, among the 264 schools, 157 (59.5%) had a S. mansoni prevalence above 24%, 
78 (29.5%) schools had a prevalence ranging between 10% and 24%, whilst the remaining 29 
schools (11.0%) had a prevalence below 10%. As shown in Figure 2.4, most of the villages 
meeting the sustaining control prevalence range (i.e. 10-24%) that were ultimately selected (n 
= 75) are located in the Guemon region. The schools were randomly assigned to three 
intervention arms using a computer-based randomisation procedure conducted by an 
independent statistician. 
 
 
 
 
 
 40 
 
 
Figure 2.3: Range of prevalence of S. mansoni infection in the 264 villages screened in 
western Côte d’Ivoire to identify moderate S. mansoni endemicity areas (10-24%). 
At the unit of the school, we examined 50 children aged 13–14 years with duplicate Kato-
Katz thick smears from a single stool sample. 
 
 
Figure 2.4: Map showing point prevalence of S. mansoni in 264 schools of western Côte 
d’Ivoire, as determined by an eligibility survey in late 2011/early 2012. 
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2.3.6. Data collection in the main study 
Collection of stool samples and administration of a questionnaire 
At the beginning of the main activities of the sustaining S. mansoni control study in the 
western part of Côte d’Ivoire, a small designated team informed district and village authorities 
and children’s parents. Detailed information was provided about the forthcoming cross-
sectional parasitological and questionnaire surveys. Each year, shortly before the annual 
parasitological survey, teachers will be re-informed about the purpose and procedures of the 
study. Teachers assist by preparing class lists, including name, age, sex and school grade. In 
each school, children aged 9–12 years are enrolled from grades 2–6 until 100 pupils will be 
reached. Moreover, at baseline and in the final year of the study, 100 pupils will be randomly 
selected from the class list of grade 1 and their age will be recorded. Before sample collection 
commences, the study is explained in lay terms to the selected children and they are invited to 
provide three stool samples over consecutive days. Stool samples are collected in 125 ml 
plastic containers. 
Children are asked to return the containers within an hour, filled with an apricot-sized 
portion of their own stool. We collect the containers and label them with individual IDs. The 
stool collection procedure is repeated over three consecutive days. Children without written 
consent from their parents and those who are unable to produce at least two stool samples are 
withdrawn, but they receive praziquantel treatment as the other children in the same village. 
For final analysis those children who have written consent and results from at least four Kato-
Katz thick smears are included.  
Upon visiting the school by our team, the community leader is contacted and 
interviewed with a pre-tested questionnaire to record characteristics of demography, main 
activities, health system, water contact sites, and sources of water and sanitary facilities in the 
village. Demographic information includes the number of households and total population. 
The health system is characterized by accessibility to health infrastructures, and availability of 
praziquantel against schistosomiasis and artemisinin-based combination therapy (ACT) 
against malaria. Information pertaining to water contact sites comprises the number of 
stagnant and non-stagnant freshwater bodies. The questionnaire also allows determining 
which type of water the population uses for drinking, bathing and cleaning. We also assess 
which type of sanitary facilities the population uses (i.e. pit latrine, ventilated improved pit 
latrine, toilet or any other kind of facilities). 
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Overall, the plan is to collect 22,500 stool samples from children aged 9–12 years and 
7,500 stool samples from first-grade children at baseline (year 1) and at the end of the study 
(year 5). In years 2, 3 and 4, a total of 15,000 stool samples will be collected from children 
aged 9–12 years. Children on “drug holidays” will not be subjected to stool examination. 
 
Laboratory procedures to assess S. mansoni infection 
Fresh stool samples are transferred to central laboratories at the hospitals of Bangolo, 
Biankouma, Danané, Douékoué, Guiglo, Kouibly and Man. The stool samples are subjected 
to the Kato-Katz method (Katz et al., 1972; Knopp et al., 2013). In brief, duplicate Kato-Katz 
thick smears are prepared from each sample using standard 41.7 mg templates. After a 
clearing time of at least 60 min, the thick smears will be examined under a microscope by 
experienced laboratory technicians. Eggs of S. mansoni and soil-transmitted helminths (A. 
lumbricoides, hookworm and T. trichiura) are counted and recorded for each species 
separately. For quality control, 10% of the slides are randomly selected and re-examined by a 
senior microscopist. The results are compared with the results of the first examination by the 
team. Slides identified with discrepant results (e.g. S. mansoni egg-positive vs. egg-negative 
or difference of S. mansoni egg counts of more than 20%) are reexamined until agreement has 
been reached. Given the large number of slides processed in the eligibility survey, parts of the 
slides were transferred to Abidjan and were examined microscopically within a maximum of 
3 months after stool collection. All record sheets will be transferred to the Université Félix 
Houphouët-Boigny, where data entry, cleaning and database management take place. 
 
SBT and assessment of coverage 
District and community medical personnel are associated with the SBT in Côte d’Ivoire. 
Teachers and community health workers are trained to sensitize the communities, to 
administer drugs to the children and to monitor adverse events. Different sensitization tools 
are implemented such as radio and television announcements, along with other IEC strategies. 
During SBT, praziquantel is administered by trained teachers to all children attending school. 
Children in all schools in the community are treated, even if the school is not among the 75 
schools where children are being tested. Efforts are made to reach out to non-enrolled children 
to enhance treatment coverage. Treatment is supervised by physicians and implemented by 
trained school teachers. Praziquantel tablets are delivered using a WHO dose pole (Montresor 
et al., 2002). Children are monitored for adverse events for 4 hours after treatment and, if 
need be, appropriate medical action is taken. Treatment will be led by the PNL-SGF, and 
 43 
 
supported by staff from the Programme National de Santé Scolaire et Universitaire (PNSSU). 
Financial support to facilitate treatment is provided by SCORE, while praziquantel tablets are 
supplied by the Schistosomiasis Control Initiative (SCI). 
 
Data collection, management and statistical analysis 
In the eligibility and baseline surveys, data are collected on paper form, but then, starting at 
year 2, smartphones have been utilised for data collection in the field and laboratory. Data 
cleaning and management is done by a designated database manager (PKY) at the Université 
Félix Houphouët-Boigny in Abidjan. Demographic and parasitological data directly entered in 
smartphones are uploaded to a database maintained on a central server (Open Data Kit) hosted 
by the SCORE secretariat at the Task Force for Global Health in Atlanta, United States of 
America. Data from questionnaire records will be entered in Microsoft Excel (2010 Microsoft 
Corporation). Statistical analyses will be carried out in STATA version 12 (StataCorp.; 
College Station, TX, USA). The primary outcome will be the change in prevalence and 
intensity of S. mansoni infection in the cohort of 9- to 12-yearold children over the four years 
of intervention. For each year, prevalence and infection intensity data will be calculated as 
described below. The results from the different study arms will be compared on an annual 
basis and at the end of the 4-year intervention period. Each child with at least one S. mansoni 
egg identified in at least one of the Kato-Katz thick smears will be considered as positive. 
Eggs per gram of stool (EPG) will be determined for each child by calculating the arithmetic 
mean S. mansoni egg counts from all Kato-Katz thick smear readings and by multiplication 
with a factor 24. The S. mansoni infection intensity will be categorised according to WHO 
guidelines into light infection (1–99 EPG), moderate infection (100–399 EPG) and heavy 
infection (≥400 EPG) (WHO, 2002). 
School attendance rate will be documented throughout the study. The treatment 
coverage will be determined by (i) calculating the percentage of pupils treated among the total 
children registered in the school and (ii) calculating the percentage of school-aged children 
not attending school who are treated according to data from community health workers.  
To guarantee the privacy of individuals, a separate and confidential file will be kept, 
detailing names against ID numbers. All data will be stored in purpose-built MS Excel files 
with no names but only ID numbers and will be kept by the data manager at the Université 
Félix Houphouët-Boigny. A safety copy will be stored in a secured locker. Only authorized 
persons will have access to the data within the context of the project, and the data will be 
backed-up regularly and safely. In addition, all work stations of data entry clerks will be 
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protected by case-sensitive passwords and there will be no sharing of any account or 
password information between staff and other individuals not concerned with the project. 
When discussing or showing the results of analyses in public venues, the information will 
always be reported at an aggregate level so that individual participants cannot be identified. 
 
Protocol review and ethical clearance 
The study protocol has been approved by the institutional research commissions of Swiss 
TPH in Basel and CSRS in Abidjan. Ethical approval was obtained from the ethics 
committees in Basel (reference no. EKBB 279/10; Basel, 21 October 2010) and Côte d’Ivoire 
(reference no. 1994 MSHP/CNER; Abidjan, 5 May 2010). The trial is registered at controlled-
trials.com (identifier: ISRCTN99401114; date assigned: 12 November 2014). Informed 
consent is obtained from parents or legal guardians of all pupils involved in the study. 
Children are treated with praziquantel (40 mg/kg) using a dose pole (Montresor et al., 2002) 
in the frame of SBT. Efforts will be made to reach out to non-enrolled children.  
The results of this study may be published, but subjects’ names or identities will not be 
revealed. Records will remain confidential and the results of tests will be codified to prevent 
association with participants’ names. Data entered into computerized files will be accessible 
only by authorized personnel directly involved in the study. Subject-specific information will 
be provided to medical personnel only with the subject’s permission. 
 
2.4. Discussion 
Human schistosomiasis is a chronic and debilitating disease responsible for an estimated 
global burden of 3.3 million disability-adjusted life years (Murray et al., 2012). In Africa, 230 
million people currently require preventive chemotherapy (Vos et al., 2012). The goal set by 
the WHO for the year 2020 is to treat at least 75% of school-aged children at risk of 
schistosomiasis with praziquantel as the only drug (WHO, 2013). Various partners, 
institutions and pharmaceutical companies have agreed in the London Declaration of 2012 
that they will contribute to achieving this goal with donation of praziquantel and other support 
to facilitate and sustain drug administration at large scale (WHO., 2012a). The SCORE study 
described here will provide an evidence base for programme decisions about the type and 
frequency of preventive chemotherapy that is required to sustain control of schistosomiasis 
mansoni in areas where the baseline prevalence of infection ranges between 10% and 24%. 
The study will show for well characterized settings across Africa which treatment scheme 
(yearly treatment of school-aged children, or treatment interspaced by holidays) will yield the 
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best result and at what cost. Moreover, factors that determine the effectiveness of large-scale 
deworming will be identified. These factors will help to develop measures of force of 
transmission that can be utilised to make decisions about the most cost-effective means of 
lowering the prevalence and intensity of Schistosoma infection and the force of the 
transmission in a given setting. The data generated might shape future treatment schedules to 
sustain the control of schistosomiasis at low level elsewhere in sub- Saharan Africa and 
perhaps in Asia and Latin America where schistosomiasis also remains endemic, in 
preparation for a move to eliminate this disease in suitable locations. 
In western Côte d’Ivoire, infections with S. mansoni are common (Doumenge et al., 1987; 
Utzinger et al., 1998; Raso et al., 2005) but until the mid-1990s, the extent of endemicity was 
not well understood. Some control efforts had been implemented in the 2000s, but due to a 
decade-long socio-political crisis, control had been interrupted (Tchuem Tchuenté & 
N’Goran, 2009; Bonfoh et al., 2011). The large eligibility study conducted to select 75 
villages with a moderate S. mansoni prevalence (10-24%) clearly revealed that S. mansoni in 
the western part of Côte d’Ivoire is rampant; among 264 schools screened, 157 (59.5%) had a 
S. mansoni prevalence above 24%, while 78 schools (29.5%) were in the desired prevalence 
range of 10-24% and only 29 schools (11.0%) had a prevalence below 10%. The eligibility 
survey employed an insensitive diagnostic approach (i.e. duplicate Kato-Katz thick smears 
based on a single stool sample). Had more intensive sampling and a more sensitive diagnostic 
method been employed (e.g. three stool samples subjected to triplicate Kato-Katz per stool 
sample or a point-of-care circulating cathodic antigen (POC-CCA) urine cassette test), a much 
higher overall prevalence of S. mansoni would have been found (de Vlas & Gryseels, 1992; 
Utzinger et al., 2001; Booth et al., 2003; Enk et al., 2008; Colley et al., 2013). In order to 
respect World Health Assembly (WHA) resolution 54.19 endorsed in May 2001, which 
emphasizes preventive chemotherapy targeting school-aged children to control morbidity 
(WHO, 2001), and in view of a more ambitions WHA resolution 65.21 put forth in May 2012, 
the new declared goal is to move from morbidity control to elimination of schistosomiasis 
(Knopp et al., 2013; Rollinson et al., 2013). Hence, authorities of Côte d’Ivoire have 
established the PNL-SGF in June 2007 (Tchuem Tchuenté & N’Goran, 2009). Hand-in-hand 
with the SCORE sustaining schistosomiasis control operational research study reported here, 
the national schistosomiasis control programme was reinforced, with additional support from 
SCI. This study will provide data that may be used by SCORE, SCI, WHO and other partners 
to deploy the best tools and strategies to control morbidity due to schistosomiasis, and thus 
contribute to the reduction of poverty in schistosomiasis-endemic countries. 
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3.1. Abstract 
Schistosomiasis poses a considerable public health burden in sub- Saharan Africa and a sound 
understanding of the spatial distribution facilitates to better target control interventions. The 
objectives of this study were i) to assess the prevalence of Schistosoma mansoni among 
school-aged children in four regions of western Côte d’Ivoire; ii) to determine demographic, 
climatic and environmental factors that influence the distribution of S. mansoni; and iii) to 
map and predict the distribution of S. mansoni in non-sampled locations. Parasitological 
surveys were carried out in 264 schools from June to December 2011. In each school, we 
aimed to examine 50 children for S. mansoni infection using duplicate Kato-Katz thick 
smears. Schools were georeferenced using a hand-held global positioning system receiver. 
Demographic data were obtained from readily available school lists, while climatic and 
environmental data were extracted from open-access remote sensing databases. Multivariable, 
binary non-spatial models and a Bayesian geostatistical logistic regression model were used to 
identify demographic, climatic and environmental risk factors for S. mansoni infection. Risk 
maps were developed based on observed S. mansoni prevalences and using Bayesian 
geostatistical models to predict prevalences at non-sampled locations. Overall, 12,462 
children provided a sufficiently large stool sample to perform at least one Kato-Katz thick 
smear. The observed overall prevalence of S. mansoni infection was 39.9%, ranging from 0 to 
100% at the unit of the school. Bayesian geostatistical analysis revealed that age, sex, altitude 
and difference between land surface temperature at day and night were significantly 
associated with S. mansoni infection. The S. mansoni risk map presented here is being been 
used by the national schistosomiasis control programme for spatial targeting of praziquantel 
and other interventions. 
 
3.2. Introduction 
Despite increasing efforts to control schistosomiasis, this chronic, parasitic disease still affects 
more than 250 million people and causes a global burden of 3.3 million disability-adjusted 
life years (DALYs) (Murray et al., 2012; Hotez et al., 2014). There are six Schistosoma 
species infecting humans and the most important ones are: S. haematobium, S. japonicum and 
S. mansoni (Gryseels et al., 2006; Colley et al., 2014). In sub-Saharan Africa, urogenital 
schistosomiasis (caused by S. haematobium) and intestinal schistosomiasis (caused by S. 
mansoni) inflict a considerable public health problem, particularly in poor rural communities 
(King, 2010; Utzinger et al., 2011). 
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The main measures for controlling schistosomiasis are i) preventive chemotherapy 
(i.e. large-scale distribution of the antischistosomal drug praziquantel to populations at risk of 
infection to prevent morbidity); ii) improvement of clean water supply and sanitation; iii) 
intermediate host snail control; and iv) information, education and communication (IEC) 
targeting high-risk populations to limit their infection exposure by behavior change (Engels et 
al., 2002; WHO, 2002; Utzinger et al., 2011; Knopp et al., 2013; Rollinson et al., 2013; 
Grimes et al., 2014). To adequately target preventive chemotherapy and other control 
measures against schistosomiasis, the endemicity levels need to be known. High-risk 
communities can be identified, for example, by screening urine or stool specimens of school-
aged children for Schistosoma eggs, or by assessing self-reported blood in urine or stool, or 
self-reported exposure to natural open freshwater bodies using questionnaires (Lengeler et al., 
2002a; WHO, 2002).  
Numerous studies have demonstrated that geographical information system (GIS), 
remote sensing and geostatistical analysis are powerful approaches for disease risk profiling 
and risk mapping at large-scale (Brooker et al., 2003; Raso et al., 2006; Clements et al., 2009; 
Karagiannis-Voules et al., 2015). Particularly in developing countries, where resources for 
disease control are scarce, these means can assist health authorities in identifying high risk 
areas, including very remote settings, which are difficult to access, and in adequately targeting 
intervention measures for disease control (Stensgaard et al., 2005). In Côte d’Ivoire, these 
epidemiological and geostatistical tools were previously applied to study the impact of 
environmental change on the prevalence of Buruli ulcer (Brou et al., 2008) and to map and 
predict the spatial distribution of schistosomiasis in the mountainous region of Man (Raso et 
al., 2005) and across the country (Chammartin et al., 2014).  
Schistosomiasis is characterised by a focal distribution, which is the result of a 
complex interplay of behavioural, climatic and environmental factors that influence the 
dynamics and density of intermediate host snails and the infection prevalence and intensity in 
humans. For example, distance from people’s residency to open freshwater bodies is usually 
negatively associated with the prevalence of S. haematobium (Rudge et al., 2008) and S. 
mansoni (Handzel et al., 2003; Odiere et al., 2012). Altitude is also an important factor 
associated with the occurrence of schistosomiasis (Kabatereine et al., 2004; Raso et al., 2005). 
Biomphalaria pfeifferi, the intermediate host snail of S. mansoni, requires temperature values 
ranging between 15 and 31°C and pH values ranging from 6.8 to 8.6, to thrive successfully 
(Utzinger et al., 1997; McCreesh and Booth, 2014; Walz et al., 2015). Bulinus globosus, one 
of the intermediate host snails of S. haematobium, shows preferences for freshwater bodies 
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with temperatures ranging from 14 to 32°C and pH values from 6.0 to 7.8  (Woolhouse and 
Chandiwana, 1990; Yapi et al., 2014b; Walz et al., 2015). Hence, for schistosomiasis risk 
prediction, it is important that multiple environmental factors are considered. 
 The goal of the current study was to generate a risk map for S. mansoni in four regions 
of western Côte d’Ivoire that can help the national schistosomiasis control programme in 
decision making for adequately targeting preventive chemotherapy and other control 
interventions. The data were obtained from a large-scale eligibility survey conducted as part 
of a sustaining schistosomiasis control project requested by the Schistosomiasis Consortium 
for Operational Research and Evaluation (SCORE) (Assaré et al., 2014). The risk maps 
already proved useful for the national schistosomiasis control programme in Côte d’Ivoire. 
 
3.3. Materials and methods 
 
3.3.1. Ethical considerations 
The institutional research commissions of the Swiss Tropical and Public Health Institute 
(Basel, Switzerland) and the Centre Suisse de Recherches Scientifiques en Côte d’Ivoire 
(Abidjan, Côte d’Ivoire) approved the study protocol. Ethical clearance was provided by the 
ethics committees in Basel (reference no. EKBB 279/10) and the Ministry of Public Health in 
Côte d’Ivoire (reference no. 1994 MSHP/CNER).  
Before launching any field activities, the region education directors, education 
inspectors and officers were informed about the objectives and procedures of the study. These 
authorities informed village leaders and teachers who then informed village committees and 
schoolchildren, respectively. At the day of the survey, teachers and schoolchildren were 
provided with additional information about the study purpose and field and laboratory 
procedures. Written informed consent was obtained from parents and legal guardians of 
children. Children found infected with S. mansoni were treated with praziquantel, 
administered at a single oral dose of 40 mg/kg of body weight (WHO, 2002). 
 
 
3.3.2. Study area and population 
The study was carried out in four regions of western Côte d’Ivoire: Cavally, Guemon, 
Tonkpi and Haut-Sassandra, extending from 6°28’47.5’’ to 7°52’10.0’’ N latitude and from 
6°44’09.8’’ to 8°21’30.0’’ W longitude (Figure 3.1). The Cavally, Guemon and Tonkpi 
regions  
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Figure 3.1: Map of Côte d’Ivoire with the four study regions in the western part of the 
country. 
 
are mountainous areas with an average elevation ranging from 300 m above mean sea level 
(amsl) to slightly above 1000 m amsl (Raso et al., 2005; Kouassi et al., 2012; Gone Bi et al., 
2013). The rainy season occurs from March to October. The Haut-Sassandra region is located 
east of the Sassandra River and its average altitude ranges between 200 and 300 m amsl (Yapi 
et al., 2014a). The climate is sub-equatorial, characterised by two rainy seasons. The long 
rainy season lasts from March to July and the short rainy season occurs in September and 
October. 
 People living in the western part of Côte d’Ivoire belong to two main ethnicities: 
Mandé and Krou. People are mainly engaged in subsistence agriculture (cassava, maize, 
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plantain and rice). Rice growing is the most important agricultural activity, leading to a high 
frequency of contact with water. There is also production of cash crops (coffee, cocoa and 
rubber cultivation) and a small forestry industry in the town of Man (Utzinger et al., 2000).  
Schistosomiasis, soil transmitted helminthiasis, malaria, giardiasis and amoebiasis are 
highly endemic in the study area (Raso et al., 2005; Matthys et al., 2006; Ouattara et al., 
2008; Silué et al., 2008). 
 
3.3.3. Parasitological survey 
A cross-sectional parasitological survey was carried out in 264 schools from June to 
December 2011. The schools were selected based on accessibility by 4 wheel drive cars and 
number of registered children (≥200 pupils). Lists of schools and sketch maps of the four 
regions were used for planning the surveys. After receiving consent from the headmaster, 
teachers prepared class lists, including name, age and sex of all children. In each school, we 
aimed at selecting 50 children attending grades 4-6, as described elsewhere (Assaré et al., 
2014). In brief, children aged 13 years and above were selected from grades 4-6 until the 
number of children reached 50. In settings where less than 50 children in this age range were 
present, the sample was completed with younger children. Children with written informed 
consent from their parents or legal guardians were given a 125 mL plastic container and asked 
to return it with a small portion of their own stool. The containers were collected and labelled 
with unique identification numbers.  
Stool specimens were transferred to central laboratories in Douékoué and Man and 
processed with the Kato-Katz technique (Katz et al., 1972). Duplicate Kato-Katz thick smears 
were prepared from each stool specimen using 41.7 mg templates. After a clearing time of 60 
min, the thick smears were examined under a microscope by one of five experienced 
laboratory technicians. S. mansoni eggs were counted and recorded. For quality control, 10% 
of the slides were selected (one slide chosen out of each 10 slides read) and re-examined the 
same day by a senior microscopist. In case of conflicting results, the slides were read a third 
time and the results discussed until agreement was reached (Speich et al., 2015). 
 
3.3.4. Climatic and environmental data 
Geographical coordinates of each school were collected using a hand-held global positioning 
system (GPS) receiver (Garmin Etrex 30; Garmin, Olathe, KS, USA). Climatic data were 
obtained from readily available remote sensing sources (Table 1). Land surface temperature at 
day (LSTDay), land surface temperature at night (LSTNight) and rainfall estimate (RFE) 
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were obtained for the period of 2011-2012. Rainfall estimate data with an 8×8 km spatial 
resolution from Meteosat 7 satellite were obtained from the Africa Data Dissemination 
Service (http://earlywarning.usgs.gov/adds/index.php). Land surface temperature at day and 
night data were downloaded from the Moderate Resolution Imaging Spectroradiometer 
(MODIS) from the United States Geographical Survey - Earth Resources Observation and 
Science Data Center (http://modis.gsfc.nasa.gov). 
 
3.3.5. Statistical analysis 
Children were classified into three age groups (i.e. 8-12, 13-14 and 15- 19 years). Land cover 
was included into the model as categorical covariate. Continuous variables were standardised 
to mean zero, including standard deviation (SD). Pearson’s correlation was calculated 
between continuous variables and was further used to check for variables with a high 
correlation coefficient (>0.9) to avoid colinearity. 
Table 3.1: Remote sensing data sources used for risk profiling of Schistosoma mansoni in 
western Côte d'Ivoire. 
Source Data type Data period Temporal 
resolution 
Spatial 
resolution 
MODIS
a
 LST
g
 03/2011-02/ 2012 8 days 1 km 
MODIS
a
 NDVI
h
 03/2011-02/ 2012 16 days 1 km 
MODIS
a
 Land cover 2001-2004 Year 1 km 
WorldClim
b
 Elevation 2000 - 1 km 
FEWS NET
c
 Rainfall 03/2011-02/ 2012 10 days 8 km 
SWBD
d
 Water bodies 2000 - 30 m 
ISRIC
e
 Soil types - - 8 km 
Bayesian Kriging
f
 Improved sanitation 1991-2012 - 5 km 
Bayesian Kriging
f
 Better drinking-water  1991-2012 - 5 km 
LSTDay
g
 SD
j
 of LSTDay 03/2011-02/ 2012  1 km 
LSTNight
h
 SD
j
 of LSTNight 03/2011-02/ 2012  1 km 
diffLST
i
  LSTDay minus LSTNight 03/2011-02/ 2012  1 km 
Rainfall SD
i
of rainfall data  03/2011-02/ 2012  1 km 
a
The moderate resolution imaging spectroradiometer (MODIS; https://mrtweb.cr.usgs.gov/). 
b
Global climate data (WorldClim) (http://www.worldclim.org/current).   
c
The famine early warning systems network (FEWS NET; 
http://earlywarning.usgs.gov/adds/index.php). 
d
The shuttle radar topography mission (SRTM) water body data (SWBD; 
http://gis.ess.washington.edu/data/vector/worldshore/index.html). 
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e
The international soil reference and information center (ISRIC; 
http://www.isric.org/data/isric-wise-derived-soil-properties-5-5-arc-minutes-global-grid 
version-12). 
f
Based on household data from demographic and health surveys (DHS; 
http://www.measuredhs.com), multiple cluster indicator surveys (MICS; 
http://www.childinfo.org/mics.html), world health surveys (WHS; 
http://www.who.int/healthinfo/survey/en/index.html) and living standards measurement study 
(LSMS; http://iresearch.worldbank.org/lsms/lsmssurveyFinder.htm). 
g
Land surface temperature at day. 
h
Land surface temperature at night. 
h
The normalized difference vegetation index. 
i
Difference between LSTDay and LSTNight 
j
Standard deviation. 
 
We implemented Bayesian variable selection to identify the best set of predictors. Briefly, 
normal mixture of inverse Gammas with parameter expansion (peNMIG) spike-and-slab 
priors was applied on the model (Scheipl et al., 2012). We used mixed inverse Gamma 
distributions for the priors of the coefficients. One component (exclusion component) is a 
narrow spike around zero, while the other component (inclusion component) is a wide slab 
away from zero. For categorical variables, we applied a peNMIG prior that allows to 
simultaneously including or excluding all coefficients related with the categories of the same 
variable, by improving shrinkage properties (Scheipl et al., 2012). We included the variables 
with the inclusion component predominant (i.e. a posterior probability higher than 50%) into 
our final geostatistical model. The details of the method have been described elsewhere (Lai 
et al., 2013). 
Bayesian geostatistical logistic regression models with spatially structured random 
effects were applied to obtain spatially explicit S. mansoni estimates. Specifically, we 
assumed that the number of positive individuals Yi arises from a binominal distribution Yi 
~Bn(pi, ni), where logit(pi) = 0 + k=1k×Xi
(k)+i+i. ni and pi indicate the number of those 
examined and the probability of infection at location i (i=1,2,…, L). k, i and i represent the 
regression coefficient of the k
th
 covariate Xi
(k)
, location-specific random effect and 
exchangeable non-spatial random effect, respectively. We assumed ~MVN(0,) with a 
covariance function ij =
2
sp exp(–dij), where dij is the Euclidean distance between location i 
and j, and corresponds to the rate of correlation decay. We assumed an inverse gamma 
hyper-prior distribution for 2sp and a gamma hyper-prior distribution for . The spatial 
range, which is considered as the minimum distance of the spatial correlation less than 10%, 
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can be calculated as – log(0.1)/. i was assumed to follow a zero-mean normal distribution 
i~N(O,
2
nonsp). We assigned the prior distributions as follows: 0,k~N(0,100), 
2
sp ~ 
IG(0.01,0.01),
2
nonsp ~ IG(0.01,0.01) and ~G(0.01,0.01). Markov chain Monte Carlo 
simulation was employed to estimate the model parameters in Openbugs version 3.0.2 
(Imperial College London and Medical Research Council, London, UK) (Lunn et al., 2009). 
Gelman and Rubin diagnostics was used to assess the convergence by the coda library in R 
(Gelman & Rubin, 1992; Plummer et al., 2006). A 1×1 km grid was overlaid to the study 
region, resulting in 53,820 pixels. Bayesian kriging was done to predict the S. mansoni 
infection risk at the centroids of the grid’s pixels. 
 
3.3.6. Model validation 
We randomly selected a subset of the data (training set), including approximately 80% 
of survey locations for model fitting and subsequently assessed the model performance on the 
remaining 20% (test set). Mean error (ME), that is the expectation of differences between the 
observed and predicted prevalence, and the percentage of observations included in Bayesian 
credible intervals (BCI) of various probability coverages of predictions on test set locations 
were calculated. 
 
3.4. Results 
 
3.4.1. Study cohorts 
Sufficiently large stool samples were collected from 12,462 schoolchildren. There were 8151 
(65.4%) males and 4311 (34.6%) females. The age ranged between 8 and 19 years; 1914 
children (15.4%) were 8- 12 years old, 9043 (72.6%) were 13-14 years old and the remaining 
1505 (12.0%) were 15-19 years old. Around half of the schools (n=131, 49.6%) were located 
in to the Tonkpi region. There were 113 schools (42.8%) in the Guemon region, while only 13 
(4.9%) and 7 (2.7%) schools were included in the Haut-Sassandra and Cavally region, 
respectively. 
 
 
3.4.2. Parasitological data 
Among the 264 schools, 157 (59.5%) had a S. mansoni prevalence above 24%, 78 (29.5%) 
schools had a prevalence ranging between 10 and 24%, whilst the remaining 29 schools 
(11.0%) had a prevalence below 10%. The overall prevalence of S. mansoni was 39.9%. Boys 
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showed a statistically significantly higher prevalence of S. mansoni than girls (42.9% vs 
34.2%; χ²= 88.76, P<0.001). The prevalence of infection was 33.5, 41.0 and 40.9% among 
children aged 8-12, 13-14 and 15-19 years, respectively. Figure 3.2 displays the S. mansoni 
infection prevalence in each of the 264 schools. At the unit of the school, the prevalence of S. 
mansoni ranged from 0 to 100%. High prevalence rates were predominantly found in the 
Tonkpi region. Moderate infection prevalences (10-24%) were mostly found in Gomon and 
Cavally regions. In the schools of Haut-Sassandra, the prevalence of S. mansoni was 
consistently below 24%. 
 
3.4.3. Spatial statistical modelling and validation result 
The Bayesian variable selection identified the following predictors: sex, age group, difference 
of LST between day and night (diffLST) and altitude. The Bayesian geostatistical logistic 
regression model was able to correctly estimate (within a 95% BCI) 81.2% for S. mansoni at 
the test locations. The ME was 4.6%, which means the model may underestimate the risk of S. 
mansoni infection.  
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Figure 3.2: Observed Schistosoma mansoni infection prevalence in 264 schools in western 
Côte d'Ivoire, as assessed in a cross-sectional survey from June to December 2011. 
 
3.4.4. Relationship between Schistosoma mansoni and environmental factors 
Table 2 summarises the key findings with respect to the relationship between S. mansoni and 
demographic, environmental and climatic factors. Children from the oldest age group (15-19 
years) had higher odds of S. mansoni infection compared to those aged 8-12 years (odds ratio 
(OR)=1.35, 95% BCI: 1.12; 1.65). We did not find significant difference of S. mansoni 
prevalence rates between children aged 13-14 years and 8-12 years. Boys had higher odds of 
S. mansoni infection than girls (OR=1.58, 95% BCI: 1.43; 1.73). 
Altitude was negatively associated with the prevalence of S. mansoni (OR=0.49, 95% 
BCI: 0.28; 0.70). We found a positive correlation between diffLST and S. mansoni infection 
(OR=1.36, 95% BCI: 1.12; 1.60). 
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Table 3.2: Posterior summaries (median and 95% Bayesian credible interval) of odds 
ratios of the geostatistical model parameters for Schistosoma mansoni infection. 
Variable Multivariable non-spatial Binary non-spatial Geostatistical model 
Sex 1.43 (1.32; 1.55)* 1.45 (1.34; 1.55)* 1.58 (1.43; 1.73)* 
Age group 1 1.36 (1.22; 1.51)* 1.38 (1.25; 1.54)* 1.15 (0.99; 1.35) 
Age group 2 1.34 (1.16; 1.54)* 1.38 (1.20; 1.58)* 1.35 (1.12; 1.65)* 
Altitude 1.01 (0.98; 1.05) 1.03 (0.99; 1.06) 0.49 (0.28; 0.70)* 
diffLST 1.00 (0.96; 1.04) 1.01 (0.98; 1.05) 1.36 (1.12; 1.60)* 
Range   181.31 (72.98; 460.24) 
σ2sp   3.03 (1.36; 8.26) 
σ2nonsp   0.88 (0.63; 1.14) 
 
diffLST, difference between land surface temperature at day and at night. *Significant 
correlation based on 95% confidance interval or 95% Bayesian credible interval. 
 
3.4.5. Spatial analysis of Schistosoma mansoni infection 
The main results derived from the multivariable and the binary nonspatial logistic regression 
models are summarised in Table 2. The nonspatial multivariable logistic regression model 
revealed a significant association between the prevalence of S. mansoni and sex (OR=1.43, 
95% BCI: 1.32; 1.55), and age (age group 13-14 years, OR=1.36, 95% BCI: 1.22; 1.51; and 
age group 15-19 years, OR=1.34, 95% BCI: 1.16; 1.54 compared to age group 8-12 years). 
There was no association between S. mansoni infection and altitude and diffLST. The binary 
non-spatial model showed that disease transmission was significantly associated with sex 
(OR=1.45, 95% BCI: 1.34; 1.55) and age (age group 13-14 years OR=1.38, 95% BCI: 1.25; 
1.54; age group 15- 19 years, OR=1.38, 95% BCI: 1.20; 1.58 compared to age group 8-12 
years). However, there was no association between S. mansoni infection and climatic and 
environmental factors. Table 2 also shows the principal findings of the Bayesian geostatistical 
logistic regression model. Age, sex and diffLST were positively correlated with S. mansoni, 
whilst altitude showed a significant negative association with S. mansoni infection 
prevalence. 
 
3.4.6. Spatial prediction of Schistosoma mansoni infection 
Figure 3.3 shows the predicted S. mansoni infection prevalence in the study area for boys and 
girls with different age groups, and Figure 3.4 displays the corresponding prediction 
uncertainty. A very high prevalence of S. mansoni (>50%) was predicted predominantly in the 
Tonkpi region. Some focal high-prevalence schools were also predicted in central Gomon and  
northern Haut-Sassandra regions. 
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Figure 3.3: Predicted Schistosoma mansoni infection prevalence in the four study regions 
of western Côte d'Ivoire. 
Predicted prevalence among girls aged 8-12 years (A), boys aged 8-12 years (B), girls aged 
13-14 years (C), boys aged 13-14 years (D), girls aged 15-19 years (E) and boys aged 15-19 
years (F). 
 
 66 
 
 
Figure 3.4: Prediction uncertainty of the posterior predictive distribution of Schistosoma 
mansoni infection prevalence in western Côte d'Ivoire. 
Standard deviation (SD) of the posterior predictive distribution among girls aged 8-12 years 
(A), boys aged 8-12 years (B), girls aged 13-14 years (C), boys aged 13-14 years (D), girls 
aged 15-19 years (E) and boys aged 15-19 years (F). 
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Moderate prevalences of S. mansoni infection according to SCORE definition (10-24%) were 
predicted for large parts of Cavally, Haut-Sassandra and Gomon regions. Low prevalences 
(<10%) were predicted for East Cavally, south-western Haut-Sassandra and a small area in 
the northern part of Gomon region. The predicted prevalence of S. mansoni for boys was 
higher than the predicted prevalence for girls. 
 
3.5. Discussion 
Schistosomiasis remains of considerable public health importance in sub-Saharan Africa and 
a precise knowledge of high-risk areas is required for spatial targeting of control 
interventions. Within the frame of a large eligibility survey to identify schools where the 
prevalence of S. mansoni among school-aged children is 10-24%, more than 12,000 children 
were screened by duplicate Kato-Katz thick smears in four regions of western Côte d’Ivoire. 
We adhered to the SCORE harmonization protocol and aimed for children aged 13-14 years, 
but in order to have sufficient children per school, children’s age finally ranged between 8 and 
19 years. We found an overall prevalence of S. mansoni of 39.9%. Our results therefore 
confirm that S. mansoni is highly endemic in the western part of Côte d’Ivoire (Utzinger et 
al., 2000; Raso et al., 2005; Beck-Worner et al., 2007), and that the geographical extent of the 
problem is larger than previously thought. Our study also confirms that schistosomiasis is 
highly focal; (Ratard et al., 1990; Lengeler et al., 2002b; Raso et al., 2005; Hodges et al., 
2012). Indeed, while in some schools no child was infected with S. mansoni, more than half of 
the children were infected in other schools. High prevalences of S. mansoni were mostly 
found in the northern Tonkpi region, which is in line with results from previous studies (Roux 
et al., 1980; Utzinger et al., 2000; Keiser et al., 2002; Matthys et al., 2007). In the schools 
located in the Cavally and Gomon regions, S. mansoni infection prevalences mainly ranged 
between 10 and 45%. The prevalences of S. mansoni in the schools in the southern Haut-
Sassandra region were consistently below 25%. Bayesian spatial statistical analysis showed 
that demographic, environmental and climatic covariates were useful predictors explaining the 
spatial distribution of S. mansoni infection prevalence. Altitude was negatively associated 
with the distribution of S. mansoni. These observations confirm results from previous digital 
elevation models and Bayesian geostatistical analysis (Raso et al., 2005; Beck-Worner et al., 
2007). Indeed, it has been shown that children living in western Côte d’Ivoire at locations 
below 400 m amsl were at a 5-fold higher risk of S. mansoni infection when compared with 
those living at higher locations (Raso et al., 2005). However, the altitude threshold limit for S. 
mansoni transmission varies from one study setting to another (Ghebreyesus et al., 2002; 
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Kabatereine et al., 2004; Rubaihayo et al., 2008). Our study also revealed that a diffLST was 
correlated with the prevalence of S. mansoni infection. Several epidemiological studies using 
Bayesian geospatial, Gaussian and Poisson modelling documented that LSTDay was 
negatively associated with S. mansoni, while LSTNight was positively associated with the 
prevalence of S. mansoni (Hu et al., 2013a; Hu et al., 2013b; Schur et al., 2013; Scholte et al., 
2014). In contrast, previous geostatistical analysis from the Tonkpi region found no 
relationship between S. mansoni infection and diffLST (Raso et al., 2005). However, a 
limitation of the latter study was that all surveyed schools were located in the same region 
with similar environmental and climatic features such as diffLST. 
Environmental factors such as elevation influence flow velocity of rivers and LST 
shapes temperature of freshwater bodies. In turn, these factors impact on the presence of 
intermediate host snails, the parasite development within the snails and the infectivity of 
Schistosoma cercariae (Foster, 1964; Appleton, 1978; Kloos et al., 2001; Malone, 2005; 
McCreesh and Booth, 2014). A possible explanation for the observed higher prevalences of S. 
mansoni infection in the lower parts of the mountainous Tonkpi region may be the favourable 
temperature and velocity of rivers for B. pfeifferi (Shiff and Husting, 1966). Indeed, recent 
malacological studies carried out in Tonpki region confirmed a high population density of B. 
pfeifferi (Tian-Bi et al., 2013; Yapi et al., 2014b). The lower S. mansoni prevalences in the 
Haut-Sassandra region might be due to less favourable environmental conditions for 
the development of B. pfeifferi. Instead, the conditions in this area seem to rather suit the 
development of B. globosus, an important intermediate host snail of S. haematobium (Cadot et 
al., 1998; Fournet et al., 2004). 
A limitation of our study is that no intermediate host snails were collected. Moreover, 
only one stool sample per individual was subjected to duplicate Kato-Katz thick smears. This 
diagnostic approach has a low sensitivity for S. mansoni, particularly for detection of light-
intensity infections (Engels et al., 1996; Utzinger et al., 2001; Booth et al., 2003; Enk et al., 
2008). Few schools were surveyed in Cavally and Haut- Sassandra regions. The relatively 
small number of survey locations in this area may have negatively affected the prediction 
accuracy. Lastly, our final model did not include rainfall and socioeconomic status, as these 
factors were not picked up by our variable selection procedures. However, both variables play 
a role for snail breeding and human infection as shown before (Raso et al., 2005; Muhumuza 
et al., 2009; Xue et al., 2011). 
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3.6. Conclusion 
In conclusion, pursuing a Bayesian geostatistical analysis using a large set of georeferenced S. 
mansoni prevalence data from a SCORE eligibility survey (Assaré et al., 2014) allowed risk 
profiling of S. mansoni in four regions of western Côte d’Ivoire. The generated risk maps 
have already been utilised by the national schistosomiasis control programme. As control 
efforts in the western part of Côte d’Ivoire and elsewhere in the country move ahead, it will 
be very interesting to monitor changes over time. 
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4.1. Abstract 
We report baseline findings before the implementation of a 4-year intervention trial designed 
to assess the impact of three different school-based treatment schedules with praziquantel to 
sustain the control of intestinal schistosomiasis. The baseline survey was conducted in 75 
schools of western Côte d’Ivoire previously identified with moderate Schistosoma mansoni 
endemicity (prevalence: 10-24% in children aged 13-14 years). Three stool samples collected 
over consecutive days were subjected to duplicate Kato-Katz thick smears each. A 
questionnaire was administered to collect village-specific information that is relevant for 
schistosomiasis transmission. Overall, 4,953 first graders (aged 5–8 years) and 7,011 school 
children (aged 9–12 years) had complete parasitologic data. The overall prevalence of S. 
mansoni was 5.4% among first graders and 22.1% in 9- to 12-year-old children. Open 
defecation was practiced in all villages. The current baseline findings will be important to 
better understand the dynamics of S. mansoni prevalence and intensity over the course of this 
trial that might be governed by village characteristics and specific treatment interventions. 
 
 
4.2. Introduction 
Schistosomiasis, a water-associated disease, remains a relevant public health problem in the 
tropics and subtropics. Indeed, schistosomiasis affects more than 250 million people with an 
estimated global burden of 3.9 million disability adjusted life years (Murray et al., 2012; 
Hotez et al., 2014). In 2013, some 121 million school-aged children were considered at risk of 
schistosomiasis, with more than 90% of them concentrated in sub-Saharan Africa (WHO, 
2015). In this region, approximately one-third of the schistosomiasis cases are caused by the 
species Schistosoma mansoni (van der Werf et al., 2003). 
Since the mid-1980s, the World Health Organization (WHO) recommends preventive 
chemotherapy, that is, the large scale population-based mass drug administration (MDA) of 
praziquantel, as the main pillar of schistosomiasis control (WHO, 1985). The target is to treat 
at least 75% and up to 100% of school aged children at risk of schistosomiasis with 
praziquantel (WHO, 2002; WHO, 2013). In 2012, numerous institutions and private 
organizations approved and decided to support this goal (WHO, 2012a). According to WHO 
guidelines, the frequency of treatment in the school aged population (children aged 5–14 
years regardless of whether they are enrolled in school) is 1) once every year in high-risk 
communities (prevalence: ≥ 50% measured by parasitologic methods); 2) once every second 
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year in moderate risk communities (prevalence: 10–49%); and 3) twice during primary school 
age in low-risk communities (prevalence: < 10%) (WHO, 2013). To strengthen the current 
evidence base for program decisions about preventive chemotherapy to gain and sustain the 
control of schistosomiasis, the Schistosomiasis Consortium for Operational Research and 
Evaluation (SCORE; http://score.uga.edu/) designed a multi-country study with several 
treatment arms implemented over multiple years (Assaré et al., 2014; Colley, 2014). 
In contrast to other schistosomiasis-endemic parts of the world where considerable 
progress in the fight against schistosomiasis has been achieved over the past decades (e.g., 
Brazil and China) (Utzinger et al., 2005; Bergquist, 2008), control efforts in sub-Saharan 
Africa were less successful, partially explained by low coverage and rapid reinfection rates 
after MDA campaigns (Danso-Appiah and De Vlas, 2002; Clements et al., 2009; WHO, 
2015). To deepen our understanding why schistosomiasis control interventions, including 
preventive chemotherapy, are more or less successful, it is important to consider determinants 
of disease transmission, such as hydrogeographic features, access and use of clean water, 
improved sanitation and hygiene, and socioeconomic characteristics of local communities 
(Steinmann et al., 2006; WHO., 2012b; Knopp et al., 2013; Grimes et al., 2014). 
This article describes the baseline parasitologic situation and village characteristics of 
the 75 communities in western Côte d’Ivoire that were randomized to one of the three 
intervention arms of a SCORE study to determine the effect of different treatment schedules 
to sustain schistosomiasis control in moderate endemicity areas (Assaré et al., 2014). In each 
school, some 100 children (usually 9-12 years) submitted three consecutive stool samples that 
were subjected to duplicate Kato-Katz thick smears each. We also compared our S. mansoni 
prevalence data with results from a previous large-scale eligibility survey while screening 50 
children aged 13–14 years with a single stool sample subjected to duplicate Kato-Katz thick 
smears. We show how fragile the categorization into risk communities is, based on simple 
prevalence thresholds, as it depends on the age of subjects screened, sampling efforts, 
diagnostic approach, among other issues. 
 
4.3. Materials and methods 
4.3.1. Ethics statement 
Ethical approval for this study was obtained from the ethics committees of the Ministry of 
Public Health in Abidjan, Côte d’Ivoire (reference no. 1994 MSHP/CNER) and the 
‘Ethikkommission beider Basel’ in Basel, Switzerland (reference no. EKBB 297/10). The 
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purpose of the study was explained to education and health authorities. An information sheet 
was delivered to participating school children and written informed consent was obtained 
from their parents or guardians. At the end of the baseline parasitologic survey, all children 
aged 5–15 years living in the study area were offered praziquantel treatment (40 mg/kg) 
provided free of charge by the “Programme National de Lutte contre la Schistosomiase, les 
Géohelminthiases et la Filariose Lymphatique.” Praziquantel treatment was given to children 
using the WHO dose pole (Montresor et al., 2002). 
 
4.3.2. Study area and population 
As shown in Figure 4.1, the study is being implemented in four regions of western Côte 
d’Ivoire: Cavally, Guemon, Tonkpi, and Haut-Sassandra, extending from 06°28′47.5″ to 
07°52′10.0″ N latitude and from 06°44′09.8″ to 08°21′30.0″ W longitude. Previous studies 
showed that S. mansoni is highly endemic in this area, while S. haematobium coexists in some 
areas (Doumenge et al., 1987; Utzinger et al., 2000; Fournet et al., 2004; Raso et al., 2005; 
Chammartin et al., 2014). Previous malacologic surveys revealed that Biomphalaria pfeifferi 
and Bulinus globosus act as intermediate host snail of S. mansoni and S. haematobium, 
respectively (Cadot et al., 1998; Fournet et al., 2004; Matthys et al., 2007; Yapi et al., 2014a; 
Yapi et al., 2014b). In a cross-sectional survey carried out between June 19 and August 22, 
2011, and between December 4 and 22, 2011, to identify communities eligible to participate 
in this SCORE study, the S. mansoni prevalence was determined in 264 schools (Assaré et al., 
2014). In each school, 50 children aged 13–14 years were examined by duplicate Kato-Katz 
thick smears on a single stool sample. S. mansoni prevalence rates above 24% were mainly 
observed in Tonkpi region, while schools with prevalence of infection ranging between 10% 
and 24% were predominantly found in Gomon, Cavally, and Haut-Sassandra (Assaré et al., 
2015). Those 75 villages where the S. mansoni prevalence ranged between 10% and 24% and 
that fulfilled other inclusion criteria were eligible for the SCORE trial. Villages were 
randomized into one of three treatment arms. This article describes the baseline situation in 
the 75 schools including important village characteristics. 
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Figure 4.1: Study area in western Côte d’Ivoire showing schools surveyed at the eligibility 
survey (June–August 2011 and December 2011) and at the baseline survey (December 2011 
to February 2012) in blue circles. 
 
4.3.3. Field and laboratory procedures 
The baseline survey in the 75 schools was conducted from December 4 to 22, 2011, and from 
January 26 to February 27, 2012. In the first step, teachers prepared lists with the name, sex, 
and age of children enrolled in their classes. Subsequently, in each school, 100 children 
(usually aged 9–12 years) from grades 2–6 and up to 100 children from grade 1 were 
randomly selected from the lists. In case insufficient numbers of children were available in 
the desired age range, older children were invited to participate. The selected children 
received detailed information and an informed consent sheet, and they were asked to have the 
consent sheet signed by their parents or legal guardians (Assaré et al., 2014). Children with 
written informed consent were given a 125-mL plastic container and asked to provide a 
portion of their own fresh morning stool the next day. First-grade children were asked for a 
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single stool sample, while the other children were invited to submit stool samples on three 
consecutive days. Children’s parents and guardians were asked to make sure that their 
children collected their own stool. Returned stool containers were collected and identified 
with unique codes by experienced fieldworkers and transferred to nearby laboratories for 
diagnostic work-up. 
In the laboratories, stool samples were processed using the Kato-Katz technique, with 
a standard 41.7-mg plastic template (Katz et al., 1972). From each stool sample, duplicate 
Kato-Katz thick smears were prepared on two microscope slides. After a clearing time of at 
least 60 minutes, the thick smears were examined by experienced laboratory technicians under 
a light microscope at low magnification. Eggs of S. mansoni and soil-transmitted helminths 
(Ascaris lumbricoides, hookworm, and Trichuris trichiura) were counted and recorded for 
each species separately. For quality control, 10% of the slides were randomly selected and 
reexamined by a senior laboratory technician. If there were discrepancies between the two 
results (e.g., positive versus negative result, or counts differing by more than 20%), the 
respective slides were read again and the results discussed until agreement was reached. 
 
4.3.4. Assessment of village characteristics 
In parallel to the parasitologic survey, a questionnaire on factors that might influence S. 
mansoni transmission was administered to school directors and village leaders. The 
questionnaire included six main sections pertaining to 1) demographics (i.e., village name, 
number of households and individuals); 2) water-related activities in the population (i.e., 
fishing, cleaning, and irrigated rice farming); 3) health system indicators (i.e., presence and 
type of health facility, availability and quality of praziquantel and artemisinin-based 
combination therapy [ACT]); 4) water bodies (i.e., number of perennial and seasonal water 
courses/stagnant water bodies); 5) water use (i.e., water sources used for drinking, washing, 
and bathing); and 6) defecation behavior (i.e., open defecation, availability and use of 
sanitation facilities). 
 
4.3.5. Statistical analysis 
Data were entered into a Microsoft Excel workbook 2010 (Microsoft Corporation, Redmond, 
WA). Statistical analyses were done with STATA (version IC13.1; Stata Corporation, College 
Station, TX). The prevalence of S. mansoni infection from the eligibility survey was estimated 
based on the results from duplicate Kato-Katz thick smears from a single stool sample from 
children aged 13–14 years (Assaré et al., 2014). For the current analysis of the baseline 
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survey, two groups of children were considered: 1) all children aged 9–12 years who had at 
least four Kato-Katz thick smears examined after three consecutive days of stool sampling 
and 2) all first-grade children who provided a single stool sample and had one or two Kato-
Katz thick smears examined. Two different prevalence estimates were calculated for the 9- to 
12-year-old children at the baseline survey: 1) to render the sampling effort and prevalence 
comparable to the eligibility survey, the S. mansoni prevalence was calculated based on 
duplicate Kato-Katz thick smear results from the first stool sample and 2) to allow for a more 
accurate prevalence estimate, the S. mansoni prevalence was calculated from a minimum of 
four Kato-Katz thick smears from at least two consecutive stool samples. For the first-grade 
children, the S. mansoni prevalence was estimated based on at least one Kato-Katz thick 
smear from the single stool sample. Low-, moderate-, and high-endemicity areas were defined 
according to WHO (WHO, 2013) at prevalence thresholds of < 10%, 10–49%, and ≥ 50%, 
respectively, and according to SCORE at prevalence thresholds of < 10%, 10–24%, and > 
24%, respectively (WHO, 2002; Assaré et al., 2014). 
The arithmetic mean (AM) number of eggs per gram of stool (EPG) for S. mansoni 
was calculated from all available Kato-Katz thick smear readings per individual. On the basis 
of AM EPGs of each individual, infection intensity was determined according to WHO 
guidelines: 1) light (1–99 EPG); 2) moderate (100–399 EPG); and 3) heavy infections (≥ 400 
EPG) (WHO, 2002). 
Water use and defecation behavior as coded in the questionnaire (i.e., never = 0, rarely 
= 1, often = 2, and always = 3) was simplified and used as a binary variable (i.e., 0 = not 
practiced, ≥ 1 = practiced). In addition, mean prominence values based on the four code 
categories (sum of the observed code values divided by four) are provided. 
 
4.4. Results 
4.4.1. Characteristics of study population 
As shown in Figure 4.2, a total of 12,431 children were invited to participate at the baseline 
survey. There were 7,478 children aged 9–12 years and 4,953 first graders. Among the 9- to 
12-year old children, 467 were excluded, because they did not match the specified age group 
(N = 168), failed to provide even a single stool sample (N = 5), or had less than four Kato-
Katz thick smears (N = 294). A total of 6,694 children aged 9– 12 years submitted a stool 
sample on day 1 and 6,384 and 6,402 stool samples were submitted on days 2 and 3, 
respectively. At least four Kato-Katz thick smear results were available from 7,011 children 
aged 9–12 years and at least one Kato-Katz thick smear was available from 4,953 first 
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graders. These two groups were included into the main analysis of the baseline survey. Their 
mean age was 10.5 years and 6.5 years, respectively, and the sex ratio for boys to girls was 
1.4:1.0 and 1.3:1.0, respectively. 
 
 
Figure 4.2: Study participation at the baseline survey conducted in 75 schools in western Côte 
d’Ivoire in December 2011 to February 2012. 
 
4.4.2. S. mansoni and soil-transmitted infections 
Table 4.1 summarizes S. mansoni prevalence and intensity of infection and prevalence 
of soil-transmitted helminths. Examination of at least four Kato-Katz thick smears per child 
revealed that among the 7,011 children aged 9–12 years, 1,547 (22.1%) were infected with S. 
mansoni. The prevalence ranged from 1.0% to 54.0% at the unit of the school and was 
significantly higher among boys (24.3%) than girls (18.8%) (χ2 = 29.91, P < 0.001). Among  
Table 4.1: Prevalence and intensity of Schistosoma mansoni infection in first year and 9- to 
12-year-old school children and prevalence of soil-transmitted helminth infections at the 
baseline survey conducted between December 2011 and February 2012 of a SCORE study in 
western Côte d’Ivoire  
 87 
 
Variable First-year schoolchildren 
9- to 12-year-old 
schoolchildren 
No. of individuals examined 4,953 7,011 
No. of children infected (%) 
  
 S. mansoni 269 (5.4) 1,547 (22.1) 
 T. trichiura   27 (0.6)    221 (3.2) 
 A. lumbricoides   15 (0.3)      66 (0.9) 
 Hookworm    6 (0.1)      95 (1.4) 
Intensity of S. mansoni infection
*
 
   Arithmetic mean EPG (95% CI)   10 (6.7-13.4) 20.4 (17.3-23.4) 
 Light infection (%)   73.2     80.9 
 Moderate infection (%)   21.4     14.2 
 Heavy infection (%)    7.7       4.9 
CI = confidence interval; EPG = eggs per gram of stool; SCORE = Schistosomiasis 
Consortium for Operational Research and Evaluation. 
*Light infection, 1–99 EPG; moderate infection, 100–399 EPG; heavy infection, ≥ 400 EPG. 
 
the 4,953 first graders, a S. mansoni infection was found in 269 children (5.4%). For this 
group, the prevalence at the unit of the school ranged between 0% and 20.9%. There was no 
significant difference by sex (χ2 = 0.98, P = 0.321). 
In both age groups, the majority of children had light intensity infections, but the 
proportions of children with heavy infections were higher in first graders compared with 9- to 
12-year-old children (7.7% versus 4.9%). Among 9- to 12-year-old children, the overall 
prevalence of T. trichiura, hookworm, and A. lumbricoides was 3.2%, 1.4%, and 0.9%, 
respectively. The corresponding values among first graders were 0.6%, 0.1%, and 0.3% 
respectively.  
 
4.4.3. S. mansoni prevalence at the eligibility and baseline surveys 
The overall S. mansoni prevalence based on the results from duplicate Kato-Katz thick smears 
from a single stool sample was 15.8% (95% confidence interval [CI], 14.8–16.8%) in the 
12,110 children aged 13–14 years who participated in the eligibility survey and 13.0% (95% 
CI, 11.4–14.7%) in the 6,694 children aged 9–12 years who were surveyed at day 1 of the 
baseline survey. Considering the results of at least four Kato-Katz thick smears from 7,011 
children, the overall S. mansoni prevalence at baseline was 22.1% (95% CI, 19.5–24.4%). 
Figure 4.3 shows that the average S. mansoni infection prevalence was lowest at the baseline 
survey considering duplicate Kato-Katz thick smears, followed by the eligibility survey, and 
the baseline survey with a diagnostic effort of at least quadruplicate Kato-Katz thick smears. 
Figure 4.4 shows the difference of the S. mansoni prevalence in the 75 schools compared 
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between eligibility survey considering two Kato-Katz thick smears and baseline survey 
considering at least four Kato-Katz thick smears. Overall, the prevalence in the eligibility 
survey was 39.9% lower than in the baseline survey. The prevalence of S. mansoni was 
significantly higher in five schools, while significantly lower rates were observed in three 
schools (Table 4.2). Among the 75 schools, 75 (100%) and 65 (86.7%) schools at the 
eligibility and baseline surveys, respectively, matched the WHO criteria of moderate 
endemicity (S. mansoni prevalence: 10–49%). In terms of target endemicity cut-offs defined 
by SCORE, by definition, all 75 schools fulfilled the target criteria of moderate endemicity (S. 
mansoni prevalence: 10–24%) at the eligibility survey, but only 40 schools (53.4%) remained 
in this category in the baseline survey using at least quadruplicate Kato-Katz thick smear 
results, while 28 schools (37.3%) had prevalences above 24% and seven schools showed 
prevalences below 10%. Among the 28 schools that showed a S. mansoni prevalence above 
the SCORE preset maximum level at baseline, three had prevalences above 50%. 
 
 
Figure 4.3: Schistosoma mansoni prevalence in children aged 13–14 years at the eligibility 
survey and in children aged 9–12 years at the baseline (BL) survey.  
Eligibility: S. mansoni prevalence in 13- to 14-year-old children, according to results from 
duplicate Kato-Katz thick smears examined at the eligibility survey. BL1: S. mansoni 
prevalence in 9- to 12-year-old children, according to results from duplicate Kato-Katz thick 
smears examined from day 1 stool samples at the baseline survey. BL2: S. mansoni 
prevalence in 9- to 12-year-old children, according to the results from at least four Kato-Katz 
thick smears per child at the baseline survey. 
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Figure 4.4: Dynamics of the Schistosoma mansoni prevalence in 75 schools from eligibility 
(points) to baseline (BL2: S. mansoni prevalence in 9- to 12-year-old children, according to 
results from at least four Kato-Katz thick smears per child at the baseline survey; arrow head) 
surveys.  
A 10–24% prevalence determined at the eligibility survey was the defined target endemicity 
level of moderate prevalence for this Schistosomiasis Consortium for Operational Research 
and Evaluation (SCORE) project. A prevalence of 10–49% is defined as moderate endemicity 
by criteria of the World Health Organization (WHO). 
 
Table 4.2: Schools where significant changes have been observed in the Schistosoma mansoni 
prevalence comparing data from the eligibility and baseline surveys of a SCORE study in 
western Côte d’Ivoire 
 
School Eligibility  
 
Baseline  
 Change 
(%) 
 
Prevalence 
(%) 95% CI 
 Prevalence 
(%) 95% CI 
 
 Kassiapleu 10.0 1.4-18.6  29.0 20.0-38.0  +190.0 
Gohouo-Zibiao 10.0 1.4-18.6  28.1 20.7-35.5  +180.8 
Voungoué 11.4 1.6-21.1  33.7 23.9-43.5  +196.6 
Glaou 18.0 7.0-29.0  39.7 31.7-47.8  +120.7 
Kiélé I 18.0 7.0-29.0  37.3 30.7-44.3  +107.2 
Pona 2 18.4 5.5-31.3  1.2 -0.6-3.8  -93.5 
Pinhou 1 22.0 10.1-33.9  4.1 1.1-7.1  -81.5 
Guinglo-Zia 22.5 10.3-34.6  5.2 1.7-8.7  -76.9 
CI = confidence interval; SCORE = Schistosomiasis Consortium for Operational Research 
and Evaluation. 
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4.4.4. Demographic and environmental characteristics of local communities 
Table 4.3 summarizes demographic and environmental determinants for S. mansoni infection 
in the study area. The overall estimated mean population size was 3,358 inhabitants, and there 
were 1,011 households. On average, there were 6.5 inhabitants per household. The mean 
altitude was 339 m (standard error = 13 m) above mean sea level. 
Rice cultivation was practiced in 71 (95%) communities. Thirty communities had a 
health facility in the village. ACT and praziquantel were available in 21 and 11 health 
facilities, respectively. Of note, all praziquantel stocks in the 11 health facilities were expired 
and also one-third (33%) of the ACT tablets in the 21 health facilities had passed their shelf 
life. There were 57 and 48 communities with permanent and seasonal stagnant water bodies, 
respectively. The corresponding values for rivers were 67 and 51.  
Recreational and occupational risk-related behaviors for S. mansoni infection are 
shown in Table 4.4. Open defecation was practiced in all 75 communities and open surface 
water was used for washing in 48 communities and for bathing in 47 communities. Only 28 
schools reported that open surface water was used for drinking. Among sanitation facilities, 
traditional pit latrines were the most common type (84%). Village authorities reported that the 
number of permanent rivers, streams, lakes, and ponds in the communities ranged from zero 
to 12 and that of seasonal water bodies ranged from zero to eight. Natural open freshwater 
bodies were predominantly used for washing and bathing. Well water was the most widely 
used type of water for drinking, washing, and bathing. 
 
Table 4.3: Potential demographic, health system-related, and environmental risk factors for 
Schistosoma mansoni in the western part of Côte d’Ivoire 
 
Variable  Mean SE 
No. of inhabitants/locality 3,357.9 409.2 
No. of households/locality 1,010.6 291.1 
No. of persons/household 6.5 0.6 
Altitude (in meters) 338.9 12.5 
  N (%) 
Main water contact-related activities      
 Rice cultivation  71 94.7 
 Irrigated cultures  48 64 
 Fishing activities  54 72 
Health system indicators   
 Functional health center  30 40 
 Praziquantel availability  11 14.7 
 ACTs availability  21 28 
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Waterbodies   
 No permanent stagnant waterbodies (PSW) 18 24 
 No. of PSW: 1 to 3 39 52 
 No. of PSW: > 3 18 24 
 No seasonal stagnant waterbodies (SSW) 27 36 
 No. of SSW: 1 to 3 40 53.3 
 No. of SSW: > 3 8 10.7 
Rivers   
 No permanent streams or rivers (PR) 8 10.7 
 No. of PR: 1 to 3 47 62.7 
 No. of PR: >3 20 26.7 
 No seasonal streams or rivers (SR) 24 32 
 No. of SR: 1 to 3 42 56 
 No. of SR: > 3 9 12 
ACT = artemisinin-based combination therapy; PR = permanent rivers or streams; 
PSW = permanent stagnant water bodies; SE = standard error; SR = seasonal rivers or 
streams; SSW = seasonal stagnant water bodies. 
 
Table 4.4: Potential risk-related behaviors of school-aged children that govern Schistosoma 
mansoni infection in the western part of Côte d’Ivoire 
 
Variable  Practiced   Mean prominence 
  n (%)   
Drinking water sources         
 Open surface water 28 37.3 0.78  
 Cistern water 50 66.7 1.06  
 Well water 73 97.3 2.83  
 Tap water 10 13.3 0.29  
Water sources used for washing     
 Open surface water 48 64 1.38  
 Cistern water 67 89.3 1.49  
 Well water 72 96 2.49  
 Tap water 8 10.7 0.25  
Water sources used for bathing     
 Open surface water 47 62.7 1.24  
 Cistern water 62 82.7 1.33  
 Well water 72 96 2.67  
 Tap water 9 12 0.27  
Defecation behavior     
 Open defecation 75 100 2.8  
 Pit latrine 63 84 1.33  
 Improved latrine 1 1.3 0.01  
  Toilet/WC 44 58.7 0.83   
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4.5. Discussion 
Preventive chemotherapy with praziquantel is the current mainstay of schistosomiasis control, 
and efforts are underway to scale-up treatment coverage to reach the goal of globally 
controlling schistosomiasis by the year 2020. WHO recommends specific frequencies of 
praziquantel administration to school-aged children, as function of prevalence level, usually 
assessed by standardized parasitologic tests such as the Kato-Katz technique for S. mansoni 
diagnosis. To determine the best strategy of preventive chemotherapy with praziquantel to 
sustain the control of schistosomiasis mansoni in moderate endemicity settings (defined as 
prevalence in 13- to 14-year-old children ranging between 10% and 24%), a 4-year cluster 
randomized intervention trial is currently implemented in Côte d’Ivoire within the frame of a 
multi-country SCORE study (Assaré et al., 2014; Colley, 2014). Here, we report the baseline 
parasitologic situation and village characteristics before the onset of the trial and show the 
challenge of categorizing communities based on a rapid assessment procedure with a 
relatively small sample size (50 children) and an insensitive diagnostic method (Kato-Katz 
technique) (Utzinger et al., 2015). 
Examining single stool samples with duplicate Kato-Katz thick smears, we observed 
an overall S. mansoni prevalence of 15.8% in 13- to 14-year-old children at the eligibility 
survey. When 9- to 12-year-old children were examined with at least quadruplicate Kato-Katz 
thick smears at the baseline survey, the overall prevalence of S. mansoni was 22.1%. It 
follows that the overall prevalence of S. mansoni in school-aged children randomized into the 
75 intervention schools in this large part of western Côte d’Ivoire can be considered as 
moderate according to WHO (10–49%) and SCORE (10–24%) prevalence thresholds. 
However, there were quite a number of schools in the baseline survey that had a prevalence 
above 24% compared with the eligibility survey (28 schools or 37.3% above the 24% 
prevalence threshold). Three of the schools actually had a prevalence of 50% and higher, and 
hence, must be considered as high-endemicity areas when using the more conservative WHO 
definition. On the other hand, seven schools (9.3%) showed a prevalence below 10% when 
comparing baseline with eligibility survey data.  
The difference in the observed prevalence can be explained as follows. First, the 
children surveyed at baseline were slightly younger than those surveyed at the eligibility 
survey (mean age: 10.5 years versus 13.2 years). It is widely acknowledged that the 
prevalence and intensity of Schistosoma infection increase from early age, peaks around 8–15 
years, and decrease again in adulthood (Woolhouse, 1998). Second, the probability to detect a 
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S. mansoni case with four or more Kato-Katz thick smears derived from two or three 
consecutive stool samples per individual is considerably higher than when only a single stool 
sample is examined with duplicate Kato-Katz thick smears. The effect of increased sampling 
effort on the diagnostic sensitivity of the Kato-Katz method has been documented before, and 
hence, it is strongly recommended to examine multiple stool samples over multiple days to 
obtain a reliable prevalence estimate of S. mansoni and other helminths, particularly in 
settings where infection intensities are low (Utzinger et al., 2001; Booth et al., 2003; Enk et 
al., 2008; Coulibaly et al., 2012; Sayasone et al., 2015). Third, our results confirm that 
schistosomiasis is a focal disease; indeed, the prevalence of infection at the unit of the school 
showed considerable variation from one school to another (Assaré et al., 2015). Focality of S. 
mansoni is often explained with special occupational or recreational risk behaviors, proximity 
to open freshwater bodies that serve as habitat for intermediate host snails, and access to, and 
use of, sanitation facilities (Utzinger et al., 2000; Sow et al., 2008; Odiere et al., 2012; Grimes 
et al., 2015; Walz et al., 2015). In our study, for example, boys showed a higher infection 
prevalence than girls. This finding is in accordance with previous studies from Côte d’Ivoire 
and other parts of the world (Utzinger et al., 2000; Raso et al., 2005; Reta and Erko, 2013; 
Yapi et al., 2014). The most likely explanation for a higher infection level in boys compared 
with girls is that boys are more actively exploring the environments of their settlements, 
including rivers and ponds, and hence, boys are more exposed to S. mansoni infection (Rudge 
et al., 2008).  
Previous research conducted in the village of Fagnampleu, in Tonkpi region, reported 
that prevalences of hookworm, A. lumbricoides, and T. trichiura were 60.0%, 3.4%, and 
2.2%, respectively (Keiser et al., 2002). Another study, which took place in 57 schools of the 
Man region, revealed prevalences of 30.5%, 2.2%, and 1.3% for hookworm, A. lumbricoides, 
and T. trichiura infection, respectively (Raso et al., 2005). In our study, the corresponding 
values were 0.9%, 1.4%, and 3.2%, respectively. These results indicate that the prevalences of 
A. lumbricoides and T. trichiura were low in the study area. The unexpectedly low hookworm 
infection rate may be explained by the applied Kato-Katz procedure. In this study, the 
clearing time of the Kato-Katz thick smears between preparation and reading varied from 1 
hour to several weeks, mainly explained by the large scale of the study with small mobile 
teams collecting and preparing Kato-Katz thick smears in the field with laboratory analysis 
done later on. Therefore, most of the hookworm eggs were dissolved and led to an 
underestimation of the actual prevalence (Martin and Beaver, 1968). 
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At the level of demographic and environmental characteristics of the local 
communities, we found that rice farming, which has been shown to be a determinant of 
schistosomiasis (Fournet et al., 2004; Matthys et al., 2007; Yapi et al., 2005), is widely 
practiced and thus may represent a major source of exposure in the study area. The 
importance of contact with cercariae-infested water through washing and bathing, combined 
with widespread open defecation, is acknowledged for governing the transmission of 
intestinal schistosomiasis (Utzinger et al., 2000, Sow et al., 2008; Odogwu et al., 2006, 
Mohammed et al., 2015; Nalugwa et al., 2015). Among our study population, open surface 
water was predominantly used for washing and bathing. Moreover, while basic sanitation 
facilities (i.e., traditional pit latrines) were reported to exist in most of the communities 
(84%), open defecation was very common. Indeed, open defecation was practiced in all 
settlements, which might be a main reason for the fecal contamination of freshwater bodies. 
What warrants close attention over the course of the interventions, however, is the 
access to (unexpired), and use of, praziquantel and ACTs in the health facilities of the study 
communities and a potential change in the socioeconomic status, and proportion of people 
using improved sanitation. For sustainable control of schistosomiasis, it is crucial to not only 
regularly treat school-aged children with praziquantel, but also promote latrine construction 
and use, coupled with hygiene education and behavior change efforts (Schmidlin et al., 2013), 
and to make praziquantel available at all health centers so that those in need can get treatment. 
Our data showed that the proportions of first graders (mean age: 6.5 years) with heavy 
infection were higher than among 9- to 12-year-old children (mean age: 10.5 years). This 
observation might indicate an upsurge in transmission over the last few years. 
  
4.6. Conclusion 
Our findings show that prevalence estimates differ considerably, which is also influenced by 
age, sex, and sampling efforts and which needs to be taken into account when planning 
schistosomiasis control and elimination. The baseline characteristics presented here at the 
onset of a multi-year SCORE study provide important information for the years to come in 
this cluster-randomized intervention trial, which will help to determine the best strategies to 
sustainably control schistosomiasis mansoni in moderate endemicity areas. In addition, the 
results of this survey represent an extensive evidence-base for the extent of intestinal 
schistosomiasis and potential transmission sources to be addressed by the ongoing national 
schistosomiasis (and soil-transmitted helminthiasis) control program in Côte d’Ivoire. 
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5.1. Abstract 
Background: The Schistosomiasis Consortium for Operational Research and 
Evaluation (SCORE) has launched several large-scale trials to determine the best strategies 
for gaining and sustaining control of schistosomiasis and transitioning toward elimination. In 
Côte d’Ivoire, a 5-year cluster-randomized trial is being implemented in 75 schools to sustain 
the control of schistosomiasis mansoni. We report Schistosoma mansoni infection levels in 
children one year after the initial school-based treatment (SBT) with praziquantel and 
compare with baseline results to determine the effect of the intervention. 
Methodology: The baseline cross-sectional survey was conducted in late 2011/early 
2012 and the first follow-up in May 2013. Three consecutive stool samples were collected 
from 9- to 12-year-old children in 75 schools at baseline and 50 schools at follow-up. Stool 
samples were subjected to duplicate Kato-Katz thick smears. Directly observed treatment 
(DOT) coverage of the SBT was assessed and the prevalence and intensity of S. mansoni 
infection compared between baseline and follow-up. 
Principal Findings: The S. mansoni prevalence in the 75 schools surveyed at baseline 
was 22.1% (95% confidence interval (CI): 19.5–24.4%). The DOT coverage was 84.2%. In 
the 50 schools surveyed at baseline and one year after treatment, the overall prevalence of S. 
mansoni infection decreased significantly from 19.7% (95% CI: 18.5–20.8%) to 12.8% (95% 
CI: 11.9–13.8%), while the arithmetic mean S. mansoni eggs per gram of stool (EPG) among 
infected children slightly increased from 92.2 EPG (95% CI: 79.2–105.3 EPG) to 109.3 EPG 
(95% CI: 82.7–135.9 EPG). In two of the 50 schools, the prevalence increased significantly, 
despite a DOT coverage of >75%. 
Conclusions/Significance: One year after the initial SBT, the S. mansoni prevalence 
had decreased. Despite this positive trend, an increase was observed in some schools. 
Moreover, the infection intensity among S. mansoni-infected children was slightly higher at 
the 1-year follow-up compared to the baseline situation. Our results emphasize the 
heterogeneity of transmission dynamics and provide a benchmark for the future yearly follow-
up surveys of this multi-year SCORE intervention study. 
 
5.2. Author summary 
Schistosomiasis is a parasitic worm disease that is widespread in sub-Saharan Africa. To 
better understand how to gain and sustain the control of schistosomiasis and how to eliminate 
this disease in different epidemiologic settings, the Schistosomiasis Consortium for 
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Operational Research and Evaluation (SCORE) has launched several multi-year studies that 
are being implemented in East and West Africa. This article highlights how the Schistosoma 
mansoni infection levels changed one year after an initial treatment with the antiworm drug 
praziquantel given to children aged 5–15 years in western Côte d’Ivoire. Infection and 
treatment data at school level were available from more than 4,600 children in 50 schools. 
One year after the treatment that had been received by more than 80% of the children, the 
overall S. mansoni prevalence decreased from 19.7% to 12.8%, while the intensity of 
infection among S. mansoni-positive children slightly increased. In several schools, the S. 
mansoni intensity and, particularly the prevalence, increased unexpectedly. Our findings show 
that the dynamics of schistosomiasis transmission varies from one village to another. It will 
be interesting to monitor changes over longer time periods as this SCORE study unfolds. 
 
5.3. Introduction 
Schistosomiasis is a neglected tropical disease that exerts a considerable public health 
problem in 78 tropical and subtropical countries (WHO, 2014). In 2013, it was estimated that 
schistosomiasis affected more than 250 million people worldwide with 90% of the reported 
cases concentrated in sub-Saharan Africa (WHO, 2015). Since the mid-1980s, the World 
Health Organization (WHO) emphasizes morbidity control using the drug praziquantel as the 
main pillar of the global strategy to fight schistosomiasis (WHO, 1985). Praziquantel is the 
drug of choice because it is efficacious against the adult stages of all Schistosoma species 
parasitizing humans, is inexpensive (the average cost to treat a school-aged child was US$ 0.2 
per treatment in 2013), and has a good safety profile (Bergquist, 2002; Doenhoff et al., 2002; 
Singer and de Castro, 2007; Zhang et al., 2010; Thétiot-Laurent et al., 2013). For morbidity 
control, praziquantel is being administered to at-risk populations without prior diagnosis, a 
strategy commonly known as ‘preventive chemotherapy’ (WHO, 2006a). 
The recommended frequency of drug administration is based on the level of 
endemicity in a given study area. According to WHO, in areas with high schistosomiasis 
endemicity (prevalence ≥50%), all school-aged children and adult people at risk of infection 
should be treated annually (WHO, 2013). In areas with moderate endemicity (prevalence 10–
50%), all school-aged children should be treated once every two years. In low endemic areas 
(prevalence <10%), school-aged children should be treated twice during their time in school; 
first at school entry and then again in their last year of schooling (WHO, 2006b; WHO, 2012). 
However, these prevalence thresholds are arbitrary. Hence, the Schistosomiasis Consortium 
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for Operational Research and Evaluation (SCORE) launched a series of studies to strengthen 
the evidence-base how best to gain and sustain the control of schistosomiasis, including cost 
considerations (Colley, 2014). Two 5-year cluster-randomized trials are being implemented in 
Côte d’Ivoire and Kenya (Samuels et al., 2012; Assaré et al., 2014). These trials are school-
based with three treatment arms (25 schools per arm) and aim to assess whether annual 
school-based treatment (SBT) with praziquantel for four years (arm A), annual SBT in years 1 
and 2, followed by “drug holidays” in years 3 and 4 (arm B), or SBT in years 1 and 3, spaced 
by“drug holidays” in years 2 and 4 (arm C) will substantially reduce the prevalence and 
intensity of Schistosoma infection and keep infection at low levels. 
Here, we present the effect of the first SBT with praziquantel on Schistosoma mansoni 
infection among school-aged children in western Côte d’Ivoire, as revealed by a detailed 
follow-up survey conducted in May 2013, compared to baseline data collected from 
December 2011 to February 2012. Specifically, we determined changes in the prevalence and 
intensity of S. mansoni infections among children in the 50 schools that belong to treatment 
arms A and B, and discuss consequences for the ongoing cluster-randomized trial and, more 
generally, for schistosomiasis control interventions in Côte d’Ivoire and elsewhere. 
5.4. Methods 
 
5.4.1. Ethics statement 
The study protocol was approved by the institutional research commissions of the Swiss 
Tropical and Public Health Institute (Basel, Switzerland) and the ‘Centre Suisse de 
Recherches Scientifiques en Côte d’Ivoire’ (CSRS; Abidjan, Côte d’Ivoire). Ethical approval 
was obtained from the ethics committees in Basel (reference no. EKBB 279/10) and the 
Ministry of Public Health in Côte d’Ivoire (reference no. 1994 MSHP/CNER). 
At the onset of the study, regional directors of the education and health sectors, 
education inspectors, village authorities, local community members, and teachers were 
sensitized in detail about the objectives of the research project. Parents and guardians of study 
participants provided written informed consent for children to participate. After the baseline 
parasitologic survey, in the frame of the first SBT conducted in June 2012, school-aged 
children living in the catchment area of participating schools were offered treatment with 
praziquantel at a single oral dose of 40 mg/kg of body weight (WHO, 2002). 
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5.4.2. Study area and population 
The baseline survey was carried out from December 2011 to February 2012, the SBT in June 
2012, and the first follow-up survey was conducted in May 2013 in eligible schools located in 
four regions of western Côte d’Ivoire: Cavally, Guemon, Haut-Sassandra, and Tonkpi. Details 
of the study area and population surveyed have been described elsewhere (Assaré et al., 2014; 
Assaré et al., 2016). The Cavally and Sassandra rivers and their tributaries represent the major 
hydrographic features of the study area (Kouamé et al., 2007; Aregheore, 2009). Buyo, a 
hydroelectric dam built across the Sassandra River in 1981, formed a lake with an estimated 
surface area of 600 km² (Kouamé et al., 2006). In western Côte d’Ivoire, the sources of water 
are traditional wells, rain water, rivers, water supply dams, ponds, creeks, fountains, natural 
spring water, and tap water (Fürst et al., 2009). The main reasons for human water contact 
that might lead to schistosomiasis transmission are washing dishes, washing children, fetching 
water, fishing, swimming, farming, and playing (Acka et al., 2010). Despite the existence of 
latrines in numerous households, open defecation is commonly practiced (Matthys et al., 
2007; Luginbühl, 2008; Acka et al., 2010). 
 
5.4.3. Sample size 
The aim of the SCORE sustaining schistosomiasis control study implemented in western Côte 
d’Ivoire is to determine the best strategy of preventive chemotherapy with praziquantel to 
sustain schistosomiasis mansoni control in moderate endemicity settings (Assaré et al., 2014; 
Assaré et al., 2016). For this purpose, the S. mansoni prevalence in n schools in three 
treatments arms is compared over a study period of four years. The prevalence of S. mansoni 
is determined by testing m children in those schools where there is subsequent treatment. The 
effect of the different treatment intervals on the S. mansoni prevalence will be estimated using 
the following logistic regression model: log (pijt / (1 - pijt)) = µ + αi + βt + ɣik, where pijt 
denotes the prevalence of S. mansoni in school j receiving treatment i in year t, μ is an 
intercept term, αi is the effect of treatment i, βt is the effect of time t, and γik is the time by 
treatment interaction. Generalized estimating equations have been used to fit these 
longitudinal data (Diggle et al., 2014). To take into account variation in the S. mansoni 
prevalence among schools, an overdispersion parameter φ was introduced into the model. 
When φ = 1, all schools under the same treatment have identical prevalences, whereas φ 
increases with increasing variation of prevalence levels between villages. 
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The calculations revealed that studying 20 schools per arm and evaluating 100 individuals per 
school would result in minimum effect sizes of 5–12% with or without overdispersion. In 
order to increase the chance of detecting differences between the intervention arms, the 
number of intervention units was increased to 25 per arm. Consequently, a total of 75 schools 
with a S. mansoni prevalence of 10–24% according to results from an eligibility survey were 
randomized to one of the three treatment arms (Assaré et al., 2014). Treatment arm A receives 
SBT with praziquantel once every year for four years, arm B receives SBT in years 1 and 2, 
followed by “drug holidays” in years 3 and 4, and arm C receives SBT in years 1 and 3, 
alternated by “drug holidays” in years 2 and 4 (Assaré et al., 2014). Before administration of 
the first round of treatment, a detailed baseline survey was conducted. 
 
5.4.4. Study procedures 
Following the SCORE harmonization protocol, all 75 schools were included in the baseline 
parasitologic survey implemented in Côte d’Ivoire from December 2011 to February 2012. 
Children were treated with praziquantel in June 2012. Only the 50 schools belonging to 
treatment arms A and B were subjected to the first follow-up survey carried out in May 2013, 
while the 25 schools belonging to treatment arm C were not subjected to a follow-up survey, 
as they were on “drug holidays” in year 2. 
Baseline and follow-up surveys pursued cross-sectional designs. Study procedures 
have been detailed elsewhere (Assaré et al., 2014; Assaré et al., 2016). In brief, in each of the 
selected schools, approximately 100 children were invited to participate in the study. 
Inclusion criteria were as follows: (i) age of children ranging between 9 and 12 years; (ii) 
presence of an informed consent sheet signed by parents/guardians; and (iii) children 
themselves assented orally. Over three consecutive days, children were invited to submit a 
portion of their own morning stool in a 125-ml plastic container. Every day, filled stool 
containers were collected by trained field enumerators and sent to the hospital laboratories in 
the towns of Biankouma, Danané, Douékoué, Guiglo, Kouibly, and Man for processing. 
Stool specimens were subjected to the Kato-Katz method (Katz et al., 1972). In brief, 
duplicate Kato-Katz thick smears were prepared from a single stool sample, using 41.7 mg 
plastic templates. The thick smears were allowed to clear for at least 60 min and examined by 
experienced laboratory technicians under a light microscope at low magnification. Eggs from 
S. mansoni, and additionally from soil-transmitted helminth species, were counted and 
recorded for each species separately. For quality control, 10% of the slides were randomly 
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selected and re-read by a senior microscopist. In case of discrepancies, the results were 
discussed with the concerned microscopists and the slides re-read until agreement was 
reached (Speich et al., 2015). 
 
5.4.5. Praziquantel administration 
In June 2012, children aged 5–15 years enrolled in the 75 study schools and non-enrolled 
school-aged children living in the school catchment areas were offered free-of-charge 
treatment with praziquantel (40 mg/kg) using a dose pole according to WHO guidelines 
(WHO, 2002). Praziquantel was administered by trained teachers to children, following a 
directly observed treatment (DOT) approach. Children remained under medical observation 
and adverse events were recorded within 4 hours post-treatment. Treatment was led by the 
‘Programme National de Lutte contre la Schistosomiase, les Géohelminthiases et la Filariose 
Lymphatique’ (PNL-SGF), and supported by staff from the ‘Programme National de Santé 
Scolaire et Universitaire’ (PNSSU), the CSRS, and the ‘Université Félix Houphouët-Boigny’. 
Praziquantel tablets were supplied by the Schistosomiasis Control Initiative (SCI; London, 
United Kingdom).  
The overall number of school-aged children residing in each village was obtained by 
adding up the number of school-aged but non-school attending children as recorded by the 
community health workers and the number of children registered in school, as detailed by 
school teachers. Trained teachers administered praziquantel to children (those attending 
school, and the non-enrolled children) and recorded the number of treated children. 
 
5.4.6. Statistical analysis 
Baseline survey data were entered into Microsoft Excel (2010 Microsoft Corporation), while 
data from the first follow-up survey were directly entered into smartphones and then uploaded 
to a database maintained on a central server (Open Data Kit) in Atlanta, United States of 
America. Statistical analyses were performed with STATA version IC13.1 (Stata Corporation; 
College Station, United States of America). The final analysis included children aged 9–12 
years who had at least four Kato-Katz thick smear readings at the parasitologic surveys done 
both at baseline and follow-up. To obtain individuals’ eggs per gram of feces (EPG), we 
divided the total S. mansoni egg counts from the multiple Kato-Katz slides per child by the 
total number of Kato-Katz thick smears and multiplied by a factor of 24. S. mansoni-positive 
individuals were stratified into three infection intensity categories: (i) light (1–99 EPG), (ii) 
moderate (100–399 EPG), and (iii) heavy (≥400 EPG) (WHO, 2002). Moreover, we 
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calculated S. mansoni prevalence and arithmetic mean (AM) EPG for positive individuals per 
school and treatment arm. With regard to soil-transmitted helminth infections that were also 
identified with the Kato- Katz technique, a child was considered positive if at least one egg of 
Ascaris lumbricoides, hookworm, or Trichuris trichiura was detected in one of the slides. 
We employed a χ² test to assess a potential association between S. mansoni prevalence 
and age or sex. Reduction in the prevalence and intensity of S. mansoni infection per school 
was calculated using the following formulae (Montresor et al., 1998): prevalence reduction = 
[(prevalence at baseline—prevalence at first follow-up) / (prevalence at baseline)] X 100. 
Reduction in the intensity of infection = [(AM EPG at baseline—AM EPG at first follow-up) 
/ (AM EPG at baseline)] X 100. 
The treatment coverage rate was assessed by using the following formula: coverage of 
the mass drug administration (MDA) = [(number of school-aged children with DOT recorded 
by teachers) / (overall number of school-aged children registered in school and recorded by 
health workers)] X 100. 
Geographic coordinates of each school were recorded using a hand-held global 
positioning system (GPS) receiver (Garmin Etrex 30; Olathe, United States of America). Arc 
Map 10.2.1 (Environmental Systems Research Institute Inc.; Redlands, United States of 
America) was used to generate maps of the changes of S. mansoni prevalence and intensity of 
infection (AM EPG) from baseline to follow-up. 
 
5.5. Results 
 
5.5.1. Operational results from baseline survey 
The baseline survey was conducted in the 75 schools meeting eligibility criteria from 
December 2011 to February 2012, and 7,478 children were invited to participate (Fig 5.1). 
Among them, 168 pupils were excluded from further analyses, because their age was outside 
the 9–12 years range. Additionally, 299 children were excluded because they did not provide 
sufficient stool to prepare at least quadruplicate Kato-Katz thick smears. The final study 
population for analysis of the baseline survey consisted of 7,011 children. There were more 
boys (n = 4,173) than girls (n = 2,838). The mean age was 10.5 years. The number of children 
in treatment arms A, B, and C was 2,410 (34.4%), 2,348 (33.5%), and 2,253 (32.1%), 
respectively.
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Figure 5.1: Study participation of schoolchildren at the baseline survey and one-year follow-up survey. The flowcharts show the study 
participation of 9- to 12-year-old schoolchildren at the baseline survey (A), which was conducted from December 2011 to February 2012, and the 
first follow-up survey (B), which was carried out one-year post-treatment in May 2013, in western Côte d’Ivoir
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5.5.2. Operational results from first follow-up survey 
In May 2013, 4,966 children from the 50 schools belonging to intervention arms A and B 
were invited to participate in the first follow-up survey. According to the SCORE 
harmonization protocol, children attending schools belonging to study arm C were not 
surveyed. Among the pupils attending schools included in arms A and B, who were invited to 
participate, 49 children had an age outside the 9–12 years range, and 250 children did not 
provide enough stool for at least quadruplicate Kato-Katz thick smears. Hence, results of 
4,667 children were included for further statistical analyses. There were more boys (n = 
2,640) than girls (n = 2,027). The children’s mean age was 10.3 years. There were 2,379 
children in treatment arm A and 2,288 in treatment arm B. 
 
5.5.3. S. mansoni infection at baseline 
At baseline, before the implementation of the first SBT with praziquantel, the examination of 
at least four Kato-Katz thick smears per child revealed an overall S. mansoni prevalence of 
22.1% among the 75 schools surveyed. The prevalence at the unit of the school ranged from 
1.0% to 54.0%. S. mansoni infection was significantly associated with age (χ² = 25.2, p 
<0.001), higher prevalence was predominantly observed among older children. The 
prevalence of S. mansoni was significantly higher among boys than girls (24.3% versus 
18.7%; χ² = 29.9, p <0.001). The overall S. mansoni prevalence in treatment arms A, B, and C 
was 18.8% (95% CI: 17.2–20.3%), 20.5% (95% CI: 18.9–22.2%), and 27.2% (95% CI: 25.3–
29.0%), respectively. With regard to the AM infection intensity, the respective values were 
93.5 EPG (95% CI: 62.6–124.4 EPG), 96.2 EPG (95% CI: 74.5–117.9 EPG), and 88.1 EPG 
(95% CI: 71.5–104.7 EPG) (Table 1). 
 
5.5.4. Changes of S. mansoni prevalence at the first follow-up survey 
As summarized in Table 1, at the first follow-up survey, the overall S. mansoni prevalence in 
arms A and B showed a statistically significant decline from 19.7% (95% CI: 18.5–20.8%) at 
baseline to 12.8% (95% CI: 11.9–13.8%) at the 1-year follow-up. In arm A, a decrease from 
18.8% (95% CI: 17.2–20.3%) to 11.2% (95% CI: 9.9–12.4%) was observed, corresponding to 
a reduction of 40.4%, while in arm B the prevalence declined from 20.5% (95% CI: 18.9–
22.2%) to 14.5% (95% CI: 13.1–16.0%), a reduction of 29.3%. 
Fig 5.2 indicates the dynamics of the S. mansoni prevalence from baseline to first 
follow-up survey on a school-by-school basis, stratified by treatment arm. Among the 25 
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Table 5.1: S. mansoni and soil-transmitted helminth infection prevalence at the baseline and follow-up surveys, stratified by treatment   
arm. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Prevalence of S. mansoni and soil-transmitted helminth infections among 9- to 12-year-old schoolchildren in the schools belonging to treatment 
arms A and B, respectively, at the baseline survey, which was conducted from December 2011 to February 2012, and the first follow-up survey, 
which was carried out one-year post-treatment in May 2013, in western Côte d’Ivoire. 
Arms   Baseline 
 
One-year post-treatment   Change 
  
Examined Infected 
 
Prevalence 
 
Examined Infected  Prevalence  
 
  
  
N  N 
 
(%)   (95% CI) 
 
N N  (%) (95% CI) 
 
(%) 
Arm A 
    
 
  
 
 
 
    S. mansoni 
 
2,410 453 
 
18.8 (17.2-20.3) 
 
2,379 266  11.2 (9.9-12.4) 
 
-40.4 
Hookworm 
 
2,410 16 
 
0.7 (0.3-1.0) 
 
2,379 2  0.1 (0.0-0.2) 
 
-85.7 
A. lumbricoides 
 
2,410 23 
 
0.9 (0.6-1.3) 
 
2,379 11  0.5 (0.2-0.7) 
 
-44.4 
T. trichiura 
 
2,410 82 
 
3.4 (2.7-4.1) 
 
2,379 42  1.8 (1.2-2.3) 
 
-47.1 
Arm B 
    
 
    
 
    S. mansoni 
 
2,348 482 
 
20.5 (18.9-22.2) 
 
2,288 332  14.5 (13.1-16.0) 
 
-29.3 
Hookworm 
 
2,348 24 
 
1.0 (0.6-1.4) 
 
2,288 2  0.1 (0.0-0.2) 
 
-90.0 
A. lumbricoides 
 
2,348 12 
 
0.5 (0.2-0.8) 
 
2,288 10  0.4 (0.2-0.7) 
 
-20.0 
T. trichiura 
 
2,348 75 
 
3.2 (2.5-3.9) 
 
2,288 39  1.7 (1.2-2.2) 
 
-46.9 
Arm C 
    
 
    
 
    S. mansoni 
 
2,253 612 
 
27.2 (25.3-29.0) 
 
NA 
 
 
    Hookworm 
 
2,253 55 
 
2.4 (1.8-3.1) 
 
NA 
 
 
    A. lumbricoides 
 
2,253 31 
 
1.4 (0.9-1.9) 
 
NA 
 
 
    T. trichiura 
 
2,253 64 
 
2.8 (2.2-3.5) 
 
NA 
 
 
    Overall 
    
 
    
 
    S. mansoni 
 
7,011 1,547 
 
22.1 (19.5-24.4) 
 
4,667 598  12.8 (11.9-13.8) 
 
-42.1 
Hookworm 
 
7,011 95 
 
1.4 (1.1-1.6) 
 
4,667 4  0.1 (0.0-0.2) 
 
-92.9 
A. lumbricoides 
 
7,011 66 
 
0.9 (0.7-1.2) 
 
4,667 21  0.4 (0.3-0.6) 
 
-55.6 
T. trichiura 
 
7,011 221 
 
3.2 (2.7-3.6) 
 
4,667 81  1.7 (1.4-2.1) 
 
-46.9 
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Arm A: schools receive praziquantel treatment annually for four years, Arm B: schools 
receive praziquantel treatment in the first two years of the study, followed by two years of 
“drug holiday”; Arm C: schools receive praziquantel treatment in the first and third year of 
the study and have “drug holidays” in the second and fourth year. 
CI: confidence interval; NA: not assessed. 
 
Figure 5.2: Dynamics of the S. mansoni prevalence in schools of treatment arms A and 
B. The graphs show the change of the S. mansoni prevalence from the baseline survey, which 
was conducted from December 2011 to February 2012, to the first follow-up survey, which 
was carried out one-year posttreatment in May 2013, in 9- to 12-year-old schoolchildren from 
25 schools per treatment arm in western Côte d’Ivoire. Arm A: schools receive praziquantel 
treatment annually for four years, Arm B: schools receive praziquantel treatment the first two 
years of the study, followed by two years of “drug holiday”. Red star: S. mansoni prevalence 
increased significantly. 
 
schools belonging to treatment arm A, the S. mansoni prevalence dropped in 23 schools (S1 
Table). The most significant decreases occurred in Dio, Pona 2, Siambly, and Gregbeu, where 
at the 1-year follow- up, no eggs of S. mansoni were found in the stool of the children 
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examined. However, in Biélé, the S. mansoni prevalence increased significantly from 36.0% 
(95% CI: 26.4–45.6%) to 79.0% (95% CI: 70.9–87.1%), while a non-significant increase from 
12.0% (95% CI: 5.5–18.5%) to 20.7% (95% CI: 12.0–29.4%) was observed in Séohoun-
Guiglo. 
In treatment arm B, the prevalence of S. mansoni decreased in 20 out of the 25 schools 
included (S1 Table). In two schools, the prevalence dropped prominently to zero from 24.0% 
in Semien and from 25.6% in Diehiba. A significant increase in the S. mansoni prevalence 
was observed in Ziondrou from 31.6% (95% CI: 22.0–41.1%) to 62.0% (95% CI: 52.3–
71.7%). An increase in prevalence was also observed in Dah, Douandrou 1, Koulouan, and 
Guessabo 2, but without statistical significance. 
Taken together, as shown in Fig 3A, among the 50 schools surveyed at the first 
follow-up, areduction of the S. mansoni prevalence of 25% and above was observed in 39 
schools (78.0%). In six schools, the changes ranged from -25% to +25%. An increase of 25% 
and above was recorded in five schools (10.0%). The increase in prevalence was observed 
mainly in the central part of Guemon region, eastern Tonkpi region, and western part of Haut-
Sassandra region. 
 
5.5.5. Changes of S. mansoni infection intensity at the first follow-up survey 
The overall S. mansoni AM EPG in arms A and B increased from 94.9 EPG (95% CI: 
76.2–113.6 EPG) at baseline to 109.3 EPG (95% CI: 82.7–135.9 EPG) at the 1-year follow-up 
survey. However, this increase was not statistically significant. As shown in Table 2, in arm 
A, an increase from 93.5 EPG (95% CI: 62.6–124.4 EPG) to 123.7 EPG (95% CI: 70.7–176.7 
EPG) was observed, corresponding to an increase of 32.3%, while in arm B the AM EPG at 
baseline (96.2 EPG, 95% CI: 74.5–117.9 EPG) and the 1-year follow-up (97.8 EPG, 95% CI: 
75.5–120.0 EPG) remained basically the same. The proportion of children with heavy 
infections (≥400 EPG) increased from 4.9% to 6.3%. 
Fig 5.4 displays the changes of the S. mansoni AM EPG in all the schools of treatment 
arms A and B from baseline to the first follow-up. In arm A, the S. mansoni AM EPG 
decreased in 16 (64.0%) out of the 25 surveyed schools (S1 Table). However, a statistically 
significant decrease in AM EPG from 33.0 EPG (95% CI: 13.9–52.0 EPG) to 5.5 EPG (95% 
CI: 3.8–7.2 EPG) was observed in only one school; Tobly Bangolo. Increases in S. mansoni 
AM EPG were observed in nine schools. However, the increase lacked statistical significance  
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Figure 5.3: S. mansoni prevalence and infection intensity (AM EPG) at the baseline and follow-up survey. The maps show the spatial 
distribution of the changes in the S. mansoni prevalence and in the infection intensity expressed as arithmetic mean eggs per gram of feces (AM 
EPG) between the baseline survey (A), which was conducted from December 2011 to February 2012, and the first follow-up survey (B), which 
was carried out one-year post-treatment in May 2013, in western Côte d’Ivoire. Arm A: schools receive praziquantel treatment annually for four 
years, Arm B: schools receive praziquantel treatment the first two years of the study, followed by two years of “drug holiday”. 
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Table 5.2: S. mansoni infection intensity in the schools belonging to treatment arms A, B, and C. 
 
Arm Baseline 
 
One-year post-MDA 
    
Change 
 
No. No. 
Arithmetic mean 
EPG 
Light Moderate Heavy 
 
No. No. 
Arithmetic mean 
EPG 
Light Moderate Heavy 
  
  examined positive (95% CI) (%) (%) (%) 
 
examined positive (95% CI) (%) (%) (%) 
 
(%) 
Arm A 2,410 453 93.5 (62.6-124.4) 85.9 9.5 4.6 
 
2,379 266 123.7 (70.7-176.7) 79.3 13.5 7.2  -32.2 
Arm B 2,348 482 96.2 (74.5-117.9) 81.1 12.9 6.0 
 
2,288 332 97.8 (75.5-120.0) 75.6 18.7 5.7  -1.7 
Arm C 2,253 612 88.1 (71.5-104.7) 77.1 18.8 4.1 
 
NA NA NA NA NA NA   
Overall 7,011 1,547 92.2 (79.2-105.3) 80.9 14.2 4.9  4,667 598 109.3 (82.7-135.9) 77.3 16.4 6.3  -18.5 
 
S. mansoni arithmetic mean intensity of infection among 9- to 12-year-old schoolchildren in the schools belonging to treatment arms A, B, and C, 
respectively, as determined at the baseline survey, which was conducted from December 2011 to February 2012, and the first follow-up survey, 
which was carried out one-year post-treatment in May 2013, in western Côte d’Ivoire. 
Arm A: schools receive praziquantel treatment annually for four years, Arm B: schools receive praziquantel treatment in the first two years of the 
study, followed by two years of drug holiday; Arm C: schools receive praziquantel treatment in the first and third year of the study and have 
“drug holidays” in the second and fourth year. 
NA: not assessed; CI: confidence interval; EPG: eggs per gram of feces. 
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Figure 5.4: Dynamics of the S. mansoni infection intensity in schools of treatment arms 
A and B. The graphs show the change of the S. mansoni infection intensity expressed as 
change in arithmetic mean eggs per gram of feces (AM EPG) from the baseline survey, which 
was conducted from December 2011 to February 2012, to the first follow-up survey, which 
was carried out one-year post-treatment in May 2013, in 9- to 12-year-old schoolchildren 
from 25 schools per treatment arm in western Côte d’Ivoire. Arm A: schools receive 
praziquantel treatment annually for four years, Arm B: schools receive praziquantel treatment 
the first two years of the study, followed by two years of “drug holiday”. Red star: S. mansoni 
infection intensity decreased significantly. 
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in all schools. In treatment arm A, the proportion of children with moderate (100–399 EPG) 
and heavy infections (≥400 EPG) increased from 9.5% to 13.5% and from 4.6% to 7.2%, 
respectively. 
In arm B, a decrease of the S. mansoni infection intensity was observed in 13 (52.0%) 
out of the 25 schools (S1 Table). With the exception of one school, this decrease was not 
statistically significant. The AM EPG decreased significantly in Mangouin school from 178.0 
EPG (95% CI: 77.7–278.3 EPG) to 30.4 EPG (95% CI: 4.2–56.6 EPG). In the remaining 12 
schools, the AM EPG increased, but these increases lacked statistical significance. The 
proportion of children with moderate and heavy infection intensities increased from 12.9% to 
18.7%, while the proportion of heavy infections decreased slightly from 6.0% to 5.7%. 
Fig 3B shows the spatial distribution of S. mansoni AM EPG reduction after the 
intervention in the study area. The AM EPG decreased by at least 25% in 25 schools (50.0%). 
In eight schools (16.0%), the change varied from -25% to +25%. The AM EPG increased by 
25% and more in 17 schools (34.0%). An increase of S. mansoni infection intensity by 25% 
and more was only focally observed; in Tonkpi region and central Guemon region. 
 
5.5.6. Coverage of SBT 
During the SBT carried out in June 2012, the estimated number of the school-aged population 
in the study area was 31,832 children. Among them, 26,804 swallowed praziquantel tablets at 
the SBT, resulting in an overall DOT coverage of 84.2%. Stratified by treatment arm, we 
found a DOT coverage of 79.2% (range: 31.9–97.9%) for arm A, 84.8% (range: 61.5–98.5%) 
for arm B, and 88.4% (range: 75.1–98.9%) for arm C. 
The individual DOT coverage rates achieved in the 75 villages are shown in S2 Table. 
A coverage of 75% and above was achieved in 57 schools (76.0%), while a coverage of less 
than 75% was reported in the remaining 18 schools. Yaoudé (in arm A) reported a coverage 
below 50%. The DOT coverage was not significantly correlated with changing levels of S. 
mansoni prevalence (Spearman ρ = -0.11; p = 0.43), while it was significantly correlated with 
AM EPG (Spearman ρ = 0.32; p = 0.02) (Fig 5.5). 
 
5.6. Discussion 
Preventive chemotherapy with praziquantel is the backbone of the global strategy against 
schistosomiasis and other helminthiases (WHO, 2006b; Webster et al., 2014). Our findings 
show that one year after an initial treatment with praziquantel in 50 schools of western Côte 
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d’Ivoire that met inclusion criteria of a SCORE harmonization protocol (prevalence ranging 
between 10% and 24%) (Assaré et al., 2014), the overall S. mansoni prevalence was reduced 
from 19.7% to 12.8%, while there was no significant change in the overall AM EPG. The 
overall DOT coverage in the study area was 84.2%; hence, above the 75% coverage 
recommended by WHO (WHO, 2002). At school level, the picture on the impact of the SBT 
was less clear cut. Decreases in prevalence and infection intensity were observed in some 
schools and increases in others. Among the six schools that showed higher prevalences of S. 
mansoni at the 1-year follow-up compared with baseline, in only one school, the treatment 
coverage was <75%. The changes in the AM EPG level were significantly correlated with the 
coverage rate. 
 
Figure 5.5: Correlation between coverage rate and the changes in the S. mansoni 
infection intensity. Scatter plot illustrating the correlation between the coverage rates 
achieved in a directly observed school-based treatment round implemented in 50 schools in 
western Côte d’Ivoire in June 2012, and the % changes in the S. mansoni arithmetic mean 
infection intensity observed between the baseline survey, which was conducted from 
December 2011 to February 2012, and the first follow-up survey, which was carried out one 
year post-treatment in May 2013, in 9- to 12-year-old schoolchildren. 
The overall reduction of the S. mansoni prevalence in the first year of this SCORE 
project (35.0%) is in line with studies assessing the S. mansoni prevalence 12 months post-
MDA in central Sudan and Uganda, where reductions of S. mansoni prevalence of 36.7% and 
Chapter 5 – SCORE Study, One Year after Initial Praziquantel Administration 
 
120 
 
39.5% were observed, respectively (Zhang et al., 2007; Ahmed et al., 2012). The treatment 
coverage in these two studies was reported to be 100% and 79.2%, respectively (Kabatereine 
et al., 2006; Ahmed et al., 2012). In the Sudan study, treatment of children with praziquantel 
was conducted by trained nurses and medical officers, while in Uganda, the treatment was 
carried out by trained teachers and community drug distributors (Kabatereine et al., 2006; 
Ahmed et al., 2012). A survey conducted 6 months after praziquantel treatment in Sierra 
Leone where the overall treatment coverage was 94.0% found a reduction of the S. mansoni 
prevalence of 44.6% (Hodges et al., 2012). Another study carried out in Sierra Leone reported 
an even higher reduction in the S. mansoni prevalence of 67.2%, as determined three years 
after three rounds of praziquantel administration (Sesay et al., 2014). In contrast, studies 
conducted in Zambia and Kenya showed that 2 years after the withdrawal of praziquantel 
treatment led to an increase of S. mansoni prevalence (Sukwa et al., 1988; Masaku et al., 
2015). It is important to note that these studies showed that the impact of MDA on the S. 
mansoni prevalence varied depending on the infection status in a given area, and the 
frequency and number of treatment rounds. Repeated treatments over short time periods can 
lead to a high reduction in S. mansoni prevalence compared to longer treatment intervals. 
Similar baseline S. mansoni prevalences were observed in two preceding studies in Sierra 
Leone and Uganda (49% and 42%, respectively), but the decrease in S. mansoni prevalence 
was lower in Uganda, where the intensity of infection, and thus the level of transmission, was 
higher. A plausible explanation of this observation arises from rapid re-infection, which is 
related to the force of infection, and which is likely higher where S. mansoni transmission is 
intense. Indeed, the level of schistosomiasis transmission, which is governed by various 
factors, such as local environmental determinants, climate, water contact patterns, 
intermediate host snail distribution, and ecology, may affect the impact of MDA (Zein, 1989; 
Ndyomugyenyi and Minjas, 2001; Gazzinelli et al., 2006; Stothard et al., 2009b). When 
interpreting these results, one has to bear in mind, however, that the prevalence of S. mansoni 
was determined by an insensitive diagnostic approach; single stool samples subjected by 
single (Uganda) or duplicate Kato-Katz thick smears (Sierra Leone). Hence, the diagnostic 
approach was less rigorous than in the current study in Côte d’Ivoire, where only those 
children who had at least quadruplicate Kato-Katz thick smears examined before and after 
treatment were included in the final analysis. 
In our study, in the schools Biélé and Ziondrou, the S. mansoni prevalence had 
significantly increased one year after SBT with levels in excess of 60%. Since the DOT 
Chapter 5 – SCORE Study, One Year after Initial Praziquantel Administration 
 
121 
 
coverage in both schools was high (75.2% in Biélé and 91.9% in Ziondrou), we assume that 
there are major transmission hotspots in the area, where children become rapidly re-infected. 
Re-emergence of S. mansoni and S. haematobium after treatment in high-endemicity areas has 
previously been reported from other studies in Côte d’Ivoire and Niger (N'Goran et al., 2001; 
Garba et al., 2013). One explanation might be migration of people, including those infected 
with S. mansoni or S. haematobium, into treated villages. A considerable population 
movement has, for example, been observed in Côte d’Ivoire due to socio-political unrest in 
2011 (Bonfoh et al., 2011), hence at the start of our study. A lack of access to safe water, 
sanitation, and hygiene (WASH) might also be the reason for rapid reinfection. Noteworthy, 
when interviewing the local village leaders, they reported that people in the area frequently 
use well water for washing and bathing, while ponds and rivers serve as the main natural 
water contact sites. While some houses have latrines, many people still practice open 
defecation. Another explanation of the increase in S. mansoni prevalence might be the target 
population of the treatment strategy. The present study focused on school-aged children. 
Preschool- aged children and adults also harbor Schistosoma worms, and hence, they act as 
reservoir of transmission source of re-infections (Masaku et al., 2015). Yet, there are other 
local conditions that might foster S. mansoni transmission in Biélé and Ziondrou that warrant 
further investigation. For example, one might want to assess the frequency and duration of 
water contact in children and associated re-infection patterns, and the transmission force 
caused by intermediate host snails populating waterbodies located in close proximity to the 
surveyed schools. It will be important to assess in future surveys whether individuals had 
indeed received praziquantel in the past treatment round, or whether they were immigrating 
from other areas after the last survey, or had traveled to highly endemic areas over the past 
year. Ideally, the reinfection pattern would be determined by following a cohort of children, 
including immunological markers of the individuals that might favor or delay reinfection, and 
molecular markers of the infecting parasites. 
An increase of S. mansoni infection within the frame of ongoing treatment programs 
has also been observed elsewhere. In Senegal, for example, an elevated S. mansoni prevalence 
was found 10 months after praziquantel administration (Ernould et al., 1999). More recently, 
in Ségou district in Mali, the national control program had revealed an increase of the S. 
mansoni prevalence after four rounds of MDA in 7- to 14-year-old children (Landouré et al., 
2012). It has been assumed that these increases of S. mansoni infections after praziquantel 
treatment might be explained by partial resistance to praziquantel, the acquisition of new 
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infection, and high force of transmission (Kabatereine et al., 1999; Stothard et al., 2009a; 
Wang et al., 2012). 
Taken together, our data show that SBT resulted in marked decreases of S. mansoni 
prevalence, but the intensity of infection among infected children did not change significantly. 
Hence, with a single treatment round, the force of transmission in terms of egg excretion in 
the school-aged population has not been changed in most of our study schools. Monitoring the 
impact of multiple treatment rounds and “drug holidays” over the next years will provide 
stronger evidence of what multiple SBT rounds can achieve (Assaré et al., 2014; Colley, 
2014). 
Clearly, sustainable control and eventual elimination of schistosomiasis requires 
multiple intervention packages, such as preventive chemotherapy (perhaps extended to all age 
groups), intensified case management, control of intermediate host snails, provision of 
WASH, and setting- specific information, education, and communication (IEC) (Utzinger et 
al., 2003; Lo et al., 2015; Wang et al., 2009). In Côte d’Ivoire, the control of schistosomiasis 
at a national scale is still at an early stage. Indeed, the PNL-SGF was only launched shortly 
before this SCORE project. For the success and sustainability of schistosomiasis control in 
Côte d’Ivoire–and elsewhere in sub-Saharan Africa–it will be important that, in addition to 
preventive chemotherapy, other control measures are considered and implemented (Utzinger 
et al., 2003; Singer and de Castro, 2007; Utzinger et al., 2009; Zhang et al., 2010). 
 
5.7. Conclusion 
The present study showed that one year after SBT with praziquantel, the overall 
prevalence of S. mansoni infection had decreased significantly. However, in certain hotspot 
schools, the S. mansoni prevalence had increased unexpectedly. The infection intensity among 
S. mansoni infected children was similar at the 1-year follow-up. These results demonstrated 
that the dynamic of schistosomiasis in the study areas is heterogeneous and that a single round 
of treatment is insufficient to have a lasting effect. It will be important to monitor the dynamic 
of schistosomiasis over the course of this SCORE study, in order to deepen our understanding 
of the dynamics of schistosomiasis transmission in a moderately endemic setting. 
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6. Discussion 
The present Ph.D. thesis is embedded in a project facilitated by the Schistosomiasis 
Consortium for Operational Research and Evaluation (SCORE) that is funded by the Bill & 
Belinda Gates Foundation (Colley, 2014). The focus on the present work is epidemiology, 
spatial distribution and control of S. mansoni in four regions of western Côte d’Ivoire. In the 
first step, we contributed to the development and open-access publication of a study protocol 
for the implementation and monitoring of schistosomiasis mansoni control in areas with 
moderate endemicity (prevalence of the infection at the beginning of the study was ranging 
between 10% and 24%). The protocol was initially developed by a group of schistosomiasis 
experts from America, Europe and Africa. The study is a 4-year cluster-randomised controlled 
trial with three treatment arms, each arm including 25 schools (Assaré et al., 2014). In a 
second step, we mapped and predicted the spatial distribution of S. mansoni in the western 
part of Côte d’Ivoire. This piece of work was facilitated through the initial eligibility survey 
as part of the aforementioned cluster-randomised trial. We screened more than 250 schools, 
usually surveying 50 children per school and used Bayesian based statistics (Assaré et al., 
2015). The risk map generated for S. mansoni in four regions of western Côte d’Ivoire already 
proved useful for the national schistosomiasis control programme for spatial targeting of 
preventive chemotherapy and other control interventions, in those schools that were not 
otherwise included in any ongoing trail. Thirdly, we determined the social-ecological baseline 
characteristics of local communities at the onset of our randomised controlled trial to sustain 
schistosomiasis mansoni control (Assaré et al., 2016a). This work allowed to assess the effect 
the sampling effort and the performance of the Kato-Katz technique and to determining S. 
mansoni infection level in our study area in the western part of Côte d’Ivoire. In the fourth 
step of our work we assessed the impact of the initial treatment round using single doses of 
praziquantel targeting all school-aged children for the prevalence and intensity of S. mansoni 
infection among 9 to 12 year-old children in western Côte d’Ivoire one year after the 
intervention. Moreover, we assessed the dynamics in the prevalence and intensity of S. 
mansoni infection from baseline to the one-year post-treatment follow-up. 
Table 6.1 summarises how the current Ph.D. thesis contributes to innovation, validation and 
application, that represent some of the core concepts of the Swiss TPH. The study protocol 
and the results of the cross-sectional parasitological and questionnaire surveys, including a 
cluster-randomised controlled trial carried out in the frame of this Ph.D. thesis in four regions 
of western Côte d’Ivoire will be summarised and discussed in the following sections. Gaps, 
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future research needs and implication for sustainable control of schistosomiasis mansoni will 
be highlighted. The results of this thesis will be relevant for the national schistosomiasis 
control programme in Côte d’Ivoire and control programmes elsewhere in countries where 
schistosomiasis remains endemic. 
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Table 6.1: Contribution of the individuals chapters of this Ph.D. thesis to the innovation, validation and application nexus of Swiss TPH. 
 
 
 
Chapter Title Innovation  Validation Application 
2 Sustaining control of 
schistosomiasis mansoni in 
moderate endemicity areas in 
western Côte d’Ivoire: a 
SCORE study protocol 
Writing up the study protocol on 
determining the best strategy of MDA 
with praziquantel to sustain the control 
of S. mansoni in moderate endmicity 
areas in western Côte I’voire for peer-
reviewered literature 
Focal distribution of S. mansoni 
confirmed for four regions of western 
Côte d’Ivoire 
 
3 The spatial distribution of 
S. mansoni infection in four 
regions of western Côte 
d’Ivoire 
Risk factors for schistosomiasis mansoni 
identified and implications for the 
disease control discussed and 
disseminated to control mangers 
 Risk map for schistosomiasis mansoni for 
in western Côte d’Ivoire used for spatial 
targeting of prevalence chemotherapy  
4 Sustaining control of 
schistosomiasis mansoni in 
western Côte d’Ivoire: 
baseline findings before the 
implementation of a 
randomised trial 
Baseline parasitological situation and 
social-ecological characteristics of local 
communities in western Côte d’Ivoire 
are determined 
 
Fragility of the classification of 
communities based on WHO criteria is 
demonstrated 
Effect of sampling effort on the 
sensitivity of Kato-Katz technique 
confirmed 
 
5 Sustaining control of 
schistosomiasis mansoni in 
western Côte d’Ivoire: a 
SCORE study with results 
one year after initial 
paziquantel administration 
Effects of a school-based MDA with 
praziquantel at regional scale on 
schistosomiasis are assessed for the first 
time in Côte d’Ivoire 
 
The result of one year post-MDA 
underscored the need for an 
integrated approach for sustainable 
control schistosomiasis 
The dynamic of S. mansoni prevalence 
and intensity of infection are determined 
and implication for schistosomiasis 
control discussed 
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6.1. Epidemiology of schistosomiasis mansoni in western Côte d’Ivoire 
In western Côte d’Ivoire, S. mansoni is the predominant schistosome species. Since the 1970s, 
several research projects and control interventions have been implemented in this part of the 
country (Roux et al., 1974; Doumenge et al., 1987; Utzinger et al., 2000b; Raso et al., 2004a; 
Tchuem Tchuenté and N’Goran, 2009). Most of these preceding studies were implemented in 
the towns of Danané and Man and surrounding villages belonging to the Tonkpi region. 
Schistosomiasis is characterised by a focal distribution (Lengeler et al., 2002) hence the first 
step of any schistosomiasis control programme is an appraisal of the level of schistosomiasis 
endemicity in the area under study, in order to identify communities at risk for subsequent 
interventions. For the SCORE study presented here, we pursued a large-scale eligibility 
survey in four regions of western Côte d’Ivoire that governed a selection of target villages for 
a 4-year cluster-randomised controlled trial.  
The identification of schistosomiasis prevalence at the community level on a large 
scale is a costly endeavour (Kurowski et al., 2007). Hence, rapid and inexpensive methods 
such as self-reported blood in urine (for S. haematobium) and self-reported blood in stool or 
bloody diarrheoa (for S. mansoni), and lot quality assurance sampling (LQAS) have been used 
to assess schistosomiasis endemicity of communities selected for any intervention trial 
(N’Goran et al., 1998; Utzinger et al., 2000b; Lengeler et al., 2002; Brooker et al., 2005; 
Krauth et al., 2015). It widely acknowledged that school questionnaires are an effective and 
inexpensive tool to identify high-risk communities for S. haematobium (Lengeler et al., 2002). 
In contrast, for identification of communities at high-risk of S. mansoni, self-reported 
questionnaires only show moderate sensitivity and specificity, compared with standard 
parasitological surveys using Kato-Katz as diagnositic approach (Lengeler et al., 2002; Yang 
et al., 2015). According to WHO guidelines, the identification of S. mansoni prevalence 
should be based on a sample size of about 50 individuals (Montresor et al., 1998). During the 
eligibility surveys, we used the LQAS with 50 individuals per schools to determine 75 
villages with a S. mansoni prevalence ranging between 10% and 24% (Assaré et al., 2014). 
Several epidemiological studies have shown that LQAS is the most rapid and cost-effective 
screening strategy to classify communities based the disease endemicity level, particularly in 
low- and middle-income countries where human and financial resources are scare (Brooker et 
al., 2005; Pezzoli and Kim, 2013).  
Our large eligibility survey confirmed that western Côte d’Ivoire is highly endemic for 
S. mansoni. Indeed, the majority of schools (59.5%) surveyed had a S. mansoni prevalence 
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above 24% (Assaré et al., 2014). These high-risk schools were predominantly observed in the 
Tonpki region, while moderate S. mansoni prevalence schools were mostly found in the 
Gomon and Cavally regions (Assaré et al., 2015). Our baseline study showed that the 
categorisation of communities based on S. mansoni prevalence, determined by eligibility 
survey using a rapid appraisal approach, is fragile. Indeed, 28 of the schools that were 
determined to be of moderate endemicity in the eligibility survey showed a prevalence in 
excess of 24% during the baseline survey, while another 7 schools showed a prevalence 
below 10%. These patterns could be explained by the diagnostic strategy that was 
implemented; at eligibility, only one stool sample was collected, while at baseline multiple 
Kato-Katz thick smears were examined (at least four slides). In contrast, the lower observed 
infection prevalence in some locations might be related to the age or sex of study participants. 
The present study showed that S. mansoni prevalence increases with age and the prevalence 
of the disease being higher among boys compared with girls (Assaré et al., 2016a). The 
fragility of the categorisation of the community based on WHO thresholds as shown in our 
study calls for a more adequate tool for better categorising communities. 
As expected, we found that the S. mansoni prevalence and intensity of infection were 
higher among 9- to 12 year-old children compare with first-graders. However, heavy infection 
intensities were predominantly observed in first-graders. This finding might suggest that 
transmission occurred in recent years, probably during the last decade of socio-political crisis 
(Tchuem Tchuenté and N’Goran, 2009; Bonfoh et al., 2011).  
 
6.2. Risk factors for schistosomiasis mansoni 
Schistosomiasis is a water-borne disease that affects more than 250 million people, 
predominantly in sub-Saharan Africa (Hotez et al., 2014; WHO, 2015). Schistosomiasis is 
characterised by a micro-geographical heterogeneity (Cook and Zumla, 2009; Meurs et al., 
2013; Assaré et al., 2014; Assaré et al., 2016) that is strongly associated with the distribution 
of intermediate host snails. The risk of humans to become infected with schistosomes depends 
on environmental, climatic and anthropogenic factors, affecting the distribution of 
schistosomiasis (Walz et al., 2015). These risk factors can be used to predict the distribution 
of the diesaese. Current epidemiological studies in the assessment of S. mansoni distribution 
reported that GIS and remote sensing are useful means for identification of risk factors for 
schistosomiasis. For example, it was reported that climatic features such as rainfall and LST, 
and environmental factors such as NDVI, altitude and large water bodies were the main 
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factors explaining the heterogeneity of schistosomiasis distribution at continental, national 
and sub-national levels (Chammartin et al., 2013; Stensgaard et al., 2013; Chammartin et al., 
2014; Assaré et al., 2015b; Lai et al., 2015). In western Côte d’Ivoire, since 2005, remote 
sensing and GIS-based spatial analysis were conducted in this part of the country to map and 
predict the distribution of the disease (Raso et al., 2005; Beck-Worner et al., 2007). However, 
the studies were restricted to the town of Man and surrounding villages (within a diameter of 
approximately 30 km, in the Tonpki region). We have now generated a predictive risk map 
for schistosomiasis mansoni for four regions of western Côte d’Ivoire. Questionnaire-based 
methods have been successfully implemented to identify schistosomiasis mansoni associated 
risk factors at micro-geographical scale (Barreto, 1993; Bethony et al., 2001; Raso et al., 
2005; Matthys et al., 2007). For our study we therefore used remote sensing and GIS coupled 
with Bayesian geostatistical methods to identify risk factors at a macro-geographical scale 
(i.e. at regional level) and questionnaire-based approach to determine potential risk factors at 
micro-geographical scale (i.e. at community level). Thus, the present study determined 
schistosomiasis risk factors at both the macro- and the micro-geographical scales. 
Importantly, the risk map for S. mansoni for the four regions of western Côte d’Ivoire has 
already been used by the national schistosomiasis control programme for spatial targeting of 
control interventions (Assaré et al., 2015).  
 On the macro-geographical scale, our results showed that environmental (i.e. altitude), 
demographic (i.e. sex and age) and climatic factors (i.e. difference between LST at day and 
night) were the best predictors of schistosomiasis mansoni distribution in the study areas 
(Assaré et al., 2015). These risk factors were reported previously in other parts of the world 
and in Côte d’Ivoire (Raso et al., 2005; Schur et al., 2011; Chammartin et al., 2013; Walz et 
al., 2015).  
With regard to environmental factors, we found that altitude was associated with 
S. mansoni infection, whilst living at an altitude of at least 400 m was associated with a lower 
risk of S. mansoni than living below. Similar results have has been reported elsewhere in sub-
Saharan Africa (Raso et al., 2005; Clements et al., 2006; Koroma et al., 2010). The altitude 
threshold limit for schistosomiasis transmission is a function of the study area. For instance, a 
previous study in Uganda revealed that there was no schistosomiasis case above 1,400 m 
above sea level (Kabatereine et al., 2004). In Heging county, People Republic of China, 
schistosomiasis-positive individuals can be found in locations as high as at 2,900 m (LI and 
LI, 2013). Therefore, there is a need to assess the altitude limit for schistosomiasis in the 
present study area by using several elevation strata in order to deepen our understanding of 
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schistosomiasistransmission. Our results showed that NDVI, land cover and soil type were not 
associated with S. mansoni infection (Assaré et al., 2015). In 2005, similar observations have 
been reported in the mountainous areas of Man in western Côte d’Ivoire (Raso et al., 2005; 
Beck-Worner et al., 2007). More recently, Chammartin and colleagues analysing national 
historical data of the country found only a moderate effect of soil type on the distribution of 
schistosomiasis mansoni (Chammartin et al., 2013). In contrast, previous studies in West and 
Eastern Africa found that these environmental covariates were strong predictors for 
schistosomiasis (Schur et al., 2011; Schur et al., 2013). One explanation might be the 
difference in scale of the Côte d’Ivoire studies (district level), compared to East and West 
Africa, studies (sub-continental level).  
With regard to climatic factors, we found that the difference between LST at day and 
night was significantly associated with schistosomiasis (Assaré et al., 2015). The effect of 
temperature on schistosomiasis distribution is well documented (Hu et al., 2013; Scholte et 
al., 2014; Walz et al., 2015). Our results demonstrated that rainfall was not a good predictor 
for S. mansoni (Assaré et al., 2015). This observation confirms the result of previous studies 
in Tonkpi region (Beck-Worner et al., 2007). However, previous research revealed that 
rainfall is positively associated with schistosomiasis (Appleton, 1978; Jordan and Webbe, 
1993; Sturrock, 1993). Underlying reasons for these differing observations might be issues in 
spatial scaling or setting-specific idiosyncrasies.  
Regarding demographic factors, our study confirmed that sex and age are significantly 
associated with S. mansoni distribution (Assaré et al., 2015). It must be noted, however, that 
there are numerous other demographic covariates such socio-economic status, ethnicity, water 
contact behaviour and religion which might significantly influence the distribution of 
schistosomiasis. However, these were not included in the present investigation calling for 
future geospatial studies with a broader range of demographic covariates. 
We observed very high S. mansoni prevalence (≥50%) in the northern part of the 
Tonkpi region, while in the other parts of the study area the prevalence of the disease was 
mostly moderate to high (10–49%). Therefore, according to WHO guideline, school-aged 
children and other high-risk communities (such as fishermen) in northern Tonkpi region 
should be treated once a year with praziquantel, while in the remaining parts of the study 
areas, school-aged children should receive treatment once every two years. 
On the micro-geographical scale, we found that rice cultivation, open defecation, use of 
traditional pit latrines, use of natural open fresh water bodies for washing and bathing were 
risk factors for schistosomiasis. These recreational and occupational activities have been 
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ideentifed before as important risk factors influencing the transmission and spatial patterns of 
schistosomiasis (Sow et al., 2008; Schmidlin et al., 2013; Grimes et al., 2015). However, we 
did not assess the influence of these factors on S. mansoni transmission. In future studies, 
detailed parasitological, malacological and socio-economic factors should be investigated to 
deepen our understanding of risk factors of S. mansoni transmission forces in western Côte 
d’Ivoire. 
 
6.3. Need for cost-effective MDA approach for sustainable control of 
schistosomiasis 
Since the 1980s, WHO recommends preventive chemotherapy as the main pillar of the global 
schistosomiasis control strategy (WHO, 1985; 2002). However, the optimal timing period and 
frequency of MDA with praziquantel still needs to be determined for a more effective control 
of schistosomiasis in different settings (Colley, 2014).  
This Ph.D. thesis contributes to strengthening the evidence-base of the cost-
effectiveness of alternative MDA strategies that may be utilised to gain and sustain the control 
of schistosomiasis, and ultimately help to move to elimination. The developed study protocol 
describes a school-based cluster-randomised controlled trial that includes three treatment arms 
(A, B and C). Following the protocol design, schools of arm A are being treated once every 
year, schools of the treatment arm B receive MDA the first two years, followed by two years 
of “drug holidays”, while schools in treatment arm C receive MDA at baseline and at year 
three with “drug holidays” in the second and in fourth year (Assaré et al., 2014). Treatment 
arm A, where school-aged children receive annual MDA (subjected to the highest drug 
pressure), represents the benchmark intervention. It is well known that repeated praziquantel 
dosing leads to marked reductions in the prevalence and intensity of infection (Magnussen et 
al., 1997; King et al., 2011; Sesay et al., 2014). However, repeated MDA and community 
fatigue are major challenges to obtain high and sustained treatment coverage rates, which 
might increase treatment costs to an unexpected high level for governments of endemic 
countries where financial resources are generally limited (Brooker et al., 2008; Leslie et al., 
2011). For example, although in sub-Saharan Africa governments often receive praziquantel 
free of charge, they do not have sufficient financial resources to distribute several millions of 
tablets annually across to remote “hard to reach” areas where health centers and schools are 
often rare (Hodges et al., 2012). Thus, additional financial resources are required for covering 
the cost related to equipment, transport, information education communication materials, 
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training materials, and “per diems” (Fenwick, 2015). In our SCORE study, it is conceivable 
that treatment arm A is the intervention arm that will produce the largest reduction of 
schistosomiasis among children and showed to be the most effective in terms of morbidity 
reduction; however, this treatment arm is also the most expensive one. Therefore, it is 
relevant to determine a control strategy that provides the best balance in terms of costs and 
reductions of morbidity due to schistosomiasis. Treatments arms B and C include “drug 
holidays” hence these arms are considerably less expensive but excert a lower drug pressure. 
Long periods of “drug holiday” might be associated with re-infection among cured 
individuals. Both treatment arms include two years of drug holidays. However, in treatment 
arm B the two years of drug holiday (years 3 and 4) are consecutive, while in treatment arm 
C, the two years of drug holidays (year 2 and 4) are interspaced by a year of MDA (year 3). 
Therefore, the population in treatment arm B is more likely to be subjected to re-infection 
compared to the populations in treatment arms A and C. At the end of the study, we should be 
able to have a definitive answer on whether the treatment strategy with more (treatment arm 
B) or less (treatment arm C) extensive subjection to schistosomiasis re-infection is the better 
strategy in reducing schistosomiasis prevalence and intensity in moderate endemicity settings. 
 
6.4. Impact of MDA on schistosomiasis mansoni 
Praziquantel is the human schistosomiasis drug of choice as recommended by WHO (WHO, 
2002). Several studies have reported that MDA with praziquantel termed preventive 
chemotherapy could reduce the schistosomiasis prevalence and intensity, control morbidity 
and limit the transmission within endemic areas (Utzinger et al., 2000a; WHO, 2002; Raso et 
al., 2004b; Bockarie et al., 2013). In early 2012, numerous pharmaceutical companies and 
international donors endorsed the London declaration on neglected tropical diseases (WHO, 
2012). In line with this declaration, the company Merck KGaA promised to distribute 
250 million tablets of praziquantel in schistosomiasis endemic countries until the elimination 
of the disease (WHO, 2012). In 2013, more than 26 million people in Africa received 
praziquantel treatment (WHO, 2015). WHO recommended achieving at least coverage of 75% 
in endemic area by 2020. However, the intensive MDA with praziquantel lead to numerous 
concerns including failure to reduce schistosomiasis prevalence and intensity, low coverage 
and compliance and potential drug resistance (Wang et al., 2012; Ross et al., 2015; Tuhebwe 
et al., 2015). The current study assesses the impact of MDA with praziquantel on 
schistosomiasis mansoni in western Côte d’Ivoire one year post-treatment (Assaré et al., 
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2016b). We found that an overall coverage of 84.2% was achieved. The overall S. mansoni 
prevalence decreased, while the intensity of the infection increased. 
The overall coverage in the study area reached the WHO target and 75% coverage was 
achieved in the majority of the schools (76%). The higher coverage can be explained by the 
combined school- and community-based MDA strategies targeting school-age children. 
Indeed, in addition to the schools, the treatment was implemented in the communities in order 
to reach the maximum of school-age children. Another explanation might be the information, 
education and communication (IEC) strategy implemented. First, at the start of the study and 
before the parasitological survey, a team was designated to talk to district and village 
authorities, teachers and children’s parents and offer detailed information about 
schistosomiasis, the objectives and procedures of the study (Assaré et al., 2014). Second, 
before the implementation of the MDA, different IEC tools such as radio and television 
announcements were used to sensitize the communities (Assaré et al., 2014). These divers 
IEC approaches may have resulted in better MDA compliance, and thus higher coverage 
(Schall, 1995; Utzinger et al., 2005; Omedo et al., 2014b). In addition, the praziquantel 
delivery to schoolchildren and non-school attendees was carried out by school teachers. 
Before the MDA, school teachers were well trained in drug administration (Assaré et al., 
2014). The contribution of school teachers in helminth control programs and particularly the 
in MDA success was described elsewhere (Belizario et al., 2013).  
Although a high overall coverage was reported, low coverage was observed in few 
schools (24%), specifically in Yaoudé where a coverage rate of 31.9% was achieved. The low 
coverage in some schools might be due to many factors including lack of knowledge on 
schistosomiasis prevention, religious objection, misconception from the community members, 
conspiracy theories about the “real” purpose of treatment, and in particular the experiences of 
side effects (Raso et al., 2004b; Omedo et al., 2014a; Muhumuza et al., 2015). In Côte 
d’Ivoire, previous praziquantel-based interventions induced several mild and transient side 
effects such as abdominal pain, dizziness and (bloody) diarrhea (N’Goran et al., 2003; Raso et 
al., 2004b). However, subjects harboring a high intensity of schistosomiasis can suffer from 
severe side effects (Utzinger and Keiser, 2004). In villages with low treatment coverage, 
sensitization and health education needs to be strengthened in order to resolve the fear of the 
treatment side effects and increase the MDA compliance.  
 Our findings showed that one year post-MDA the overall S. mansoni prevalence 
dropped, while the intensity of the infection increased (Assaré et al., 2016b). This finding may 
suggest behaviour changes among school-age children due to IEC approaches. Another 
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plausible reason for the variation in infection intensity could be a lack of reliability of the 
Kato Katz technique to accurately determine worm burdens (Kongs et al., 2001; Utzinger et 
al., 2001; Sayasone et al., 2015). This result may also reflect that the transmission was 
uninterrupted after the praziquantel treatment. Indeed, the preventive chemotherapy does not 
prevent re-infection nor does it stop the life cycle of the parasite (Gray et al., 2010; Garba et 
al., 2013). First, we found that rice cultivation, washing and bathing in open fresh water were 
practiced and were common in the villages surveyed. These occupational and recreational 
activities may expose the populations of the study area to get in contact with contaminated 
water. Therefore, they are permanently exposed to schistosomiasis re-infection. Second, 
during the MDA adult, pregnant women, sick school-age children and particularly young 
children (children aged below five years of age) were not treated. Thus, these categories of 
people may ensure the continuity of the infection transmission. On one hand, this finding calls 
for the need to adopt an integrated approach to sustainable control schistosomiasis as 
underscored by other studies (Utzinger et al., 2003; Utzinger et al., 2009). On the other hand, 
this result may reveal the relevance to determine the best frequency of the MDA to decrease 
schistosomiasis prevalence to low level endemicity (Assaré et al., 2014; Colley, 2014). There 
are notable shortcomings of the study; first, the intensity of the infection was expressed based 
on the AM EPG among only the infected individuals (Montresor et al., 1998). Second, the 
present randomised controlled trial is an opened research. It is possible that a part of the 
infected individuals did not receive treatment at baseline because of specific reason. Some 
school-age children were, for instance, not treated because they were sick, absent or lived 
outside the study area. These untreated positive individuals might have increase the intensity 
of the infection.  
 Our data revealed that the proportion of children harboring heavy S. mansoni infection 
intensity was higher among first graders compared with 9–12 years old children. Based on 
this trend we state that there were some young children who might harbor heavy infection 
intensity. Heavy S. mansoni infection among young children was reported in Côte d’Ivoire 
and Sierra Leone (Hodges et al., 2012; Coulibaly et al., 2013a; Coulibaly et al., 2013b). These 
observations confirm the need to consider the treatment of young children in sub-Saharan 
Africa in order to successfully control schistosomiasis (Ekpo et al., 2012; Coulibaly et al., 
2013b; Stothard et al., 2013). 
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6.5. Conclusion 
The starting point of this Ph.D. thesis was to deepen our understanding of the epidemiology of 
schistosomiasis mansoni and to determine an appropriate strategy to sustainably control the 
disease. 
First, we developed a 5-year school-based research protocol which will allow us to determine 
a cost-effective MDA strategy for sustaining schistosomiasis control. Second, a rapid 
parasitological assessment was conducted in four regions of western Côte d’Ivoire to select 75 
schools with moderate schistosomiasis endemicity. Based on the available data, risk and 
prediction maps for schistosomiasis mansoni were generated. Third, rigorous parasitological 
surveys were carried out in the selected schools to determine the baseline situation of the local 
communities. Concomitantly, a questionnaire was delivered to collect social-ecological data 
which might influence the occurrence of the disease. After baseline parasitological surveys 
the initial school- and community-based MDA with praziquantel targeting school-age 
children was carried out in all villages of the study area. Finally, one year post-MDA a 
parasitological assessment was conducted to evaluate the effect of the initial MDA on 
schistosomiasis mansoni. Based on the result of the work presented in this thesis, the 
following conclusions can be drawn: 
 A 4-year cluster randomized control study protocol was designed and the trial is 
taking place. At the end of this study the most cost-effective MDA will be determined 
and should allow to better control schistosomiasis morbidity at a lower cost. 
Therefore, it will contribute to reduce the poverty. 
 Age, sex, altitude and difference between land surface temperature at day and night 
were correlated with S. mansoni infection at macro-geographical level, while rice 
cultivation, washing, bathing in fresh water bodies and open defecation were the 
potential factors associated with the disease at micro-geographical level. The risk and 
predicted maps generated are useful for future schistosomiasis control programmes. 
 At baseline survey parasitological and socio-ecological characteristics of local 
communities were determined and will be relevant for the ongoing randomized 
controlled trial. Moreover, we found that the increase of the sampling effort leads to 
an increase in the sensitivity of the Kato-Katz technique. In addition, the fragility of 
the classification of communities based on WHO criteria was highlighted. 
 One year post-MDA, the overall prevalence of S. mansoni decreased while the 
intensity of the infection increased. The transmission dynamics were heterogeneous 
 141 
 
varying from one village to another. This observation calls for an integrated approach 
to successfully control schistosomiasis. 
 
6.6. Recommendations 
 Malacological and parasitological should be implemented to deepen our understanding 
in the schistosomiasis mansoni dynamics across the communities. 
 Parasitological survey coupled with questionnaire including socio-economic, 
demographic and environmental factors should be administered at household level to 
confirm the association of these factors with S. mansoni at community level. 
 Intensification of the IEC approach in the community with treatment coverage lower 
than 75%. 
 To improve the involvement and the motivation of the community health workers in 
order to increase the treatment coverage. 
 Annual assessment of the impact of the MDA on schistosomiasis to better evaluate the 
changes of schistosomiasis mansoni over time. 
 Young children should be considered during the MDA. This can increase the effect of 
the MDA on the disease transmission. 
 Integrated approach including MDA, IEC and snail control to successfully control 
schistosomiasis in the four region of western Côte d’Ivoire. 
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